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Abstract
Insulin resistance in skeletal muscle is of major pathogenic importance in several
common human disorders including diabetes, hypertension and obesity, but the
underlying mechanisms are unknown. In order to define mechanisms of insulin
resistance, studies have been undertaken in skeletal muscle of the SHRSP, an animal
model of hypertension, which exhibits insulin resistance in skeletal muscle and
adipose tissue, when compared to the normotensive WKY control animal.
Anti-peptide antibodies, directed against the phosphorylated or unphosphorylated
residue Ser-II77 of human eNOS, were prepared and characterised, to allow the
study of eNOS regulation in SHRSP skeletal muscle by phosphorylation at this
residue. However, some doubt exists over the specificity of these antibodies and
future studies have not been undertaken at this stage.
Flotillin is a protein known to be involved in a PI3-kinase independent pathway,
which is required for GLUT 4 translocation and increased glucose uptake in response
to insulin. Flotillin expression is increased in skeletal muscle from SHRSP and for
this reason a yeast two-hybrid screen was undertaken using flotillin-I as bait, the aim
being to identify flotillin interacting proteins which have possible roles in insulin-
stimulated glucose uptake. A number of interesting putative flotillin interacting
proteins were identified in this screen, however one must be cautious as no duplicate
clones were identified. Also, due to time constraints no biochemical studies have
been undertaken to determine if the proteins identified do indeed bind flotillin.
Studies of the 'classical' PI3-kinase-dependent insulin-signalling pathway were also
undertaken. It was demonstrated that key proteins involved in the insulin-signalling
pathway (GLUT 4, IRS-I, IRS-2 and the PI3-kinase p85 subunit) are expressed at
similar levels and have similar subcellular distribution (on crude fractionation of
skeletal muscle) in skeletal muscle of the SHRSP and the control WKY.
Furthermore, levels and activity ofPKB (a protein kinase downstream ofPI3-kinase)..
were similar in WKY and SHRSP, suggesting that the insulin-signalling pathway
leading to activation of PKB in SHRSP skeletal muscle is intact.
iii
Regulation of glycogen metabolism in SHRSP skeletal muscle was also investigated.
Levels of muscle glycogen, glycogen synthesis, glycogen phosphorylase activity and
GSK-3a and GSK-3p activity were all shown to be similar in skeletal muscle from
SHRSP and WKY. However, expression of GSK-3a protein was decreased in
SHRSP skeletal muscle, yet the activity of the protein was similar in the two strains.
Skeletal muscle from SHRSP and WKY was subjected to fibre type analysis, in order
to determine if any differences in fibre type distribution could be observed which
may account for the insulin resistance observed in the SHRSP. However, WKY and
SHRSP skeletal muscle have similar number and distribution of the various fibre
types, suggesting that fibre abnormalities are not the cause of the observed insulin
resistance.
In this study, two defects have been presented that have been identified to occur in
SHRSP skeletal muscle, compared to WKY. These are increased expression of
flotillin and decreased expression of GSK-3a. Whether these changes in protein
expression are a cause or effect of the observed insulin resistance, or whether they
are unrelated to this defect is unknown. Further studies are required to define more
clearly the mechanism involved in the insulin resistance observed in the SHRSP.
iv
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CHAPTERl
INTRODUCTION
1.1 Glucose
Glucose has a fundamental role in cellular homeostasis and metabolism, with many
cellular processes including cell proliferation and chemotaxis requiring an increase in
glucose transport into the cell to fulfil an increased energy requirement. When taken
up into a cell, D-glucose (see figure 1.1) is phosphorylated by hexokinase to form
glucose 6-phosphate (G6P), which has a number of fates. For example G6P can be
used to form glycogen, the storage form of glucose, which is utilised when increased
energy demands are placed on the cell/tissue. G6P can also be converted to pyruvate
via the glycolytic pathway, with the subsequent release of ATP.
O~I/H
C
I
2
H-C-OH
I
3
OH-C-H
I
4
H-C-OH
I s
H-C-OH
I
6
CH20H
H OH
Figure 1.1 Linear and ring forms of D-glucose
Glucose can exist as a linear or ring form, however the predominant form in solution
is the ring form.
Blood glucose concentration is controlled by a variety of hormones. For example
when blood glucose concentration is low, the a-cells of the pancreas secrete
glucagon which acts on the liver to promote glycogen breakdown, and release of
glucose into the bloodstream. Conversely, insulin is released by the pancreatic p-
cells when blood glucose concentration increases, following ingestion of a meal.
Insulin has various actions, the main function being to increase glucose uptake and
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utilisation in peripheral tissues such as fat and muscle (see section 1.2), which results
in lowering of the blood glucose concentration.
1.1.1 The facilitative glucose transporter family
Glucose cannot freely diffuse across the plasma membrane of a cell, but is
transported across the membrane by the energy-independent process of facilitated
diffusion. A family of facilitative glucose transporters exists which transport glucose
into and out of cells. The erythrocyte glucose transporter, GLUT 1, was the first
glucose transporter to be isolated (Mueckler et aI., 1985) with subsequent
identification of a number of other transporters (GLUTs 2-7) (reviewed in Gould and
Holman, 1993). Recently a number of other transporters have been identified, due to
sequence similarities with the known GLUTs (reviewed in Joost and Thorens, 2001).
There are now at least 13 known GLUT molecules, which represent a family of
transporters that can be sub-divided into three classes (see table 1.1).
CLASS ISOFORM EXPRESSION SUGER TRANSPORTED
I GLUT I erythrocytes, brain glucose
GLUT2 liver, pancreas glucose
GLUT3 brain glucose
GLUT4 skeletal muscle, adipose glucose
II GLUT5 intestine, testis, kidney fructose transporter
GLUT7 unknown unknown
GLUT9 liver, kidney unknown
GLUT 11 heart, skeletal muscle glucose/fructose
III GLUT6 spleen, leukocytes, brain glucose
GLUT8 testis, blastocyst, brain glucose
GLUTI0 liver, pancreas unknown
GLUT12 heart, prostate unknown
HMIT brain myo-inotistol transporter
Table 1.1 The extended GLUT family (adapted from Joost and Thorens, 2001)
The 13 known GLUTs are divided into three sub-classes on the basis of sequence
similarity and preliminary functional characterisation. The nomenclature used is that
recommended by Joost and Thorens, 2001.
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The class I transporters consist of the previously identified glucose transporters
GLUTs 1-4. Class II comprises the fructose transporter, GULT 5, and three related
proteins, GLUT 7, GLUT 9 and GLUT 11, and class III consists of GLUTs 6, 8, 10,
12 and HMITI (H'zmyo-inositol co-transporter). As the class II and III proteins have
only been identified in recent years, much less is known about these proteins than the
class I transporters, thus further discussion will focus on GLUTs 1-4.
As previously stated, GLUT 1was the first glucose transporter to be isolated. GLUT
1 is expressed at high levels in erythrocyte membranes, and is enriched in brain,
placenta and retina. GLUT 1 expression is also observed in muscle and fat, however
GLUT 1 expression is very low in liver (Gould and Holman, 1993). It has been
reported that GLUT 1 may oligomerise to form tetramers, resulting in cooperativity
to further enhance glucose transport (Hebert and Carruthers, 1992). GLUT 2 is
expressed at high levels in liver, and is also expressed in pancreatic p-cells, kidney
and the small intestine (Gould and Holman, 1993). The primary functions of GLUT 2
are to permit the release of glucose from the liver during fasting states and glucose
sensing in the pancreas. GLUT 3 is predominantly expressed in brain, but with lower
levels found in placenta, liver, heart and kidney (Gould and Holman, 1993). GLUT 3
expression overlaps somewhat with the tissue expression pattern of GLUT 1, and it is
possible these proteins act in concert to meet the energy requirements of these
tissues. GLUT 4 is also known as the insulin responsive glucose transporter as it is
found in the insulin sensitive tissues, muscle and adipose tissue. In the basal state
GLUT 4 is sequestered in intracellular vesicles and insulin promotes an increase in
glucose transport by promoting the translocation of GLUT 4 to the plasma membrane
(see section 1.1.3 and Pessin et al., 1999).
1.1.2 Structure of the facilitative glucose transporters
Although no GLUT crystal structure is available, a model, based on the sequence of
GLUT 1 has been proposed (Mueckler et al., 1985) and all of the GLUTs identified
appear to fit this model (Joost and Thorens, 2001). The GLUTs are composed of 12
membrane spanning a-helices, with both the N- and C- termini being located
intracellularly (see figure 1.2). A large intracellular loop between helices 6 and 7
divides the transporter into two N- and C- terminal halves. The remainder of the
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intracellular loops are short (8-12 residues) and place severe constraints on the
structure of the molecule. It has been proposed that the transporter may form a
bilobal structure, each lobe consisting of the 6 helices from either the N- or C-
terminal domains (Bell et aI., 1993). However, recent studies using molecular
modelling of GLUT 1 have suggested a somewhat different structure for these
transporters (Zuniga et aI., 2001). The authors suggest helices 1-5, 8 and 10-12 form
a 9 membered barrel-like structure, with helix 7 projecting into the channel. They
also report the presence of two channels in the molecule. One channel traverses the
whole molecule, which they suggest may be the glucose channel. The second
channel is open only at the endofacial site, and they suggest this may be a pathway
for substrates other than sugars.
Outside
~~~~
~~~~
eOOH
Inside
Figure 1.2 Schematic of the proposed structure of the glucose transporters
The molecule is composed of 12 membrane spanning a-helices, and has such an
orientation that the N- and C-termini are located intracellularly. A large loop exists
between helices 6 and 7 that may separate the molecule into two lobes.
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1.1.3 GLUT 4 is stored in intracellular vesicles
Work in the 1980's reported that insulin caused the redistribution of a glucose
transporting activity from inside the cell to the plasma membrane in adipocytes
(Suzuki and Kono, 1980). The later isolation and characterisation of the insulin
responsive glucose transporter GLUT 4 (James et al., 1988, James et al., 1989)
helped confirm the hypothesis that insulin recruited glucose transporter proteins to
the cell surface. To date, GLUT 4 is still believed to be the major transporter
responsible for the insulin-induced increase in glucose uptake into muscle and fat.
It is generally accepted that in the basal state as much as 95% of cellular GLUT 4
resides intracellularly. Under basal conditions GLUT 4 is suggested to continually
recycle between this intracellular location and the plasma membrane. The action of
insulin has been reported to promote a large increase in the rate of GLUT 4
exocytosis from this intracellular compartment and a somewhat smaller decrease the
rate of GLUT 4 internalisation by endocytosis of the transporter (Satoh et al., 1993).
Hence, the result is an increased number of transporters at the plasma membrane.
Much research has focused on the nature of the intracellular GLUT 4-storage
compartment and how it is recruited to the plasma membrane in response to insulin.
GLUT 4 has been reported to be located in various intracellular structures including
the trans-Golgi network, (TGN), the endosomal system, clathrin-coated vesicles and
small vesicle and tubulo-vesicular structures (Pessin et al., 1999). However,
Livingstone et al. (1996) suggested that only around 40% of GLUT 4 is co-localised
with the transferrin receptor in the recycling endosomes. It was suggested that the
remaining intracellular GLUT 4 may be present in vesicles that are distinct from the
recycling endosomes, and which are specifically translocated to the plasma
membrane in response to insulin (see figure 1.3). GLUT 4 vesicles also contain the
insulin responsive aminopeptidase (IRAP), which is transported in a manner similar
to GLUT 4 (Ross et al., 1996) and has been a useful marker in studying GLUT 4
vesicle trafficking. These vesicles also contain a number of proteins that are most
likely involved in the insulin regulated trafficking of these GLUT 4 storage vesicles.
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Figure 1.3 GLUT 4 has a distinct sub-cellular localisation
GLUT 4 is found in the endosomal compartment, co-localised with the transferrin
receptor (TfR). However GLUT 4 is also present in distinct GLUT 4 storage vesicles
(GSVs) that lack the transferrin receptor.
1.1.4 GLUT 4 vesicle trafficking
Much of the knowledge of GLUT 4 vesicle trafficking has come from analogy with
the well-characterised system of synaptic vesicle exocytosis. This process involves
the mobilisation of synaptic vesicles from within the pre-synaptic cell. These vesicles
then tether or dock with the plasma membrane, and following fusion of the vesicle
membrane with its target plasma membrane (a process which is triggered by a rise in
intracellular Ca2+), the vesicle contents are released. Recycling of the synaptic
vesicle components then occurs by endocytosis (Lin and Scheller, 2000).
In eukaryotic cells, all intracellular membrane fusion events appear to be regulated
by a conserved set of proteins called SNAREs (soluble NSF attachment protein
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receptor, where NSF is N-ethyl-maleimide-sensitive fusion protein). It is thought that
the interaction of a vesicle SNARE protein (v-SNARE) with a SNARE protein on the
target membrane (t-SNARE) brings the membranes into close apposition, which may
promote membrane fusion. The SNARE proteins involved in synaptic vesicle
exocytosis are the v-SNARE VAMP 2 (vesicle associated membrane protein-
2)/synaptobrevin and the t-SNAREs syntaxin 1 and SNAP 25 (synaptosomal
associated protein, 25 kDa) (Lin and Scheller, 2000). The SNARE proteins all
contain heptad repeat sequences that form coiled-coil structures. One coil from
syntaxin 1, one from VAMP 2 and two coils from SNAP 25 come together in a
zippering mechanism, forming the core complex four-helix bundle (Sutton et al.,
1998) (see figure 1.4). Calcium influx through voltage-gated channels triggers
membrane fusion, allowing the vesicle contents to be released (Lin and Scheller,
2000).
In addition to SNARE proteins, various other proteins have been implicated in
regulating vesicle fusion, for example, the small GTP binding Rab proteins have
been suggested to function in nucleation of the complex (Chen and Scheller, 2001).
Furthermore, the ATPase NSF and the adapter protein a-SNAP (soluble NSF
attachment protein) are required in disassembly of the SNARE complex (Chen and
Scheller, 2001) and likely function after membrane fusion to allow recycling of
SNAREs to their appropriate compartments. Another important protein is
MuncI8a1nSecl, which interacts with monomeric syntaxin 1, forming a complex that
is mutually exclusive with SNARE complex formation. The role of Munc18a1nSec1
in membrane fusion has been controversial and this protein may have both positive
and negative effects on SNARE complex formation, by controlling the availability of
syntaxins (Misura et aI., 2000).
Translocation of GLUT 4 to the plasma membrane is presumed to occur by regulated
exocytosis of GLUT 4 vesicles in a manner similar to that described for synaptic
vesicle exocytosis. GLUT 4 vesicles are enriched in the v-SNARE VAMP 2, which
appears to be required for insulin stimulated GLUT 4 translocation (Pessin et aI.,
1999). Syntaxin 4 and SNAP 23 are enriched in plasma membranes of muscle and fat
cells and various studies have implicated these proteins as the t-SNAREs involved in
this process (Pessin et aI., 1999). Another important protein involved in GLUT 4-
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vesicle fusion is Munc18c (a homologue of Munc18aJnSecl) which interacts with
syntaxin 4. Synip has also been implicated in GLUT 4 vesicle fusion and is another
syntaxin 4 binding protein which may represent a target for insulin regulation of
SNARE complex assembly (Pessin et al., 1999).
N"ture Reviews I Mole<:ular Cell Biology
Figure 1.4 Vesicle fusion is driven by SNARE proteins (taken from Chen and
Scheller, 2001), see text for details.
Although much is known about the transport of GLUT 4 to the plasma membrane,
many questions still remain unanswered. For example, what is the exact nature of the
intracellular storage compartment? As calcium influx does not appear to be the signal
that causes fusion of the GLUT 4 vesicle with the plasma membrane, what is the
signal? Does the role of the SNARE proteins in bringing the membrane into close
apposition drive membrane fusion or is another signal required? As much effort is
focused on studying these processes these questions will likely be answered in due
course.
1.1.5 Studies of GLUT 4 knockout mice
To determine the role of GLUT 4 in glucose homeostasis various knockout mouse
models have been created in which GLUT 4 expression is disrupted. Surprisingly the
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whole body GLUT 4 knockout did not develop diabetes (Katz et aI., 1995). GLUT 4-
null mice were smaller than control animals and exhibited decreased adipocyte mass,
cardiac hypertrophy and died within 5-7 months, likely due to the cardiac
abnormalities. These mice also developed hyperinsulinaemia in the fed state and
increased expression of GLUT 2 was observed in liver and GLUT 1 in heart tissue
(Katz et aI., 1995), suggesting the GLUT 4-null mice develop compensatory
mechanisms to counter the loss of GLUT 4. Mice heterozygous for the expression of
GLUT 4 (GLUT 4+/) were also studied (Stenbit et aI., 1997). In contrast to the
GLUT 4 null mice, these mice did develop a diabetic phenotype. GLUT 4+1- mice
exhibited hyperglycaemia, hyperinsulinaemia, and developed hypertension and
insulin resistance in peripheral tissues such as skeletal muscle. Thus, when only one
GLUT 4 allele is disrupted, mice develop a diabetic phenotype suggesting GLUT 4 is
required to maintain glucose homeostasis, but when both alleles are disrupted
compensatory mechanisms ensue which somehow prevent the development of the
diabetic phenotype.
Selective knockouts of GLUT 4 in adipose tissue and skeletal muscle have also been
studied to investigate the importance of GLUT 4 for glucose homeostasis in these
tissues. Mice with a GLUT 4 knockout in adipose tissue showed normal growth, and
had normal adipose tissue mass, despite having greatly reduced insulin-stimulated
glucose uptake in adipose tissue (Abel et al., 2001). These mice developed insulin
resistance in liver, with the inability of insulin to suppress hepatic glucose output,
and in muscle, in that in vivo glucose uptake was greatly reduced in response to
insulin. In contrast, insulin stimulated glucose uptake in skeletal muscle was normal
when studied ex vivo, and the authors suggest the possible release of specific
molecules from fat cells may cause these effects in skeletal muscle. Whole body
glucose uptake was also decreased by up to 50% due to reductions in glycolysis and
glycogen synthesis. Hence the adipose specific GLUT 4 knockout mice became
glucose intolerant and hyperinsulinaemic. Therefore there is a requirement for GLUT
4 in adipose tissue to maintain normal glucose homeostasis. Specific knockout of
GLUT 4 in skeletal muscle resulted in development of a phenotype similar to that
observed in the adipose specific GLUT 4 knockout suggesting adipose tissue and
skeletal muscle are similarly involved in regulation of glucose homeostasis. In
muscle specific GLUT 4 knockout mice, neither insulin nor contraction could elicit
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an increase in glucose transport (Zisman et aI., 2000). However, glucose uptake into
liver was increased by around 450%, with a similar increase in glycogen content, but
no alterations in glucose uptake in adipose tissue were observed, suggesting the liver
partially compensates for the lack of glucose uptake by muscle. These mice also
developed hyperglycaemia and hyperinsulinaemia with a subset developing severe
diabetes.
1.2 Insulin signalling
The major role of insulin is in regulation of blood glucose concentration, which in
humans is strictly controlled and maintained. Blood glucose concentration is
typically around 4 mM in the fasting state and increases to around 7-8 mM in the fed
state. As blood glucose concentration increases, following ingestion of a meal,
insulin is released by the pancreatic p-cells, and acts in a number of ways to lower
blood glucose level. Insulin acts on muscle and fat causing increased glucose uptake
and acts on liver to suppress hepatic glucose output. Insulin stimulates the storage of
substrates in muscle, adipose tissue and liver by stimulating lipogenesis, glycogen
synthesis and protein synthesis and inhibiting lipolysis, glycogenolysis and protein
breakdown. Insulin also prevents gluconeogenesis in the liver.
As much as 75% of insulin-dependent glucose disposal may occur in skeletal muscle,
with only a small percentage occurring in adipose tissue. Therefore, insulin
resistance (as is observed in diabetes and the metabolic syndrome) in the peripheral
tissues can lead to elevations in blood glucose concentration.
Diabetes mellitus is a disease in which insulin is not secreted in sufficient amounts or
does not efficiently stimulate its target cells, resulting in elevated blood glucose
levels. There are two forms of diabetes. Type 1 (insulin dependent) diabetes is an
autoimmune disorder in which the p-cells of the pancreas are destroyed, resulting in
loss of insulin secretion. Type 2 (non-insulin dependent) diabetes is characterised by
insulin resistance andlor abnormal insulin secretion and is associated with a
sedentary lifestyle and obesity. Therefore in order to combat these diseases a precise
knowledge of how insulin functions at the cellular level is required.
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Insulin's actions on the vanous tissues described involves a huge number of
molecules which participate in a highly specialised and complex signalling cascade
(see figure 1.5). For example, as previously described, insulin activates a signalling
cascade described in skeletal muscle and adipose tissue, which promotes the
movement of a specialised glucose transporter (GLUT 4) from an intracellular
location to the plasma membrane to facilitate increased glucose uptake into the cell.
Insulin also activates the processes that lead to increased glycogen synthesis, and
inhibits the processes, which culminate in glycogen breakdown. The signalling
cascades involved in these processes are described below.
1.2.1 The insulin receptor
The insulin receptor is expressed fairly ubiquitously in mammalian tissues, with the
most insulin responsive tissues expressing the receptor at highest levels. The insulin
receptor is initially produced as a pro-receptor, and proteolytic processing results in
the formation of one a- and one f3-subunit.The mature receptor is a heterotetramer
consisting of 2 a- and 2 f3-subunits, with 2 a-subunits linked to a f3-subunitand to
each other by disulphide bonds. The receptor also has complex N-linked
carbohydrate side chains capped with terminal sialic acid residues (White and Kahn,
1994). The a-subunits of the molecule are extracellular, and are involved in insulin
binding. The f3-subunitsare membrane spanning, the intracellular region containing
the receptor tyrosine kinase (see figure 1.6). When insulin binds to its receptor a
conformational change occurs in the molecule, which promotes trans-auto-
phosphorylations on tyrosine residues in the kinase region of the f3-subunits.These
phosphorylations further stimulate the kinase activity of the molecule and promote
additional tyrosine phosphorylation within the receptor and the receptor substrates.
The insulin receptor belongs to a family of receptor tyrosine kinases, which includes
the insulin-like growth factor (IGF) receptor and the insulin receptor-related receptor
(Patti and Kahn, 1998). The insulin receptor and the IGF receptor can dimerise, to
form functional hybrid receptors (Soos and Siddle, 1989). For example in skeletal
muscle the insulin receptor is in excess, therefore the IGF receptor exists largely as
hybrids with the insulin receptor, while a large number of classical insulin receptors
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are also present (Bailyes et al., 1997). Hybrid receptors bind both insulin and IGF-l,
but they have been shown to have lower affinity for insulin than does an insulin
receptor homodimer (Soos et al., 1993). However, the functional significance of
these hybrids is not known.
While the insulin and IGF receptors activate similar pathways in a number of cell
types, these receptors presumably also have distinct roles. In order to delineate
distinct roles for the insulin receptor, various insulin receptor knockout mice have
been studied. The insulin receptor knockout mouse (IR-/") was developed
independently by two groups (Accili et al., 1996 and Joshi et al., 1996). IR-I- mice
(which expressed no functional insulin receptors) were born with expected frequency
and were indistinguishable from their control littermates suggesting that insulin
receptors are not required for embryonic development. From birth the mutant mice
showed growth retardation, skeletal muscle hypotrophy and liver steatosis (Joshi et
al., 1996). They developed severe hyperglycaemia, hyperinsulinaemia and
ketoacidosis (Accili et al., 1996, Joshi et al., 1996) which resulted in death a few
days after birth.
To determine the role of the insulin receptor more specifically at the tissue level, a
number of tissue specific knockout mice have been produced. Mice with a skeletal
muscle knockout of the insulin receptor (MIRKO mice) were developed in which
insulin receptor expression was reduced by around 95% in skeletal muscle (Bruning
et al., 1998). These mice had increased serum triglycerides and free fatty acids
(characteristics of the metabolic syndrome) and increased adipocyte mass, however
blood glucose, serum insulin and glucose tolerance appeared to be normal (Bruning
et al., 1998). Hence, the authors suggested skeletal muscle insulin resistance may
contribute to the altered fat metabolism observed in type 2 diabetes and other tissues
may also have roles in insulin regulated glucose disposal. Furthermore, insulin-
stimulated glucose uptake in adipocytes was shown to be increased in the MIRKO
mouse (Kim et al., 2000), suggesting a partial compensatory mechanism for the loss
of insulin receptors in muscle which likely leads to increased adiposity and
development of the pre-diabetic syndrome.
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The insulin receptor is a heterotetramer of a and r3 subunits, linked by disulphide
bonds. The a-subunits are extracellular and contain the insulin-binding region. The
r3-subunits are membrane spanning and contain the kinase and juxtamembrane
regions, which are subject to phosphorylation on activation of the molecule.
Tissue specific knockout of the insulin receptor in hepatocytes resulted in a failure of
insulin to suppress hepatic glucose output resulting in mild fasting hyperglycaemia
and resistance to the blood glucose lowering effects of insulin (Michael et aI., 2000).
Mice were also hyperinsulinaemic due to increased insulin secretion from the
pancreas and decreased insulin clearance by the liver. As these mice aged, liver
function decreased resulting in the development of fasting hypoglycaemia (Michael
et aI., 2000). The authors suggest that liver insulin receptor function is required to
maintain glucose homeostasis, but defects in other tissues are required for
development of diabetes.
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Tissue specific knockout of the insulin receptor in pancreatic ~-cells (Kulkarni et al.,
1999) resulted in defects in insulin secretion and progressive impairment of glucose
tolerance, indicating a role in glucose sensing for insulin receptors in the pancreatic
~-cell. Mice with a tissue specific knockout of the insulin receptor in brown adipose
tissue were observed to have an age-dependent loss of brown fat, accompanied by an
insulin secretion defect, which resulted in progressive glucose intolerance, without
insulin resistance. Therefore the authors suggest roles for the insulin receptor in
brown adipose tissue in insulin secretion and glucose homeostasis (Guerra et al.,
2001). Thus the insulin receptor has been assigned a number of specific roles in
various different tissues.
1.2.2 The insulin receptor substrates
A number of substrates of the insulin receptor have been identified including the
insulin receptor substrate (IRS) proteins 1-4, Gab-I, CbI and She (Patti and Kahn,
1998) which act to link the insulin receptor to a number of signalling pathways (see
figure 1.5). The juxtamembrane region of the insulin receptor (see figure 1.6) is
thought to be of importance in substrate (IRS protein) binding. At least one tyrosine
residue in this region (Tyr 960), lying within an NPXY motif (where X is any amino
acid), is known to be auto-phosphorylated on ligand binding. Mutation of this residue
was reported to interfere with downstream signal transduction (White et al., 1988),
presumably due to disruption of substrate (e.g. IRS-I) binding.
IRS-l is a large (180 kDa) cytosolic protein, which contains 21 potential tyrosine
phosphorylation sites and also contains over 30 potential serine/threonine
phosphorylation sites (White and Kahn, 1994). At least 8 of these tyrosine residues
are phosphorylated by the activated insulin receptor (Sun et al., 1993). The
phosphorylated tyrosine residues on IRS-l then act as 'docking sites' for proteins
containing SH2 (src homology 2) domains. Many of the SH2 domain-containing
proteins are adapter molecules (for example, the p85 subunit of PI3-kinase, and Grb
2) which act to recruit other downstream signalling molecules to the complex.
The IRS proteins are highly homologous and various studies have been performed to
delineate the roles of the individual proteins. Knockout mice have been created
16
which lack IRS-l (Tamemoto et al., 1994, Araki et al., 1994). IRS-I-I- mice were
smaller than their control littermates at birth and this growth retardation continued
into post-natal development. Deletion of IRS-l caused peripheral insulin resistance
and glucose intolerance and the mice also exhibited hyperinsulinaemia. In the
absence of IRS-I, IRS-2 became tyrosine phosphorylated and bound PI3-kinase in
response to insulin (Araki et al., 1994). In mice lacking IRS-2 the diabetic phenotype
was much more severe (Withers et al., 1998). IRS-2-1- mice were only around 10%
smaller than their wild type littermates (a difference which persisted throughout their
development). However, IRS-2-1- mice exhibited insulin resistance in skeletal muscle
and liver, fasting hyperglycaemia and glucose intolerance. IRS-2-1- mice had
significantly reduced ~-cell mass and due also to the presence of insulin resistance,
development of severe diabetes ensued (Withers et al., 1998). In contrast to the
increased PI3-kinase activity associated with IRS-2 in the IRS-l null mice, a 50%
reduction in insulin stimulated PI3-kinase associated IRS-l was observed in the IRS-
2 null mice (Withers et al., 1998). Therefore, whilst the roles of IRS-l and IRS-2
overlap somewhat they also appear to be distinct. For example there is a greater
requirement for IRS-l than IRS-2 for embryonic and post-natal growth. IRS-2 on the
other hand is required to prevent development of diabetes by regulation of ~-cell
mass and in shaping insulin responsiveness of the peripheral tissues. In contrast to
the phenotypes of the IRS-l and IRS-2 null mutants, mice lacking functional IRS-3
showed no abnormalities in growth, blood glucose or insulin levels (Liu et al., 1999).
IRS-4 null mice showed only mild defects in growth, reproduction and glucose
homeostasis (Fantin et al., 2000). This suggests there may be some redundancy in the
roles of IRS-3 and IRS-4, and recently it has been suggested that IRS-3 and IRS-4
may have roles in negative regulation of IRS-l and IRS-2 (Tsuruzoe et al., 2001).
1.2.3 Phosphoinositide 3-kinases
A number of growth factors (including insulin and IGF-l) activate phosphoinositide
3-kinases (pI3-kinases), leading to a rise in 3-phosphorylated inositol lipids in the
cell (Vanhaesebroeck et al., 1997). These lipids are thought to act as intracellular
signalling molecules, which activate downstream signalling cascades.
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PI3-kinase was originally identified as a PtdIns (phosphatidylinositol) kinase activity
associated with viral oncoproteins and was reported to have a role in cell
transformation (Cantley et al., 1991). PI3-kinases catalyse the phosphorylation of the
D-3 position of the inositol ring resulting in the formation ofPtdIns(3)P from PtdIns,
PtdIns(3,4)-P2 from PtdIns(4)P and PtdIns(3,4,5)P3 from PtdIns(4,5)P2 (Whitman et
al., 1988, Auger et aI., 1989, Carpenter et al., 1990) (see figure 1.7).
Ptd Ins (3)-P
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Figure 1.7 Pathways of phosphatidylinositol metabolism
PI3-kinases exist as heterodimers consisting of one regulatory and one catalytic
subunit. The p85(reulatory)/pllO(catalytic) dimer was the first PI3-kinase to be
purified and characterised (Carpenter et al., 1990) and subsequently a number of
isofonns of both the catalytic and regulatory subunits have been identified, the
mammalian isofonns of which are detailed in table 1.2. The PI3-kinase catalytic
subunits have been subdivided into 3 main classes on the basis of their lipid substrate
specificity, structure and regulation (reviewed in Vanhaesebroeck et al., 1997). Class
I PI3-kinases phosphorylate PtdIns, PtdIns(4)P, and PtdIns(4,5)-P2 with PtdIns(4,5)-
P2 likely being the preferred substrate, and are further subdivided according to the
adapter subunits with which they interact. Class lA PI3-kinases interact with adapter
proteins that contain SH2 domains and mediate interactions with phosphorylated
tyrosine residues. Class IB PI3-kinases are stimulated by G-protein py subunits and
do not interact with SH2 domain containing adapter proteins. Class II PI3-kinases
phosphorylate PtdIns, PtdIns(4)P, but not PtdIns(4,5)-P2 in vitro and class III PI3-
kinases use only PtdIns as a substrate.
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It is likely that class lA PI3-kinases (e.g. a p85a-p 11Oo heterodimer) are the major
PI3-kinases activated in response to insulin and IGF-1. The regulatory p85 subunits
binds phosphorylated tyrosine residues on IRS proteins which have been recruited to
the activated receptor. Adapter protein binding is facilitated by two SH2 domains,
which recognise phosphorylated tyrosine within the sequence YxxM (where x is any
amino acid), and it is reported that engagement of both SH2 domains is required for
recruitment and activation of PI3-kinase (Ottinger et aI., 1998). The p85 regulatory
subunit also contains an SH3 domain, a proline rich region and a break point cluster
(BeR) homology domain (BH) the roles of which are ill defined. The shorter forms
of the regulatory molecules (e.g. p55 and p50) also contain two SH2 domains and
have the ability to recruit catalytic subunits to proteins containing phosphorylated
tyrosine residues. However they lack the SH3 and BH domains, but the functional
significance of this is unknown (Shepherd et aI., 1998). The class lA catalytic
subunits contain the kinase domain and a p85-binding domain. It is likely that the
adapter mediated translocation of the PI3-kinase catalytic subunit functions to bring
the catalytic region into close proximity with its substrates, which reside in the
plasma membrane.
CLASS CATALYTIC REGULATORY
lA p110a p85a
p110~ p85~
p1108 p55a
p55y
p50a
IB p110y p101
II p170 -
III - p150
Table 1.2 Mammalian PI3-kinase isoforms (adapted from Vanhaesebroeck et
aI., 1997)
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•PtdIns(3,4,5)P3 is suggested to be the major product formed by class lA PI3-kinases
in response to growth factors (Stephens et al., 1991) with PtdIns(4,5)P2 being
produced as a breakdown product. This lipid product is thought to play a role in
downstream signalling, for example, increases in PtdIns(3,4,5)P3 have been shown to
occur before activation of downstream signalling events (van der Kaay et al., 1997).
Furthermore, the PI3-kinase inhibitors wortmannin and LY294002 were reported to
block PtdIns(3,4,5)P3 production and subsequent activation of downstream processes
(Yeh et al., 1995).
It has been suggested that the lipid signal is turned off by a tumour suppresser protein
called PTEN (Leslie and Downes, 2002). PTEN is reported to dephosphorylate
several phosphoinositides in the D-3 position, but PtdIns(3,4,5)P3 is suggested to be
the most physiologically relevant (Leslie and Downes, 2002). In PTEN null cells,
elevated levels of PtdIns(3,4,5)P3 have been detected concomitant with increased
PKB activity (Stambolic et al., 1998). Lipid phosphatases have also been identified
which remove phosphates from the D-5 position of inositol lipids, e.g. SHIP and
SHIP2. SHIP2 is widely expressed, and is thought to metabolise PtdIns(3,4,5)P3 to
produce PtdIns(3,4)P2. SHIP2 has been suggested to have a role in insulin sensitivity
as SHIP2 null mice have increased insulin sensitivity and glucose tolerance (Clement
et al., 2001).
It is generally accepted that activation of PI3-kinase is required to promote GLUT 4
translocation and increased glucose transport in response to insulin. Activation of
PI3-kinase can be blocked by the use of inhibitors such as wortmannin and
LY294002 and these compounds have been shown to inhibit GLUT 4 translocation
and glucose transport (Okada et al., 1994, Cheatham et al., 1994). In addition to this,
the presence of a constitutively active PI3-kinase p 110 subunit caused translocation
of GLUT 4 (Tanti et al., 1996). However, it has been suggested that pathways
independent of PI3-kinase may also be necessary to activate GLUT 4 translocation
and increase glucose transport (see section 1.2.7.3). For example, PDGF stimulates
PI3-kinase activity to a similar extent as insulin, however PDGF does not
significantly increase glucose transport (Wiese et al., 1995).
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1.2.4 Protein Kinase B
Phosphoinositide signals are received by molecules which contain phosphoinositide
binding domains, for example PH (pleckstrin homology) domains and FYVE
domains (reviewed in Itoh and Takenawa, 2002). PH domains are around 100
residues in size, and proteins containing a PH domain have been shown to bind a
variety of phospholipids, while FYVE domains bind solely to PtdIns(3)P. One
molecule which is known to be regulated by insulin (via activation of PI3-kinase and
production ofPtdIns(3,4,5)P3) is PKB (protein kinase B).
PKB is the cellular homologue of the product of the oncogene v-akt, of the acutely
transforming retrovirus AKT8, found in a rodent T-cell lymphoma (Bellacosa et aI.,
1991). The PKB family contains 3 isoforms, PKBa (also called Aktl), PKB~ (Akt2)
and PKBy (Akt3), which display greater than 80% sequence identity. PKBa and
PKBP are expressed ubiquitously in cells, with PKBy being expressed at highest
levels in brain and testis. Each isoform consists of an N-terminal PH domain and a
kinase domain (see figure 1.8).
Activation of PKBa requires phosphorylation of two residues (Alessi et aI., 1996),
Thr-308, which lies in the T-Ioop of the kinase domain and Ser-473, which lies in the
C-terminal region of the molecule. PKBP is also activated by dual phosphorylation
on residues equivalent to those in PKBa (Thr-309 and Ser-474), while PKBy lacks
the C-terminal extension, and activation occurs only by phosphorylation of the
residue equivalent to Thr-308 in PKBa (Thr-305 in PKBy) (Alessi and Cohen, 1998)
(see figure 1.8).
PDKI (phosphoinositide dependent protein kinase-I) has been identified as the
kinase that phosphorylates PKBa on Thr-308 (Alessi et aI., 1997). Stokoe et aI.
(1997), reported that PtdIns(3,4,5)P3 has a dual role in regulation of PKB function.
Inositide binding to the PH domain of PKB was reported to recruit PKB to the
membrane, and also cause a conformational change, allowing access ofPDKl to the
Thr-308 residue, and phosphorylation to occur, thus stimulating PKB activity. PDKI
is likely also targeted to the plasma membrane by phosphoinositides, via an
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interaction with its PH domain. The kinase that phosphorylates Ser-473 is yet to be
identified, but has been tentatively named PDK2 (Alessi et al., 1997).
Thr-308
PKBu PH domain
PKBj3
Thr-309
Thr-305
PKBy PH domain
Figure 1.8 Domain structure of PKB isoforms (adapted from Alessi et al.,
1997)
Despite the fact the PKB proteins exhibit distinct similarities in protein structure and
cellular expression patterns, studies in which knockout mice have been generated
which lack either the PKBu or PKBP protein suggest very distinct roles for these
proteins. Mice lacking PKBP (Cho et al., 2001a) were reported to develop some
features of Type 2 diabetes. PKBP null mice displayed mild hyperglycaemia and
hyperinsulinaemia and became mildly glucose intolerant. They also displayed mild
insulin resistance in adipocytes and some skeletal muscles, elevated hepatic glucose
output and increased p-cell mass, consistent with compensation for insulin resistance
(Cho et al., 2001a). Thus the authors propose PKBP is essential for the maintenance
of normal glucose homeostasis, but the effects observed were all fairly mild,
suggesting other proteins function in pathways similar to or in parallel with PKBP in
regulation of glucose homeostasis. However, mice lacking PKBu did not develop a
diabetic phenotype. PKBu null mice had normal blood glucose and normal serum
insulin levels (Cho et al., 2001a, Chen et al., 2001). Conversely, mice lacking
functional PKBa exhibited defects in both foetal and post-natal growth (Cho et al.,
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2001b, Chen et al., 2001) with a number of mice dying within three days of birth and
the surviving animals were around 20% smaller than control littermates (Cho et al.,
2001b).
As PKB has a number of downstream targets (see figure 1.5) with various cellular
functions, it may be that each isoform exists to transmit signals to specific substrates,
thus 'personalising' the response to a specific growth factor or hormone.
One of the downstream functions of PKB is suggested to be activation of GLUT 4
translocation although how this occurs is rather ambiguous. Expression of
constitutively active PKB has been reported to increase glucose uptake and GLUT 4
translocation (Kohn et aI., 1996), suggesting PKB functions to regulate GLUT 4
translocation. It has also been reported that insulin causes the recruitment of PKB to
GLUT 4 storage vesicles (Calera et aI., 1998), however the exact mechanism by
which PKB activates GLUT 4 translocation and glucose uptake is unknown.
1.2.5 PKCs and insulin action
Members of the mammalian protein kinase C (PKC) superfamily have been
implicated in a range of cellular processes. They transduce a variety of signals
mediated by phospholipid hydrolysis, with the key 'on' switch for most PKCs being
diacylglycerol (DAG). A number of PKC isoforms have been implicated in insulin
action. For example, some PKCs are suggested to be downstream targets for signals
generated by the insulin receptor, whilst others have been suggested to function as
negative feedback inhibitors of the insulin receptor and IRS proteins.
The PKCs are a family of serine/threonine kinases comprised of at least 11 members
(see table 1.3) in mammals (and many non-mammalian isoforms have also been
identified). The isoforms have been further subdivided (conventional, novel and
atypical PKCs) on the basis of their enzymatic properties (Mellor and Parker, 1998)
(see table 1.3).
The conventional PKC subfamily consists of the a., PI, PH (the PKC P gene IS
alternatively spliced, and produces 2 gene products which differ only at the extreme
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C-tenninus) and y isotypes. They are activated by phosphatidyl serine (PS) in a
Ca2+-dependent manner, and also bind DAG, increasing the specificity for PS and
shifting the affinity of Ca2+ into the physiological range. Conventional PKCs are
activated by the phorbol ester PMA, which eliminates the requirement for DAG and
decreases the concentration of Ca2+ needed for activation. The novel PKC subfamily
is comprised of the E, n, 8 and e isotypes which are Ca2+-insensitive, but are
activated by DAG or phorbol esters in the presence of PS. The atypical subfamily
consists of the t , ')...and S isofonns. These are also Ca2+-insensitive, and do not
respond to phorbol esters or DAG (Mellor and Parker, 1998).
Under basal conditions PKCs exist in a folded state in which a pseudosubstrate
sequence in the N-tenninal regulatory domain interacts with the substrate-binding
site in the catalytic domain of the protein, thus inhibiting the protein (Farese, 2002).
On activation of the protein a conformational change occurs and this auto-inhibition
is relieved, possibly allowing activation of the protein by phosphorylation by other
kinases and by autophosphorylation (Farese, 2002).
SUBFAMILY ISOFORMS REGULATION
Conventional a, PI. PII, and y Activated by PS and DAG
Ca2+-dependent
Novel E, n, 8 and e Activated by PS and DAG
Ca2+-insensitive
Atypical t , ')...and S CaH -insensitive
Not responsive to phorbol esters or DAG
Possibly activated by polyphosphoinositides
Table 1.3 The PKC family
Insulin stimulation of a variety of cell types and tissues results in a number of PKC
isofonns being translocated to the plasma membrane and/or activated. However, it is
suggested that the activation of the atypical PKCs, (PKC ~, and PKC ')..)\) is
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important for increased glucose uptake (Bandyopadhyay et al., 1997a,
Bandyopadhyay et al., 1997b, Standaert et al., 1997). Standaert et al. (1997) reported
that insulin stimulation of PKC e; was PI3-kinase dependent and resulted in PKC e;
autophosphorylation, an action which could also be mimicked by phosphoinositides
(PtdIns(3,4)P2, PtdIns(3,4,5)P3 and PtdIns(4,5)P2). Furthermore, PKC e;
phosphorylation in the activation loop was reported to be mediated by PDKI (Le
Good et al., 1998, Chou et al., 1998), suggesting PKC e; is regulated in a manner
similar to PKB.
Whilst the conventional and novel PKCs are also thought to be activated by insulin,
it is suggested that they function primarily in feedback inhibition of the insulin
receptor and IRS proteins (Letiges et al., 2002). It has also been reported that, while
PKC e; functions downstream of PI3-kinase, it may also function in a feedback loop
to IRS-I. In NIH-3T3 cells, PKC e; was shown to phosphorylate IRS-I, this
phosphorylation was accompanied by impaired IRS-I-associated PI3-kinase activity
(Ravichandran et al., 2001). Thus, while PKCs are implicated in propagating the
insulin signal, they may also function in a feedback inhibition loop, to down-regulate
the insulin signal.
1.2.6 Regulation of glycogen metabolism by insulin
1.2.6.1 Insulin inactivates GSK-3
GSK (glycogen synthase kinase)-3 was identified in 1980, as a kinase that
phosphorylates and inactivates glycogen synthase (Embi et al., 1980). Insulin was
subsequently reported to inhibit glycogen synthase by a mechanism that involved
phosphorylation of GSK-3 (Cross et aI, 1994), and the kinase mediating
phosphorylation and inactivation of GSK-3 was identified as PKB (Cross et al.,
1995).
Two isoforms of GSK-3 exist, GSK-3a and GSK-3p, which are ubiquitously
expressed in mammals. The proteins exhibit 97% sequence similarity in the kinase
domain, but vary significantly out-with this region, with GSK-3a having a glycine
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rich N-terminal extension (Frame and Cohen, 2001). The residues phosphorylated by
PKB in GSK-3, mediating inhibition of the protein, were identified as Ser 21 in
GSK-3a and Ser 9 in GSK-3~ (Cross et al., 1995).
GSK-3 has numerous substrates, including glycogen synthase, eIF2B (see section
1.1.8.3) and ATP citrate-lyase. GSK-3 appears to use a unique mechanism for
substrate recognition. It requires that many of its substrates are first phosphorylated
by another kinase before it can undertake phosphorylation of the substrate - it
requires a 'priming' phosphate to be present (Cohen and Frame, 2001). This priming
phosphate lies four residues C-terminal to the site of GSK-3 phosphorylation, and in
the case of glycogen synthase is phosphorylated by casein kinase 2 (Frame and
Cohen, 2001). It is this substrate specificity which is utilised by insulin and other
growth factors in regulation of GSK-3 activity. When the N-terminal serine residue
of GSK-3 is phosphorylated by PKB, this N-terminus can then act as a
pseudo substrate. The pseudosubstrate region is reported to interact with the residues
involved in binding the priming phosphate, thus inhibiting the activity of GSK-3 by
preventing substrate binding and blocking access to the catalytic site (Frame et al.,
2001).
1.2.6.2 Glycogen synthesis
Glycogen synthesis is performed by three enzymes: glycogenin which forms short
primer glycogen chains, glycogen synthase which extends the glycogen chains and a
branching enzyme, which makes branches on an elongated glycogen chain (Bollen et
al., 1998). Glycogen synthase performs the bulk of the glycogen synthesis,
transferring glucose units onto the growing glycogen chain, using UDP (uridine
diphosphate)-glucose as the glucosyl donor. Glycogen synthase is subject to
regulation by allosteric effectors for example, glucose 6-phosphate is a potent
allosteric activator of glycogen synthase, and by phosphorylation (phosphorylation
causing a decrease in activity of the protein). The muscle isoform has at least nine
phosphorylation sites that may be phosphorylated by multiple protein kinases, at
least seven of which are located in the C-terminus of the molecule (Lawrence, Jr. and
Roach, 1997). GSK-3 is reported to phosphorylate glycogen synthase at three serine
residues, termed sites 3a, 3b and 3c (Rylatt et al., 1980), causing its inactivation, an
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effect which is inhibited by insulin (Parker et al., 1983). It is suggested that insulin
may also function to increase the activity of glycogen-targeted phosphatases that
function to dephosphorylate glycogen synthase (Newgard et al., 2000).
1.2.6.3 Glycogen breakdown
Glycogen is degraded by the action of phosphorylase and debranching enzyme
(Bollen et al., 1998). Phosphorylase liberates glucose l-phosphate from the glycogen
chain (in the presence of inorganic phosphate), the glucose I-phosphate being
converted to glucose 6-phosphate by phosphoglucomutase, for entry into glycolysis.
Glycogen phosphorylase is subject to regulation by allosteric effectors, for example,
glucose and glucose 6-phosphate are allosteric inhibitors of phosphorylase, and by
phosphorylation (Browner and Fletterick, 1992). Phosphorylase exists in two forms:
phosphorylase a, which is active and phosphorylase b, which is usually inactive (in
muscle phosphorylase b is active only in the presence of high levels of AMP).
Phosphorylase b is phosphorylated by phosphorylase kinase which, converts it to
phosphorylase a, the active form of the enzyme. Dephosphorylation by PP! returns
the enzyme to the inactive conformation (Browner and Fletterick, 1992). It IS
possible that insulin inhibits glycogen phosphorylase activity by activating PP1.
1.2.7 The role of caveolae in insulin signalling
1.2.7.1 Caveolae, structure and function
Cavoelae are flask-like invaginations in the plasma membrane, which are around 50-
100 nm in diameter. Caveolae may also fuse forming larger structures with sizes
significantly larger than 100 nm (Smart et al., 1999). Caveolae are a subtype of lipid
microdomain referred to as 'lipid rafts' and are abundant in various cell types,
including adipocytes (Mastick et al., 1995), endothelial cells (Lisanti et al., 1994),
and muscle cells (Chang et al., 1994). Lipid rafts are resistant to solubilisation in cold
non-ionic detergents and hence are often referred to as detergent resistant membranes
or DRMs (Simons and Toomre, 2000). The detergent insolubility of lipid rafts has
greatly facilitated their biochemical characterisation.
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Caveolae are enriched in cholesterol and sphingolipids (sphingomyelin and
glycosphingolipids). The cholesterol and sphingolipids form a liquid ordered phase,
that has a higher melting temperature (Tm) than phospholipid rich domains, and are
resistant to detergent solubilisation (Brown and London, 1997). Depending on the
cell type, caveolae reportedly contain up to 30% of plasma membrane cholesterol
and as much as 95% of cellular sphingomyelin, indicating that these lipids are highly
enriched within caveolar microdomains of the plasma membrane. Caveolae are also
enriched in a number of signalling lipids including Ptdlns( 4,5)P2, ceramide and
diacylglycerol. It is thought that the precise lipid composition of caveolae is likely to
be different in distinct cell types, and that altering lipid composition may be a way of
regulating caveolar function (Smart et aI., 1999).
Caveolin is the major structural protein of caveolae and it belongs to a caveolin
family of 21-25 kDa proteins. Molecular cloning has identified 3 caveolin genes
(caveolin-1, -2 and -3) from which 4 caveolin proteins are transcribed: caveolin-1a
and -1p are derived from alternative initiation during translation. Caveolin-1 and -2
are predominantly expressed in adipocytes, endothelial cells and fibroblasts, and
caveolin-3 is muscle specific (Okamoto et al., 1998). Caveolin proteins interact to
form homo- and hetero-oligomers that bind directly to cholesterol. Caveolin-l has a
central hydrophobic domain (residues 102-134) which is thought to associate with
the membrane, with both the N- (residues 1-101) and C- (residues 135-178) termini
being completely cytosolic (Okamoto et al., 1998). A region (residues 82-101) within
caveolin-1 has been named the scaffolding domain, as it is required for interaction
with various caveolar signalling molecules. This scaffolding domain has been shown
to interact directly with eNOS (endothelial nitric oxide synthase) (Ju et al., 1997),
wild-type Src (c-Src) (Li et al., 1996), a-subunit ofG-proteins (Li et al., 1995), and a
number studies suggest that this interaction with caveolin-1 scaffold domain causes
inactivation of these proteins. Other caveolin interacting proteins include Ha-Ras,
many Src-family tyrosine kinases, the EGF receptor and related receptor tyrosine
kinases, PKC isoforms and the insulin receptor (Anderson, 1998). Therefore, the role
of caveolae may be to concentrate various signal transducers within a distinct region
of the plasma membrane, and functionally regulate their activation state.
28
To further define the function of caveolae/caveolin, mice deficient in caveolin-I have
been produced (Razani et al., 2001, Drab et al., 2001). Caveolin-I null mice are
viable, but lack caveolae. Expression of caveolin-2 protein is reduced, and the
remaining caveolin-2 is retained in an intracellular compartment (Razani et aI.,
2001), suggesting the presence of caveolin-l is required for caveolin-2
oligomerisation and plasma membrane localisation. Caveolin-I is expressed at high
levels in lung tissue and these caveolin-l knockout mice displayed various lung
abnormalities including endothelial cell hyperproliferation and thickening of the
alveolar septa, which resulted in a reduction in physical ability (Razani et al., 2001,
Drab et aI., 2001). eNOS has been suggested to be inhibited by caveolin-I and in
caveolin-l-I-mice nitric oxide release was increased, due to an increase in eNOS
activity (Razani et aI., 2001) and abnormalities in calcium signalling were observed
in the cardiovascular system (Drab et aI., 2001). Caveolin-l null mice have a
tendency to be smaller than their wild type littermates and were shown to be resistant
to diet induced obesity (Razani et aI., 2002a). They were shown to have smaller fat
pads, although levels of serum insulin, glucose and cholesterol were all normal.
However, caveolin-I deficient mice have elevated triglycerides and free fatty acids,
although lipoprotein lipase activity was normal. Hence the authors propose a role for
caveolin-l in lipid homeostasis.
To dissect any functional differences between caveolin-I and caveolin-2, caveolin-2
null mice were created. In these mice caveolae still form with little change in
expression of caveolin-I protein observed (Razani et aI., 2002b) unlike in the
caveolin-I knockout where caveolin-2 expression was greatly reduced. Caveolin-2
mice exhibit similar lung abnormalities to those reported for the caveolin-l knockout
and the authors suggest the lung abnormalities observed in the caveolin-l knockout
are likely due to the concomitant decrease in caveolin-2 expression and suggest a
specific role for caveolin-2 in pulmonary function.
Mice deficient in caveolin-3 have also been created (Galbiati et aI., 2001). Caveolin-
3 is muscle specific and associates with dystrophin and dystrophin-associated
glycoproteins and in humans mutations in caveolin-3 have been reported to result in
development of a form of limb girdle muscular dystrophy (Volonte et aI., 1999).
Caveolin-3 null mice were shown to lack sarcolemmal caveolae and the loss of
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caveolae from muscle cells resulted in loss of the dystrophin-glycoprotein complex
from lipid raft domains and alterations in T-tubule organisation. Thus, caveolin-3 is
required to maintain the integrity of the skeletal muscle architecture.
1.2.7.2 Insulin receptors are localised in, and signal from, caveolae
Insulin receptors are localised in caveolae by interaction with caveolin, but unlike a
large number of proteins that are sequestered and inactivated in caveolae, it has been
suggested that the insulin receptor is positively modulated by caveolar association. In
1999, Gustavsson and colleagues showed using immunogold electron microscopy
and immunofluorescence microscopy, that insulin receptors are highly enriched in
caveolae, and co-localise with caveolin in the plasma membrane of adipocytes. They
reported that insulin receptors are functional in caveolae and indeed suggested that
signalling through the insulin receptor was dependent upon caveolar association.
This work supported previous studies showing that the insulin receptor co-
fractionates with caveolae (Yamamoto et al., 1998) and that caveolin is an activator
of the insulin receptor (Yamamoto et al., 1998). It has recently been reported that the
insulin receptor catalyses the phosphorylation of caveolin-l on tyrosine 14 (Kimura
et al., 2002) although the functional significance of this is not yet understood.
1.2.7.3 The CAP-Cbi pathway of insulin signalling
For a number of years investigators believed that activation of PI3-kinase was the
major or only pathway required to promote insulin-stimulated GLUT 4 translocation
to the plasma membrane. For example, blocking PtdIns(3,4,5)P3 generation by PI3-
kinase prevented this insulin-stimulated GLUT 4 translocation (Cheatham et al.,
1994, Sharma et al., 1998). However, a number of studies suggested that activation
of PI3-kinase dependent and independent mechanisms may be required for increased
glucose transport to occur. For example, inhibition of insulin stimulated IRS-PI3-
kinase complex formation does not necessarily inhibit glucose uptake (Sharma et al.,
1997), and in adipocytes, stimulation of integrin receptors mimics insulin action by
recruiting PI3-kinase to IRS proteins, and activates the downstream effector PKB,
without effecting GLUT 4 movement (Guilherme and Czech, 1998).
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Thus, it was hypothesised that PI3-kinase independent pathways exist and Baumann
and colleagues (2000) recently identified components of such a pathway (see figure
1.5). The pathway suggested involves the recruitment of an adapter protein, APS, to
the activated insulin receptor. APS in turn recruits a protein called CbI (Liu et aI.,
2002) and CbI associated protein (CAP). CbI is phosphorylated on recruitment to the
insulin receptor. On phosphorylation of CbI, the CAP-CbI complex translocates to a
lipid raft domain (Baumann et aI., 2000), the translocation being mediated through
the interaction of the sorbin-homology domain of CAP with flotillin, a protein
enriched in lipid rafts, (Kimura et aI., 2001). This localisation is likely to be needed
for activation of glucose transport as a CAP deletion mutant that does not interact
with flotillin (CAP~SoHo) prevents insulin stimulated glucose transport (Kimura et
aI., 2001). CbI is reported to recruit the CrkII-C3G complex to the lipid raft domain
(Chiang et aI., 2001), CrkII is an adapter protein, and C3G a guanine nucleotide
exchange factor. C3G activates the small GTP-binding protein TC10, a process
which is independent of PI3-kinase activation (Chiang et aI., 2001). The authors
report activation of TC10 to be essential for insulin-stimulated glucose uptake and
GLUT4 translocation. They also suggest this pathway functions in parallel with the
PI3-kinase pathway to stimulate GLUT 4 translocation in response to insulin. Further
studies on TC10 (Chiang et aI., 2002) suggest a role in the regulation of cortical actin
structure, which may have a role in movement of GLUT 4 vesicles. A recent report
details the identification of a TC10 interacting protein (CIP4/2), which is also
required for insulin-stimulated GLUT 4 translocation (Chang et aI., 2002). The
functional significance of this interaction is not known, however CIP4/2 is suggested
to act as an adapter protein, recruiting additional molecules to the plasma membrane
in response to insulin, which may influence the trafficking of GLUT 4 vesicles
(Chang et aI., 2002).
1.2.8 Mitogenic actions of insulin
The insulin-regulated proteins described thus far are mainly involved in the actions
of insulin to increase glucose uptake into the cell. However, insulin also acts to
increase cell proliferation and protein synthesis.
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1.2.8.1 Signalling via the MAP kinase pathway
p42/44 mitogen activated protein (MAP) kinases (ERK2IERK1) are ubiquitously
expressed in mammalian cells and activation results from a number of external
stimuli. Activation of the MAP kinase pathway occurs via the adapter protein Grb2,
which is recruited to the activated insulin receptor via an interaction with IRS-1
(Skolnik et al., 1993). Alternatively Grb2 can be recruited through an interaction
with She, a 60 kDa adapter molecule which is a substrate for the insulin receptor
kinase (Goalstone and Draznin, 1998). Grb2 recruits the guanine nucleotide
exchange factor SOS to the activated receptor, via an interaction of the SH3 domain
of Grb2 with a proline rich region in SOS. Recruitment of Grb-2/S0S to the plasma
membrane brings the complex into close proximity to the small G-protein Ras, a
substrate of SOS. SOS promotes the exchange of GDP for GTP on Ras, thus
promoting the active conformation of the molecule. Ras binds the serine/threonine .
kinase Raf 1 (Vojtek et al., 1993) and is thought to modulate the activity of the
kinase. Raf 1 phosphorylates and activates MEK (MAP kinase kinase) (Kyriakis et
al., 1992). MEK is a dual specificity kinase with serine/threonine and tyrosine kinase
activity, which acts to phosphorylate and activate ERK 1 and ERK 2 (P42/44 MAP
kinases), as depicted in figure 1.5.. MAP kinase phosphorylation and activation
results in phosphorylation of their substrate proteins including the Ser/Thr kinase,
p90 ribosomal S6 kinase (p90RSK) (Sturgill and Wu, 1991) and the transcription
factors c-Myc and c-Jun (Pulverer et al., 1991).
1.2.8.2 Signalling through mTOR
mTOR (mammalian target ofrapamycin) is a large protein (290 kDa) which has been
assigned to a family of protein kinases called the phosphatidylinositol kinase-related
kinases (PIKKs). mTOR has been shown to have homology with lipid kinases,
although no lipid kinase activity has been identified in the protein (Brown et al.,
1995), however the protein is known to be a Ser/Thr kinase. Homologous proteins
have also been identified in yeast (TORI and TOR2) and Drosophila (dTOR)
(Raught et al., 2001).
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mTOR is reported to be regulated by insulin, in that insulin treatment increased the
activity of mTOR (Scott et al., 1998). Additionally, mTOR was reported to be
downstream of PKB in the insulin-signalling pathway, and it was demonstrated that
PKB directly phosphorylated mTOR (Nave et al., 1999).
mTOR regulates a number of proteins that function in control of translation. mTOR
is reported to activate p70 S6 kinase (Brown et al., 1995). S6 is thought to function in
regulation of translation of 5'TOP (terminal oligopyrimidine) tract mRNAs, which
encode ribosomal proteins and elongation factors (Jefferies et al., 1997). mTOR also
functions to phosphorylate eukaryotic initiation factor (elF) 4E binding protein 1
(4E-BP1) and 2. eIF 4E has a key role in initiation of translation. When 4E-BPl is
hypophosphorylated it binds eIF 4E, thus preventing an interaction with the 5'cap
(Sonenberg and Gingras, 1998). Phosphorylation of 4E-BPI by mTOR, in response
to insulin, releases binding of elF 4E, allowing it to act in initiation of translation
(Proud et al., 2001). mTOR is also suggested to regulate the eukaryotic elongation
factor 2 (eEF2). Phosphorylation of eEF2 at Thr-56 inhibits its activity. In response
to insulin this residue is dephosphorylated, due to the decreased activity of an eEF2
kinase (Redpath et al., 1996), possibly due to phosphorylation by mTOR.
1.2.8.3 Regulation of protein synthesis by GSK-3
Insulin also promotes initiation of translation through regulation of GSK-3. GSK-3
phosphorylates and inhibits the eukaryotic initiation factor 2B (elF 2B). In the
presence of insulin, GSK-3 is inhibited, due to phosphorylation by PKB, thus elF 2B
becomes dephosphorylated and activated, allowing initiation of translation to occur
(Welsh et aI., 1998).
1.3 Activation of glucose transport in skeletal muscle
The majority of the insulin signalling pathways described above have been identified
in skeletal muscle. However, in skeletal muscle glucose transport is also activated by
muscle contraction, and insulin and contraction are reported to activate glucose
transport by distinct mechanisms. Thus it is appropriate to discus's these processes in
somewhat more detail.
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1.3.1 Skeletal muscle is composed of distinct fibre types
Skeletal muscle cells/fibres are long, multi-nucleated cells that may span the entire
length of the muscle and skeletal muscles are composed of different fibre types,
which have different contractile and metabolic properties. For example, skeletal
muscle fibres are traditionally characterised as slow or fast twitch. Slow twitch (type
I) fibres are rich in mitochondria and participate in oxidative phosphorylation whilst
fast twitch (type II) fibres typically have fewer mitochondria and perform anaerobic
glycolysis (Voet and Voet, 1995). Type II fibres are capable of a short burst of rapid
activity whereas type I fibres participate in more sustained activity.
Histochemical analysis of skeletal muscle reveals the presence of three fibre types
(Armstrong and Phelps, 1984): fast twitch oxidative glycolytic (FOG, type lIA), fast
twitch glycolytic (FG, type lIB) and slow twitch oxidative (SO, type I). Whole
muscles typically contain these fibres in varying quantities, for example rat soleus
muscle was reported to consist of 87% SO, 13% FOG and 0% FG fibres, whereas rat
EDL muscle was reported to contain 2% SO, 42% FOG and 56% FG fibres
(Armstrong and Phelps, 1984). However, it is known that changes in fibre type
composition can occur in skeletal muscle in the presence of changes in innervation,
electrical stimulation or mechanical factors (Daugaard and Richter, 2001).
One protein whose expression is shown to differ in skeletal muscle fibre types is the
insulin responsive glucose transporter, GLUT 4. GLUT 4 protein is expressed at
highest levels in type I compared to type II fibres (Daugaard and Richter, 2001).
GLUT 4 expression in muscle has also been shown to correlate with the ability of a
particular muscle to increase glucose uptake in response to insulin and contraction
(Henriksen et al., 1990). GLUT 4 expression in skeletal muscle has been reported to
correlate with physical activity, with inactivity reducing GLUT 4 content and
exercise increasing GLUT 4 content in various muscle fibre types (reviewed in
Daugaard and Richter, 2001).
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1.3.2 Role of the T-tubule system in skeletal muscle glucose transport
Skeletal muscle fibres are covered in a membrane known as the sarcolemma. The T-
tubule system is continuous with the sarcolemma and forms invaginations, which
penetrate deep into the centre of the muscle. T-tubules are suggested to function in
transmission of membrane depolarisation to the central part of the muscle and are
also hypothesised to function in delivering nutrients. such as glucose. deep into the
muscle body (Dohm and Dudek. 1998).
GLUT 4 has been reportedly localised to the T-tubule membrane using a variety of
techniques including immunogold labelling. using cell impermeable photolabels and
cell fractionation and membrane isolation techniques (reviewed in Dohm and Dudek.
1998). Furthermore. as shown in figure 1.9. GLUT 4 is reportedly recruited to the T-
tubule membrane in response to insulin and contraction (Munoz et al., 1995. Roy and
Marette. 1996). suggesting this organelle may indeed be the site of glucose uptake in
skeletal muscle.
1.3.3 Exercise-stimulated glucose transport
It is generally accepted that both insulin and exercise/contraction of skeletal muscle
cause an increase in glucose uptake into the muscle. However, it is believed that
these processes act independently and utilise distinct signalling pathways in order to
promote glucose uptake. It has been demonstrated that stimulation of skeletal muscle
with insulin and exercise/contraction produces additive effects on glucose transport
(Ploug et al., 1987, Wallberg-Henriksson et al., 1988). Insulin and contraction are
also reported to recruit GLUT 4 from distinct intracellular pools (Douen et al., 1990).
however the exact nature of these intracellular GLUT 4 compartments is not well
defined. Furthermore. contraction-stimulated glucose transport. unlike insulin-
stimulated glucose transport. is reported to be PI3-kinase independent. It has been
demonstrated that no change in skeletal muscle insulin receptor and IRS-l tyrosine
phosphorylation or PI3-kinase activity occurs in response to exercise/contraction
(reviewed in Hayashi et al., 1997 and Sakamoto and Goodyear. 2002). Additionally,
wortmannin (a PI3-kinase inhibitor) does not inhibit contraction-induced glucose
transport in skeletal muscle (Yeh et al., 1995). Therefore. studies of contraction
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induced glucose transport have focused on delineating the mechanisms responsible
for this process.
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Figure 1.9 The T-tubule system of skeletal muscle (taken from Hayashi et al.,
1997)
GLUT 4 is recruited to the T-tubules and the sacrolemmalplasma membrane III
response to exercise/contraction and insulin
1.3.3.1 Role of calcium in exercise-stimulated glucose transport
Calcium has a role in muscle contraction, in that on release from the sarcoplasmic
reticulum in response to membrane depolarisation, the concentration of intracellular
calcium increases causing stimulation of the contractile filaments, and the onset of
muscle contraction. Hence, calcium has been postulated to function in contraction-
stimulated glucose transport. It has been reported that agents which increase
intracellular calcium promote increased skeletal muscle glucose transport, whilst
agents that decrease intracellular calcium concentration prevent increases in muscle
glucose transport (reviewed in Hayashi et al., 1997 and Wojtaszewski and Richter,
1998). However, it is suggested that calcium ions do not directly activate glucose
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transport as increases in intracellular calcium concentration occur for only a very
short time, but increased glucose transport in response to contraction is sustained
over longer periods. Hence it is postulated that calcium acts to activate other factors
which will function over a prolonged period to increase glucose transport, for
example calcium-dependent PKCs have been implicated in contraction-stimulated
glucose transport (Hayashi et al., 1997).
1.3.3.2 Regulation of PKB and GSK-3 by exercise
Historically, the role of PKB in contraction-stimulated glucose transport has been
controversial, with some studies reporting no activation of PKB in response to
contraction and others suggesting some degree of activation in response to
contraction/exercise. However, one very recent study (Sakamoto et al., 2002) reports
that contraction does activate PKB in skeletal muscle. In this study in situ contraction
of five different hindlimb muscles was performed. Contraction was shown to
promote a rapid and transient activation of all three PKB isoforms (Sakamoto et al.,
2002). However, the function of PKB in regulation of contraction-stimulated glucose
transport is not known.
Like insulin, exercise has also been reported to inhibit the activity of GSK-3
(Markuns et al., 1999), but the mechanism of GSK-3 inhibition by insulin and
contraction is reportedly different. Insulin was reported to inhibit GSK-3 activity by
promoting its phosphorylation by PKB. Exercise was also reported to decrease GSK-
3 activity, but it did so without promoting phosphorylation of the protein (Markuns et
al., 1999). Again the function of GSK-3 inhibition by exercise is uncertain, but likely
involves increasing glycogen synthase activity (Sakamoto and Goodyear, 2002).
1.3.3.3 Role of AMPK in exercise-stimulated glucose transport
AMP-activated protein kinase (AMPK) has been postulated to act as a 'fuel gauge' in
monitoring cellular energy levels. When AMPK senses decreased energy levels in
cells it acts to switch off ATP-consuming process and switch on pathways of ATP
generation (reviewed in Winder, 2001). AMPK is comprised of3 subunits (a, ~ and
y), with two known a (al and (2) subunits, two ~ (~I and ~2)subunits and three Y (YI,
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12, and 13) subunits having been identified. All three subunits are required for
expression of full AMPK activity, and the various a, P and 1 subunits have been
found in a variety of combinations in different cell types. The a subunit is the
catalytic subunit and contains the protein kinase domain, whilst the P and 1 subunits
are regulatory components. In skeletal muscle the a2 isoform is more abundant than
the al isoform and whilst PI and P2 are both expressed in EDL muscle, only PI is
found in soleus muscle (Winder, 2001).
AMPK is activated allosterically by increasing concentrations of AMP and is
inhibited by ATP and creatine phosphate. In addition, AMPK is activated by
phosphorylation by the upstream kinase, AMPK kinase (Hawley et al., 1996), which
is also allosterically activated by AMP. AMPK and AMPKK can be artificially
activated using the compound 5-aminoimidazole-4-carboxamide-riboside (AICAR).
AICAR is taken up into cells and phosphorylated, thus forming the AMP analogue
ZMP, which activates AMPK and AMPKK without affecting the AMP:ATP ratio of
the cell.
AMPK is rapidly activated in skeletal muscle in response to various conditions of
metabolic stress, including contraction, hypoxia, and hyperosmolarity (Hayashi et aI.,
2000) which are all likely to alter the fuel status of the muscle. Specifically,
contraction has been reported to stimulate AMPK activity in rat skeletal muscle
using a variety of protocols including treadmill running and in situ muscle
contraction. The activation of AMPK in skeletal muscle has been suggested to be
dependent on work rate/load in that the greater the force generated by contraction or
the greater the intensity of the treadmill run, the greater the activation of AMPK is
observed (Sakamoto and Goodyear, 2002). Studies in human skeletal muscle have
also demonstrated activation of AMPK in response to exercise/contraction (Fujii et
al., 2000, Wojtaszewski et al., 2000).
AMPK was first suggested to have a role in contraction-stimulated glucose transport
in studies using AICAR, in which AICAR was shown to stimulate glucose transport
in perfused hindlimb skeletal muscle (Merrill et al., 1997). Since then various studies
have implicated AMPK in regulation of contraction-stimulated glucose transport by
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activation of AMPK using AICAR. For example AICAR has been shown to promote
glucose uptake in a manner similar to contraction in that the effects of insulin and
AICAR are partially additive in promoting the glucose transport response, while the
effects of AICAR and contraction are not (Hayashi et aI., 1998). Furthermore,
wortmannin was shown not to inhibit AICAR stimulated glucose transport (Hayashi
et aI., 1998). AICAR has been shown to promote GLUT 4 translocation in skeletal
muscle (Kurth-Kraczek et aI., 1999). However, no selective inhibitors of AMPK are
available, and it is possible that AICAR has other deleterious effects, in addition to
activation of AMPK. To address these issues studies have been undertaken using
dominant negative forms of AMPK. Expression of a dominant negative AMPK in
mouse skeletal muscle prevented the action of AICAR to increase glucose uptake
(Mu et aI., 2001). This dominant negative AMPK also reduced contraction-
stimulated glucose transport, but only partially, which the authors suggested implies
the presence of an AMPK-independent pathway leading to glucose uptake, which is
activated by contraction. The molecules that are downstream of AMPK in
contraction-stimulated glucose transport are unknown, however endothelial nitric
oxide synthase (eNOS) has been proposed as a target for AMPK (Fryer et al., 2000).
As discussed below, NO may have a role in regulation of contraction-stimulated
glucose transport in skeletal muscle.
1.3.3.4 Role of nitric oxide and eNOS in exercise-stimulated glucose transport
Nitric oxide (NO) functions in a range of cellular processes including neural
signalling, vasoregulation and the immune response (Reid, 1998). One of the main
actions of NO is activation of soluble guanylyl cyclase, resulting in production of
cGMP, leading to activation of a range of physiological responses (reviewed in
Schmidt et al., 1993), including vasodilation. Studies in the 1970's reported that
nitrite containing compounds (for example, nitroglycerin) stimulated guanylate
cyclase, promoting an increase in cGMP production, leading to vascular relaxation, a
phenomenon which was suggested to occur via the formation of NO (Katsuki et aI.,
1977). Later studies suggested that vessel relaxation, in response to a variety of
agonists, occurred due to the release of an endothelial derived relaxing factor
(EDRF) (Cherry et al., 1982). Subsequently, two groups independently identified
EDRF and NO as being the same molecule (Palmer et al., 1987, Ignarro et al., 1987).
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NO is produced by nitric oxide synthases (NOSs) with the net overall reaction being
conversion of L-arginine and molecular oxygen to form NO and L-citrulline. The
reaction occurs in the presence of the cosubstrate nicotinamide adenine dinucleotide
phosphate (NADPH) and the cofactors flavin mono-nucleotide (FMN), flavin
adenine nucleotide (FAD), tetrahydrobiopterin (BH4), haem and calmodulin (Reid,
1998). Three NOS isoforms have been identified. These include two proteins that are
expressed constitutively: neuronal NOS (nNOS), so called because it is highly
expressed in neuronal cells and endothelial NOS (eNOS), originally identified in
endothelial cells. The final enzyme (iNOS) is induced by various stimuli including
inflammatory cytokines. Each NOS isoform has a similar structure, shown in figure
1.10. They consist of a C-terminal reductase domain, containing binding sites for
FMN, FAD and NADPH and an N-terminal oxygenase domain, which contains
binding sites for L-arginine, BH4 and haem (Mayer and Hemmens, 1997). The
calmodulin-binding region is at the interface of the oxygenase and reductase
domains. The extreme N-terminal regions of the proteins are different and are
thought to be important for intracellular targeting (Mayer and Hemmens, 1997). NOS
proteins are reported to function as dimers and BH4 has been suggested to be
required for dimer formation (Fleming and Busse, 1999). Calcium-dependent
calmodulin binding is the primary regulator of NO synthesis by nNOS and eNOS,
whereas iNOS binds calmodulin with high affinity and is not regulated by calcium,
rather it is regulated primarily at the level of transcription (Reid, 1998). Once
calcium-calmodulin binds eNOS/nNOS, NADPH donates electrons to the reductase
domain. The electrons are subsequently shuttled through the calmodulin-binding
domain, towards the oxygenase domain, which may result in formation of NO
(Govers and Rabelink, 2001).
COOH
Oxygenase Reductase
Figure 1.10 Schematic diagram of nitric oxide synthase structure
The diagram depicts regions where substrates and cofactors bind the NOS proteins
CaM = calmodulin, Arg = L-arginine.
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Each of the NOS isofonns are reported to be expressed in skeletal muscle. nNOS is
expressed at highest levels in type II muscle fibres, whereas eNOS expression is
found in all fibre types and although iNOS is not expressed constitutively in skeletal
muscle it can be induced during the immune response (Reid, 1998). Skeletal muscle
was first reported to release NO by Balon and Nadler in 1994. They showed that
electrical stimulation of skeletal muscle increased this NO release and that a NOS
inhibitor, L-NMMA ~-monomethyl-L-arginine monoacetate), decreased NO
release and glucose uptake. A role for NO in regulation of glucose transport was
further suggested by subsequent studies showing NOS inhibition reduced basal and
exercise-stimulated glucose transport, but was without effect on insulin-stimulated
glucose transport (Balon and Nadler, 1997). In addition, the use of sodium
nitroprusside (SNP, a nitric oxide donor) increased glucose uptake in a dose-
dependent manner and chronic treadmill training of rats resulted in increased
expression of both eNOS and nNOS (Balon and Nadler, 1997). Studies in treadmill
run rats also demonstrated that an acute bout of exercise promoted increased NOS
activity (Roberts et al., 1999).
It has been suggested that increased NO production in skeletal muscle in response
contraction may involve AMPK (Fryer et al., 2000) through AMPK-mediated
phosphorylation and activation of eNOS, leading to NO production. In this study
NOS inhibitors were shown to block increased glucose transport in response to
AMPK activation. However, recent studies have cast some doubt over the
involvement of NO in contraction-stimulated glucose transport. In one study, the
effects of insulin and the NO donor SNP were shown to be fully additive in respect
to glucose uptake. However, addition of the NOS inhibitor L-NAME ~-nitro-L-
arginine methyl ester) to the drinking water of rats for two days had no effect on
glucose uptake in response to treadmill exercise (Higaki et al., 2001). Hence, the
authors suggest that NO stimulates glucose uptake using a mechanism that is distinct
from both the insulin and contraction signalling pathways.
1.3.3.5 Exercise effects insulin sensitivity in skeletal muscle
After a single bout of exercise insulin action is increased in the muscles which had
previously been active during the exercise period (reviewed in Wojtaszewski et al.,
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2002). Using one-legged exercising, it has been shown that this is a local response
and is restricted to the exercised muscles (Hayashi et al., 1997). The increase in
insulin action is reported to involve glucose transport, glycogen synthesis and amino
acid transport. This increased insulin sensitivity appears to be due to glycogen
depletion, which occurs in skeletal muscle during exercise (Wojtaszewski et al.,
2002). While the underlying mechanisms behind this phenomenon are not
understood, it is important due to the fact that physical activity will improve the
insulin sensitivity of insulin resistant/diabetic patients.
1.4 Diabetes, hypertension and insulin resistance
1.4.1 Diabetes
Diabetes is a disease that was once believed to be of minor importance to world
health, however diabetes is now considered to be a major cause of morbidity and
mortality worldwide. In the year 2000 it was estimated that around 150 million
people were affected by diabetes, a figure which is expected to double by the year
2025 (Zimmet et al., 2001).
There are two main forms of diabetes. Type 1 (insulin dependent) diabetes is an
autoimmune disorder in which the B-cells of the pancreas are destroyed, resulting in
loss of insulin secretion. People with type 1 diabetes require daily insulin injections
to regulate blood glucose levels and promote survival. Type 2 (non-insulin
dependent) diabetes is characterised by insulin resistance and/or abnormal insulin
secretion and is associated with a sedentary lifestyle and obesity. In type 2 diabetic
individuals, blood glucose concentration may be controlled by diet and exercise, but
where this is not the case, exogenous insulin may be required. The frequency of type
1 diabetes is low compared to type 2 diabetes, which accounts for around 90% of
cases (Zimmet et al., 2001). Development of type 2 diabetes accounts for the large
increase in diabetes observed in recent years and is primarily due to environmental
and behavioural factors including the sedentary lifestyle, fast-food culture and
increasing prevalence of obesity.
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Adults with diabetes have an increased mortality rate and their life expectancy is
decreased by around 5-10 years, which is due to development of microvascular
(retinopathy, nephropathy and neuropathy) and macrovascular (heart disease, stroke
and peripheral vascular disease) complications (Donnelly et al., 2000). Type 2
diabetes is also associated with the metabolic syndrome (or syndrome X), which is a
multifactorial disease that includes conditions such as glucose intolerance,
hyperinsulinaemia, dyslipidaemia, hypertension and obesity (Zimmet et al., 2001).
However, the primary cause leading to development of type 2 diabetes and metabolic
syndrome is unknown.
1.4.2 Hypertension in diabetes
Diabetes and hypertension are inter-related diseases which are frequently found to
coexist and it has been reported that type 2 diabetes is almost 2.5 times more likely to
develop in hypertensive patients, compared to normotensive subjects (Sowers et al.,
2001). The use of anti-hypertensive agents to lower blood pressure in diabetic
individuals was reported to reduce cardiovascular disease-related morbidity and
mortality in type 2 diabetic patients and in lowering microvascular and
macrovascular diabetic complications (Sowers et al., 2001). Furthermore, reducing
blood pressure in hypertensive individuals is also suggested to prevent the
development of diabetes (Sowers et al., 2001). The mechanisms by which
hypertension, and subsequently, diabetes develop are not understood, however it is
probable that genetic as well as environmental factors are involved (Donnelly and
Connell, 1992).
1.4.3 Molecular mechanisms of insulin resistance and diabetes
Insulin resistance can be described as a condition in which insulin's actions at the
peripheral tissues are impaired (Hunter and Garvey, 1998). Whilst this definition
could be applied to any of insulin's actions it is generally used to describe resistance
to insulin's effects on glucose transport. Insulin resistance is frequently accompanied
by hyperinsulinaemia, which occurs as the pancreatic ~ cells attempt to compensate
for reduced insulin sensitivity in the peripheral tissues. Insulin resistance is reported
to be the primary defect in type 2 diabetes and can lead to a variety of abnormalities
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that lead to development of obesity, hypertension, polycystic ovanan syndrome
(peDS) and dyslipidaemia and atherosclerosis (Saltiel, 2000).
Various studies have been undertaken in order to determine the cellular basis of
insulin resistance. It has been suggested that any defect is likely to occur in the
insulin signal transduction pathway, or in the trafficking, docking or fusion of the
GLUT 4 vesicle, with the plasma membrane (Hunter and Garvey, 1998). A number
of studies have identified genetic defects that are causes of human insulin resistance
syndromes. For example in many patients with type A severe insulin resistance,
mutations in the insulin receptor have been identified, leading to reduced tyrosine
kinase activity of the receptor (Hunter and Garvey, 1998). In contrast, mutations in
the insulin receptor, leading to reduced insulin binding have been reported to cause
leprechaunism, a syndrome that is also characterised by severe insulin resistance.
The hyperinsulinaemia associated with insulin resistance is suggested to have a role
in insulin-induced insulin resistance (Pessin and Saltiel, 2000). The high
concentration of circulating insulin is suggested to stimulate serine phosphorylation
of the insulin receptor ~ subunits, thus decreasing insulin receptor tyrosine kinase
activity. PKe is a kinase implicated in the process, as PKCs are activated in a
number of insulin resistant models (Pessin and Saltiel, 2000). Insulin resistance in
peDS is associated with hyperphosphorylation of the insulin receptor and a decrease
in insulin-stimulated tyrosine autophosphorylation and tyrosine kinase activity of the
receptor (Hunter and Garvey, 1998).
Defects in downstream signalling events have also been reported in insulin resistant
states. For example reduced IRS-l tyrosine phosphorylation and PI3-kinase activity
was observed in lean to moderately obese type 2 diabetics (Zierath et al., 2000) and
decreased association of PI3-kinase with IRS proteins in insulin resistant skeletal
muscle has also been reported (Pessin and Saltiel, 2000). Some reports also suggest
PKB phosphorylation is reduced in skeletal muscle from type 2 diabetic patients
however, other reports suggest this is not the case (Zierath et al., 2000), therefore a
role for PKB in insulin resistance has still to be confirmed.
Defects in GLUT 4 are also reported to result in insulin resistance. In adipocytes,
GLUT 4 expression at both the protein and mRNA level was reported to be reduced
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by up to 80% in type 2 diabetes (Hunter and Garvey, 1998), resulting in reduced
basal and insulin-stimulated glucose uptake in this tissue. Conversely, in skeletal
muscle from type 2 diabetic patients, expression of GLUT 4 was reported to be
normal. However, in these patients, GLUT 4 translocation in response to insulin was
reduced (Hunter and Garvey, 1998). Fractionation of skeletal muscle determined that
in the type 2 diabetic patients, more GLUT 4 was residing in dense membrane
vesicles, as opposed to low-density vesicles, suggesting subcellular localisation of
GLUT 4 is altered in insulin resistant skeletal muscle (Hunter and Garvey, 1998) and
further studies suggest this may also be the case in adipocytes.
1.5 Animal models of insulin resistance/diabetes and hypertension
Whilst vanous observations have been made pertaining to insulin resistance in
human tissue, the underlying biochemical mechanisms are not known due to the
difficulty in performing many studies on the small amounts of biopsy material
available. For this reason many animal models of insulin resistance, diabetes and
hypertension are useful in studying these diseases.
1.5.1 The Zucker rat
The Zucker rat is a model of obesity and insulin resistance. Initially the peripheral
tissues of these animals are hyper-responsive to insulin's action on glucose transport,
however this response declines with age until the animals become insulin resistant in
skeletal muscle at around 70 days of age. Adipose tissue remains hyper-responsive to
insulin for a prolonged period, but insulin resistance also affects adipose tissue of
older animals (Abel et al., 1996). Insulin resistance in skeletal muscle of Zucker rats
is not associated with changes in expression of GLUT 4 mRNA or proteins.
Conversely, in adipose tissue the hypersensitive response to insulin is associated with
increased expression of GLUT 4 protein, which declines to levels lower than in lean
controls, when the adipose tissue becomes insulin resistant (Abel et al., 1996). The
major cause of insulin resistance in skeletal muscle of the Zucker rat is suggested to
be a defect in GLUT 4 translocation to the plasma membrane (Abel et al., 1996).
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1.5.2 The spontaneously hypertensive rat (SHR)
The spontaneously hypertensive rat (SHR) is an animal model of hypertension,
which has also been proposed as a model of human insulin resistance syndromes.
Studies by Mondon and Reaven (1988) and Reaven et al. (1989), reported the
existence of insulin resistance in this strain. The SHR has also been reported to have
elevated triglycerides and free fatty acids (Iritani et al., 1977, Aitman et al., 1997).
Using genetic mapping techniques Aitman and colleagues identified a gene, Cd36 (or
Fat, fatty acid translocase), that was reported to have peak linkage to the defects of
glucose and fatty acid metabolism in the SHR (Aitman et al., 1999). The Cd36 gene
was deleted in the SHR and was suggested to underlie the insulin resistance,
hypertriglyceridaemia and defective fatty acid metabolism observed in this animal.
1.5.3 The stroke-prone spontaneously hypertensive rat (SHRSP)
The stroke-prone spontaneously hypertensive rat (SHRSP) was established by
Okamoto and colleagues by selective breeding of the SHR (Okamoto et al., 1974).
However, the SHR and the SHRSP (as well as the Wistar-Kyoto (WKY) rat, the
normotensive control strain) were imported by the National Institute of Health (NIH)
in the United States before the strains were inbred. This resulted in the existence of
genetic differences between all the colonies that were separated before full
inbreeding (Kurtz et al., 1989, Kurtz and Morris, Jr., 1987, Samani et al., 1989,
Matsumoto et al., 1991) (see figure 1.11). Therefore, direct comparison of
experimental data produced using different colonies can be difficult.
The SHRSP exhibits elevated blood pressure compared to control strains and in
males stroke is reported to develop around 40 weeks of age (Okamoto et al., 1974).
During the course of this work, studies in this laboratory (Collison et al., 2000)
showed that like the SHR, the SHRSP also exhibited insulin resistance. Adipocytes
from the SHRSP showed reduced insulin-stimulated glucose uptake and a reduced
ability of insulin to inhibit catecholamine mediated lipolysis, compared to adipocytes
from the WKY. This defect could not be explained by expression of a defective Cd36
gene, as the deletion mutation observed in the SHR was not present in the SHRSP
(Collison et al., 2000). These results suggested that while the Cd36 gene may have a
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role in the defective fatty acid metabolism reported in the SHR, the defect in insulin
action in the SHRlSHRSP is likely due to other factors.
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Figure 1.11 Genealogical origin of the SHR and the SHRSP
The SHRSP strain, maintained at Glasgow, was obtained from colonies maintained at
the University of Michigan, whose breeding stocks had been obtained from NIH
(Davidson et al., 1995, Jeffs et al., 1997).
Work in this laboratory (James et al., 2001), confirmed that the SHRSP also
exhibited insulin resistance in skeletal muscle, the major site of post-prandial glucose
disposal. This defect was shown to be specific for the insulin-signalling pathway, as
in the SHRSP, glucose transport was decreased in response to insulin, but was
similar in response to activation of AMPK (which is suggested to have a role in
mediating exercise-stimulated transport), compared to the control WKY muscle.
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1.6 Aims of this study
The aim of the current study was to investigate the possible causes of the observed
insulin resistance in skeletal muscle of the SHRSP. This was examined using three
approaches. Firstly, antibodies specific for eNOS protein, phosphorylated or
dephosphorylated at residue 1177, were raised and characterised in order to study
regulation of eNOS in skeletal muscle from SHRSP and WKY. Secondly, various
aspects of the insulin signalling cascade were studied in order to determine if any
defects were present which may account for altered insulin signalling in skeletal
muscle from the SHRSP. Finally a yeast two-hybrid screen was carried out using the
protein flotillin. This protein is known to be localised in lipid rafts and is reported to
localise molecules involved in insulin signalling to glucose transport in these lipid
raft domains (see section 1.2.7.3). During the course of this work, studies in our
laboratory illustrated over-expression of flotillin skeletal muscle from SHRSP (James
et aI., 2001). A yeast two-hybrid screen was undertaken to identify flotillin
interacting proteins, which may be involved in regulation of glucose transport.
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CHAPTER2
MATERIALS AND METHODS
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2.1 Materials
All reagents used were of the highest quality available and were obtained from the
following suppliers:
2.1.1 General Reagents
Anachem Ltd, Luton, Bedfordshire, UK
30% acrylamidelbisacrylamide
Complete supplement mixture (-Ade/-His/-Leul-Trp)
Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK
Activated CH Sepharose 4B
PD 10 disposable columns
Protein G Sepharose
Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK
Electroporation cuvettes
'Econo-pak' disposable columns
BDH Laboratory Supplies, Poole, Dorset, UK
Acetic acid
Ammonium persulphate
Calcium chloride solution
di-Potassium hydrogen orthophosphate
Magnesium acetate
Magnesium chloride
Magnesium sulphate
Methanol
Orthophosphoric acid
Potassium chloride
Potassium dihydrogen orthophosphate
Sodium acetate
Sodium azide
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Sodium dihydrogen orthophosphate
Sodium hydrogen carbonate
Tetra-Sodium pyrophosphate
Calbiochem (CN Bio-sciences) Beeston, Nottingham, UK
Calmodulin
Hepes
Keyhole limpet haemocyanin
MOPS
Okadaic acid
Clontech, Palo Alto, California, USA
Human muscle Matchmaker™ II library in pACT2
Human testis Matchmaker™ II library in pACT2
Human testis Protein MedlelM lysate
Difco Laboratories, Detroit, USA
Yeast nitrogen base (without amino acids)
Bacto agar (for yeast agar plates)
Fisher Scientific, Loughborough, Leicestershire, UK
Dimethyl sulphoxide (DMSO)
Glycine
Hydrochloric acid
Potassium hydroxide
Sodium dodecyl sulphate (SDS)
Sodium diaminoethanetetra-acetic acid (EDT A)
Sodium hydroxide
Sucrose
Fisons Chemicals, Leicestershire, UK
OptiFlow Safe 1 scintillation fluid
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Invitrogen, Groningen, The Netherlands
pCRII-rOPO™ TA cloning kit
OneShot rOPIO competent Escherichia coli
Konica Europe, GmbH, Hohenbrunn, Germany
Konica medical film
Melford Laboratories Ltd, Ipswich, UK
Dithiothreitol
Merck Pharmaceuticals, West Drayton, UK
Aquamount
Disodium succinate
Isopentane
Millipore Corporation, Bedford, MA
Microcon YM-IO centrifugal filters
MWG Biotech, Germany
Oligonucleotide primers
New England Biolabs (UK) Ltd, Hitchin, Herfordshire, UK
Prestained protein marker, broad range (6-175)
NovoNordisk, DK-2880, Bagsvaerd, Denmark
Human Actrapid® Insulin solution - 100 Il.l/rnl
Oxoid Ltd, Hampshire, UK
Bacteriological Agar
Yeast extract
Tryptone
Premier Brands UK, Knighton Adbaston, Staffordshire, UK
Marvel powdered milk
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Promega, Southampton, UK
All restriction enzymes
Alkaline phosphatase
Piu polymerase
Taq polymerase
Nuclease-free water
Deoxynucleotide triphosphates (dNTPs)
Qiagen Ltd, Crawley, West Sussex, UK
QIAprep spin miniprep kit
QIAprep gel extraction kit
Plasmid maxi kit
Roche Diagnostics, GmbH, Mannheim, Germany
Complete™ Protease Inhibitor Tablets
Hexokinase
Glucose-6-phosphate dehydrogenase
Schleicher & Schuell UK Ltd, Brunswick Park, London, UK
Nitrocellulose membrane (0.45 J.lM)
Sigma Chemical Company Ltd., Poole, Dorset, UK
2-deoxy-D-glucose
3-amino-l,2,4-triazole (3-AT)
3-maleimidobenzoic acid N-hyroxysuccinimide ester (MBS)
5-amino-imidazolecarboxamide riboside (AICAR)
Adenosine 5' -triphosphate (ATP)
Adenosine monophosphate (AMP)
Amino acids
Ampicillin
Amyloglucosidase
Benzamidine
Bovine serum albumin (BSA)
Bromophenol blue
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Cobalt chloride
Coomassie G
Ethylene glycol-bis (p-aminoethylether) -N,N,N' ,N' -tetra acetic acid (EGT A)
D-glucose
Glycerol
Glycogen
Kanamycin
P-Nicotinamide adenine dinucleotide phosphate (NADP)
N, N, N', N',-tetramethylethylenediamine (TEMED)
Nitro blue tetrazolium (Nitro BT)
Phenazine methosulphate (PMS)
Phenylmethylsulfonyl fluoride
Polyethylene glycol (PEG) 3,350
Poly-l-lysine
Ponceau S solution
Potassium fluoride
Protein A Sepharose
Sodium chloride
Sodium fluoride
Sodium orthovanadate
Tris Base
Triton X-lOO
Trypsin inhibitor, from soyabean (SBT!)
Tween20
YPDPowder
TCS Cellworks, Botolph Claydon, Buckinghamshire, UK
Human aortic endothelial cells
Large vessel endothelial cell medium
Whatman International Ltd., Maidstone, Kent, UK
Whatman 3mm filter paper
Whatman number I filter paper
Phosphocellulose (P-81) paper
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2.1.2 Antibodies
Amersham Pharmacia Biotech, Little Chalfont. Buckinghamshire, UK
Horseradish peroxidase (HRP)-conjugated donkey anti rabbit IgG antibody
HRP-conjugated donkey anti mouse IgG antibody
ECL western blotting detection system
BD Transduction Laboratories
Anti-GSK-3p (mouse monoclonal IgG) - raised against the N-terminal 160 residues
ofrat GSK-3p
Anti-caveolin-l (mouse monoclonal IgG) - raised against N-terminal 97 residues of
human caveolin-l
Anti-flotllin-l (mouse monoclonal IgG) - raised against C-terminal region, amino
acids 312-428, of mouse flotillin
Anti-PKC ex. (mouse monoclonal IgG) - raised against a protein fragment
corresponding to amino acids 270-427 ofrat brain PKC ex.
Anti-PKC p (mouse monoclonal IgG) - raised against a protein fragment
corresponding to residues 126-324 of human PKC p
Anti-PKC 8 (mouse monoclonal IgG) - raised against a protein fragment
corresponding to amino acids 114-289 of rat PKC 8
Anti-PKC E (mouse monoclonal IgG) - raised against protein fragment
corresponding to N-terminal residues 1-175 of rat PKC E
Anti-PKC e (mouse monoclonal IgG) - raised against a protein fragment
corresponding to residues 21-217 of mouse PKC 8
Anti-PKC t (mouse monoclonal IgG) - raised against a protein fragment
corresponding to C-terminal amino acids 404-587 of human PKC t
New England Biolabs (UK) Ltd, Hitchin, Herfordshire, UK
Anti-PKB, phospho Thr 308 (rabbit polyclonal antibody) - raised against a phospho-
Thr 308 synthetic peptide
Sigma Chemical Company Ltd., Poole, Dorset, UK
HRP-conjugated donkey anti sheep IgG
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Anti-eNOS (sheep polyclonal IgG) - raised against the synthetic peptide
SGPYNSSPRPEQHK corresponding to amino acids 594-607 of bovine
eNOS
FITC-linked goat anti-rabbit IgG
Upstate Biotechnology UK, Botolph Claydon, Buckinham, UK
Anti-IRS-l (rabbit irnmunoaffinity purified IgG) - raised against C-terminal 14
amino acid peptide ([C]YASINFQKQPEDRQ) of rat liver IRS-l
Anti-IRS-2 (rabbit polyclonal IgG) - raised against a GST fusion protein
corresponding to amino acids 976-1094 of mouse IRS-2
Anti-PI3-kinase, p85 (rabbit polyclonal IgG)
Anti-AktIPKB, PH domain, clone SKBI (mouse monoclonal IgG) - raised against a
GST fusion protein corresponding to residues 1-149 of human Akt 1
Anti-phospho AktllPKBa (Ser 473) (sheep immunoaffinity purified IgG) - raised
against a synthetic peptide corresponding to C-terminal residues 467-477 of
rat Aktl (KHFPQF[pS]YSAS)
Anti-GSK-3a (sheep immunoaffinity purified IgG) - raised against a 13 residue
synthetic peptide [QAPDATPTLTNSS] corresponding to residues 471-483 of
rat GSK-3a
Anti-phospho-eNOS (Thr 495) (rabbit immunoaffinity purified IgG) - raised against
a synthetic peptide corresponding to amino acids 489-501 of human eNOS
(GITRKK[pT]FKEVAN)
Anti-GLUT 4 (rabbit affinity purified polyclonal IgG) directed against the C-
terminal 14 amino acids of human GLUT 4 was prepared in-house (Brant et al.,
1992).
Anti-phospho eNOS (Ser-1177) was a generous gift from Prof. D.G. Hardie,
University of Dundee, Dundee, UK.
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2.1.3 Radioactive Materials
Amersham Pharmacia Biotech. Little Chalfont. Buckinghamshire. UK
Adenosine 5' [y_32p] triphosphate
D_[U_14C]glucose
a-D-[U_14C] glucose-l-phosphate
NEN DuPont (UK) Ltd., Stevenage, Herts, UK
2-eH(G)] deoxy-D-glucose
[U_14C]Sucrose
2.1.4 Pep tides
PKB substrate peptide (RPRAA IF) was a generous gift from Dr. R. Plevin,
University of Strathclyde, Glasgow, UK.
GSK-3 substrate peptide, phospho-glycogen synthase peptide-2
(YRRAA VPPSPSLSRHSSPHQ(PS)EDEEE), and the GSK-3 non-substrate peptide,
glycogen synthase peptide-2 (Ala 21) (YRRAA VPPSPSLSRHSSPHQAEDEEE),
were both from Upstate Biotechnology UK, Buckingham, UK.
For anti-eNOS antibody production, peptides corresponding to residues 1172 to 1183
of human eNOS, CRl172IRTQSFSLQER1183 (dephosphorylated) and
CRl172IRTQSpFSLQERl183 (phosphorylated) were produced by Dr G. Bloomberg,
University of Bristol, Bristol, UK.
2.1.5 Escherichia coli strains
DH5a
XLI-blue
KC8 (all from lab stocks)
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2.1.6 Saccharomyces cerevisiae strain for yeast 2 bybrid
PJ69-2A was the only yeast strain used in this study (James et al., 1996). It has the
following genotype:
MATa, trpl-90l, leu2-3,1l2, ura3-52, his3-200, gaI4~, gaI80~, LYS::GALluAs-
GALl TATA-HIS3,GAL2uAs-GAL2TATA-ADE2
2.1.7 Miscellaneous
Purified AMPK was a generous gift from Prof. D.G. Hardie. University of Dundee,
Dundee. UK.
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2.2 General Buffers
Electrode Buffer 25 mM Iris, 192 mM glycine, 0.1% (w/v) SDS
HES buffer 20 mM Hepes, pH 7.4, 1 mM EDIA, 250 mM
sucrose,2mMNa3V04, 10mMNaF, 1 mMN34P207
IP buffer 50 mM Iris-HCl, pH 7.4 at 4°C, 1% (v/v) Triton X-
100,1% (v/v) glycerol, 150 mM NaCl, 50 mM NaF, 5
mM N34P207, 1 mM Na3V04, 1 mM EDIA, 1 mM
EGTA, 1 mM DTT, 0.1 mM benzamidine, 0.1 mM
PMSF,5 ug/ml SBTI
KH (Krebs Henseleit) buffer 118 mM NaCl, 4.7 mM KCl, 1.2 mM K2HP04, 1.2
mM MgS04.7 H20, 25 mM NaHC03, 2.5 mM CaCh,
pH 7.4, supplemented with 25 mM D-glucose and
0.1% (w/v) BSA
KRH 20 mM Hepes, pH 7.4, 119 mM NaCI, 5 mM
NaHC03, 4.75 mM KCI, 1.3 mM CaCh, 1.2 mM
MgS04.7H20
LB (Luria-Bertani Broth) 10% (w/v) NaCI, 10% (w/v) tryptone, 5% (w/v) yeast
extract
Lysis buffer 50 mM Iris-HCl pH 7.4 at 4°C, 50 mM NaF, 1 %
(v/v) Triton X-lOO, 250 mM mannitol, 1 mM
N34P207,l mM Na3V04,1 mM EDTA, 1mM EGTA,
1 mM DTT, O.l mM benzamidine, O.l mM PMSF, 5
ug/ml SBTI
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HP04, 1.8
mMKH2P04
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TAB 40 mM Tris-acetate, 1 mM EDTA
TBS 20 mM Tris-HCI, pH 7.4, 150 mM NaCI
TBST 20 mM Tris-HCI, pH 7.4, 150 mM NaCI, 0.02% (v/v)
Tween-20
TE 10 mM Tris, pH 8.0, 1 mM EDT A
Transfer Buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol
2X sample buffer 4% (w/v) SDS, 20% (v/v) glycerol, 125 mM Tris, pH
6.8, bromophenol blue
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2.3 Methods
2.3.1 General Methods
2.3.1.1 Gel electrophoresis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out using Bio-
Rad mini-protean II gel kits. The resolving gel consisted of 8%-15% acrylamide
(depending on the mass of the proteins to be studied), 375 mM Tris, pH 8.0, 0.1%
(w/v) SDS, polymerised with 0.1% (w/v) (NH4)2S20gand 0.08% (v/v) TEMED. The
stacking gels consisted of 5% acrylamide, 125 mM Tris, pH 6.8, 0.1% (w/v) SDS,
polymerised with 0.1% (w/v) (NH4)2S20gand 0.1% (v/v) TEMED. Sample buffer
(2X) was added to samples before boiling for 5 min and loading onto the gel. Gels
were electrophoresed at a constant voltage, typically 80 V, until the proteins had
passed through the stacking gel, and then 120-180 V (depending on the percentage of
acrylamide in the resolving gel) to resolve the proteins.
2.3.1.2 Western blotting
After gel electrophoresis, proteins were transferred to nitrocellulose, using Bio-Rad
trans-blot apparatus. Briefly, nitrocellulose was cut to size and equilibrated in
transfer buffer. The gel was then laid on the nitrocellulose, and sandwiched between
two pieces of Whatman 3MM filter paper. This was then placed in a transfer cassette,
in the trans-blot apparatus. Transfer of proteins was achieved at a constant current of
220 rnA for 2 hr, or 40 rnA overnight. Protein transfer was confirmed by immersing
nitrocellulose in Ponceau S solution for 1min.
2.3.1.3 Coomassie staining of SDS-PAGE gels
To allow visualisation of proteins separated by SDS-PAGE a Coomassie blue stain
was used. This consisted of 5% glacial acetic acid, 45% methanol and 0.25 gil
Coomassie Brilliant Blue R and was filtered through Whatman No. 1 filter paper.
The gel was submerged in stain for around 15 min before rinsing and destaining in
the same acetic acid, methanol, H20 mixture, without the Coomassie dye. Destaining
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was for at least 3 hrs or overnight with a number of changes of destain buffer. The
gel was then placed between clear polythene sheets and scanned to provide digital
. records, or layered between two sheets of cellophane and dried overnight at 37°C.
2.3.1.4 Immunodetection of proteins
Nitrocellulose was incubated with antibodies, as per manufacturer's instructions.
Typically, nitrocellulose was incubated for 1 hr at room temperature (or overnight at
4°C) in TBST containing 5% (w/v) non-fat milk powder, to promote blocking of
non-specific binding. Nitrocellulose was then incubated with antibody, diluted to the
required concentration in TBST containing 1% (w/v) non-fat milk powder.
Nitrocellulose was washed 3 times for 10 min in TBST, before incubation with
secondary antibody. Secondary antibodies were typically HRP (horseradish
peroxidase) conjugated and used at a 1:1000 dilution in TBST containing 1% (w/v)
non-fat milk powder. Nitrocellulose was again washed 3 times for 10 min in TBST.
Immuno-labelled proteins were visualised using the ECL (enhanced chemi-
luminescence) system according to the manufacturers instructions. The nitrocellulose
was then exposed to film and developed using an X-Omat processor.
2.3.1.5 Immunoprecipitation of proteins
Antibody was bound to Sepharose beads (Protein A-Sepharose, for mouse and rabbit
antibodies, Protein G-Sepharose for sheep antibodies) by incubation in IP buffer for
1 hr at 4°C. Beads were washed 3 times in IP buffer, before addition of muscle
lysate. Beads and lysate were incubated for 2 hr at 4°C. Beads were again washed 3
times in lysis buffer. For gel electrophoresis beads were boiled in 2X SDS sample
buffer and for kinase assays beads were washed 3 times in kinase assay buffer (see
below).
2.3.1.6 Preparation of Bradford reagent and protein assays
Protein concentration of samples was determined by the method of Bradford
(Bradford, 1976). Bradford reagent was prepared in house (5% (v/v) ethanol, 5.5%
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(v/v) phosphoric acid, 40 mg/l Coomassie G) and filtered through Whatman No. 1
filter paper and stored protected from light. For protein determination, 1 ml of this
reagent was added to 100 J..lIof sample and the absorbance measured against a
reference sample which contained 1 ml Bradford reagent and 100 J..lIof water or
buffer, as appropriate. Values obtained were compared to those of a standard curve
prepared by analysing samples containing 1-6 J..lgBSA.
2.3.2 SHRSP
2.3.2.1 Animals
Rats were reared in-house, as described in (Jeffs et al., 1997, Davidson et al., 1995),
and maintained under controlled conditions of temperature (21°C) and light (12 hr
light-dark cycle). Rats were fed on normal rat chow (rat and mouse no. I maintenance
diet, Special Diet Services, UK) and had access to water ad libitum (as described in
Jeffs et al., 1997).
2.3.2.2 Muscle dissection and tissue preparation
Male 12 week old rats were killed by CO2 overdose. Muscles were carefully and
quickly dissected and cleaned of connective tissue without stretching and with
tendons intact. Muscles were allowed to recover for 30 min in KH buffer at 37°C
with continuous gassing (95%02/5%C02). Muscles were pinned at resting length
before performing stimulations.
2.3.2.3 Insulin stimulation of muscles
Muscles were quickly dissected, and allowed to recover, as described above, and
incubated in the presence or absence of 1 J..lMinsulin, in KH buffer containing 0.1%
(w/v) BSA. Unless otherwise stated, muscles were quickly washed twice in 5 ml KH
buffer without BSA, before being snap- frozen and stored at -80°C until required.
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2.3.2.4 Glucose transport assays
Flexor digitorum brevis (FDB) muscles were placed in KH Buffer and were allowed
to recover as described above. Muscles were incubated for 30 min in the presence or
absence of 1 J..lMinsulin. Muscles were then rapidly washed 3 times with glucose-
free KH Buffer supplemented with 1% BSA and incubated for 10 min at 37°C in
uptake buffer (KH buffer containing IJ..lMinsulin, lOI1M deGlc (1 J..lCi/ml)and
[14C]-Sucrose(0.2 J..lCi/ml;used as an extracellular marker». Muscles were washed 3
times with 5 ml ice-cold PBS, blotted on filter paper, weighed and solubilised in 1ml
0.5 N NaOR at 60°C for 45 min. Tissue associated radioactivity was determined by
liquid scintillation counting.
2.3.2.5 Preparation of muscle Iysates
Muscles were prepared as described in section 2.3.2.3. Muscles were pulverised in
liquid nitrogen using a mortar and pestle on dry ice. The powdered muscle was then
homogenised using a Polytron hand-held homogeniser in 2.5-5 volumes ice cold
lysis buffer. The homogenate was centrifuged at 14,000 x g for 10 min at 4°C to
remove unsolubilised material.
2.3.2.6 Crude skeletal muscle fractionation
Muscles were prepared as described in section 2.3.2.3. Frozen tissue was then
powdered in liquid nitrogen using a mortar and pestle on dry-ice and resuspended in
RES buffer supplemented with proteinase inhibitor tablets, prior to homogenisation
using a Teflon coated homogeniser. The homogenate was centrifuged at 12,000 x g
for 20 min at 4°C and the pellet collected (heavy membrane fraction). The
supernatant from this step was further centrifuged at 140,000 x g for 1 hr at 4°C and
the pellet (light membrane fraction) and supernatant (soluble protein fraction)
collected.
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2.3.2.7 PKB assays
Soleus and EDL (extensor digitorum longus) muscle extracts were prepared as
described in section 2.3.2.5. PKB (protein kinase B) immunoprecipitations were
carried out using 200 ug soluble muscle extract and 2.5 ug anti-PKB-PH domain
antibody, and assays performed on the immunoprecipitated protein. Reaction
mixtures containing 20 ul HEPES-DTT (50 mM HEPES, pH 7.4, 1 mM DTT), 10 ul
JP in HEPES-DTT and 10 Jll150 JlM substrate peptide (RPRAATF) in HEPES-DTT
were prepared on ice. The reaction was initiated by the addition of 10 JlI ATP
solution (250 JlM [y_32p] ATP, specific activity 500,000-1,000,000 cpmlnmol,
50 mM MgCh). Blank reactions were prepared by substituting HEPES-DTT for
substrate peptide. Reactions were allowed to proceed for 15 min at 30°C, at which
time 40 JlI of reaction mixture was spotted onto phosphocellulose paper and the
paper dropped into 1% (v/v) phosphoric acid. The papers were washed, air-dried and
the incorporation of 32p into the substrate peptide determined in a scintillation
counter.
2.3.2.8 GSK-3 assays
aSK (glycogen synthase kinase)-3 activity was assayed in immunoprecipitates
obtained from muscle extracts, prepared as described in section 2.3.2.5, but in the
absence of NaF. aSK-3a or aSK-3p immunoprecipitations were performed using
250 ug soluble muscle extract and 2.5 ug antibody. Reaction mixtures containing 20
JlI IP in reaction buffer (8 mM MOPS, pH 7, 0.2 mM EDTA, 10 mM magnesium
acetate) and 10 Jll400 JlM substrate peptide (Phospho-glycogen synthase peptide-2)
were prepared on ice. The reaction was initiated by the addition of 10 JlI ATP
solution (450 JlM [y_32p] ATP, specific activity 500,000-1,000,000 cpmlnmol, 75
mM MgCh). Blank reactions were prepared by substituting substrate peptide for an
unphosphorylated form of the peptide, which cannot act as a substrate. When non-
substrate peptide was not available H20 was used, as it was found that the non-
substrate peptide and H20 resulted in similar values being obtained for blank
reactions. Reactions were allowed to proceed for 30 min at 30°C, at which time 30 JlI
of reaction mixture was spotted onto phosphoceUulose paper and the paper dropped
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into 1% (v/v) phosphoric acid. The papers were washed, air-dried and the
incorporation of 32p into the substrate peptide determined in a scintillation counter.
2.3.2.9 Determination of muscle glycogen levels
Soleus and EDL muscles were prepared as described in sections 2.3.2.2 and 2.3.2.3.
Muscles were pulverised in liquid nitrogen using a mortar and pestle on dry ice. The
powdered muscle was then homogenised using a Polytron homogeniser in 2.5
volumes (w/v) 0.2 M sodium acetate, pH 4.8, containing 1% (v/v) Triton X-lOO.
Extracts were then briefly sonicated, before addition of 250 mU amyloglucosidase
(prior to addition of amyloglucosidase, 20 J.lIof sample was removed for protein
determination). Extracts were incubated for 2 hr at 40°C and vortexed regularly,
prior to incubation with assay cocktail (0.1 M Tris-HCI, pH 8.0, 0.3 mM ATP, 6mM
MgCh, 5 mM DTT, 1 mM NADP, 2.5 U/ml hexokinase, 1 ug/ml G6P-
dehydrogenase) for 5 min at room temperature. Changes in fluorescence, as a result
of NADPH production, were determined using an excitation wavelength of 355 nm
and emission wavelength 460 nm. Reaction blanks were determined on samples that
had not been treated with amyloglucosidase.
2.3.2.10 Glycogen synthesis
Glycogen synthesis was determined as [14C]-glucose incorporation into glycogen.
Freshly dissected and cleaned FDB muscles were incubated in KH buffer containing
5 mM glucose for 30 min at 37°C. Muscles were then pinned at resting length, and 3
ml KH buffer (containing 5 mM glucose) added. Muscles were incubated in the
presence or absence of 1 J.lMinsulin, with the addition of[U-14C]_glucose (1 J.lCilml,
final) for 1 hr at 37°C. At this time, muscles were rapidly washed 3 times with 5 ml
of ice cold PBS. Muscles were blotted on filter paper, weighed and solubilised in 200
J.lIof 20% (w/v) KOH at 60°C for 30 min-lhr. Once fully dissolved, the lysate was
neutralised by the addition of 200 J.lI1M HCl and 400 J.lIwater was added. Tubes
were vortexed and 500 J.lIof the extract was transferred to screw cap eppendorfs and
boiled for 8 min. Bovine glycogen (20 J.lIof 250 mg/ml) was added to give a final
concentration of -5 mg/ml. To precipitate glycogen 700 J.!lof ethanol was added, and
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tubes were mixed overnight at 4°C. The samples were centrifuged at 2500 x g for 10
min and the pellets redissolved in 100 III formic acid and 400 III water, with warming
of the tubes to 37°C. The radioactivity was determined by liquid scintillation
counting.
2.3.2.11 Glycogen Phosphorylase Assay
The activity of glycogen phosphorylase was measured in the direction of glycogen
synthesis using a method adapted from (Gilboe et al., 1972) and (Halse et al., 2001).
Soleus and EDL muscles were prepared as described in sections 2.3.2.2 and 2.3.2.3.
Muscles were pulverised in liquid nitrogen using a mortar and pestle on dry ice. The
powdered muscle was then homogenised in 2 volumes of glycogen phosphorylase
extraction buffer (10 mM Tris-HCI, pH 7.8, 150 mM KF, 15 mM EDTA, 60 mM
sucrose 1mM DTT, 1 mM benzamidine, 1mM PMSF, 5 J.lg/J.lISBTI). Homogenates
were then subject to sonication for lOsee, amplitude 10. To 200-250 J.lgof protein
(in 10 III total volume extraction buffer) 190 III of reaction cocktail (33 mM MES,
pH 6.3, 20 mM EDTA, 100 mM KF, 1% (w/v) glycogen, 100 mM glucose-I-
phosphate, 60 dpm/nmol l'T glucose-I-phosphate; for phosphorylase A also 10 IlM
AMP and 5 mM caffeine, for phosphorylase A + B, 2 mM AMP) was added to start
assay. Tubes were briefly vortexed and incubated at 30°C for 10 min. At this time
point 175 J.lIwas removed and spotted onto 3 cm x 3cm 3MM filter paper squares.
Reactions were terminated by dropping filter paper into ice cold 60% ethanol. Filter
papers were washed in 60% ethanol at room temperature for 2.5 hr, dried and subject
to liquid scintillation counting.
2.3.2.12 Muscle fibre-typing
EDL muscles from WKY and SHRSP rats were dissected quickly and immediately
prepared for cryotomy by freezing in iso-pentane cooled with liquid nitrogen. The
frozen muscles were stored in a liquid nitrogen fridge until sectioning using a Bright
cryostat. Sections were cut at l Oum and mounted on poly-I-lysine coated coverslips
then stained using the following panel of histochemical reactions.
67
2.3.2.12.1 Staining sections for succinate dehydrogenase
Sections were stained for succinate dehydrogenase following the method of Martin et
al. (1988). Sections were incubated in incubation medium (100 mM phosphate
buffer, pH 7·6, 10 JlM sodium azide, 1.5 mM Nitro B.T (Nitro blue tetrazolium), 5
mM EDTA, 48 mM disodium succinate, 20 JlM PMS (Phenazine methosulphate) at
37°C for 15-60 min (or until at least some fibres were strongly blue in colour) and
then washed in water. Stained sections were mounted in aquamount.
2.3.2.12.2 Staining sections for myosin ATPase
Myosin ATPase staining was carried out using the method of Round et al. (1980).
Briefly, for the routine pH 9.4 method, sections were incubated at 37°C for 30
minutes in the routine substrate incubation medium (1 mM ATP, 50 mM glycine, 50
mM NaCI, 100 mM CaCh, 2.5 JlM DTT, pH 9.4) before performing three 2 min
washes in 1% CaCh. Sections were incubated in 2% cobalt chloride for 2 min before
washing thoroughly with water. Sections were then incubated in 1% ammonium
sulphide (until specimens tum black, usually a few minutes), washed in water and
mounted in aquamount. For the acid reverse method sections were pre-incubated in
acetate buffer (20 mM sodium acetate, 66 mM acetic acid, pH 4.3 or 50 mM sodium
acetate, 50 mM acetic acid, pH 4.6) at 37°C for 10 minutes. Sections were washed
quickly in dilute buffered calcium chloride (10 mM glycine, 10 mM NaCI, 20 mM
CaCh) before incubating in routine substrate incubation medium at 37°C for 30
minutes. Sections were washed three times for 2 min in 1% CaCh before being
incubated in 2% CoCh for 2 min and then thoroughly washed with water. Sections
were then incubated in 1% ammonium sulphide, washed in water and mounted in
aquamount.
Stained sections were examined using a Zeiss Axiophot microscope and images
captured with a JVC TK-1280E camera and Iomega Buz. These images came from
the same area in each stained specimen and were representative of the overall fibre
distribution.
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2.3.3 Molecular Biology
2.3.3.1 Amplification of DNA by Polymerase Chain Reaction (PCR)
All PCRs were performed in thin-walled PCR tubes, in a Techne Progene
thennocycler. Amplification of DNA was performed using Piu polymerase enzyme.
Reactions were typically set up as follows:
lOX polymerase buffer
forward primer (O.lmg/ml)
reverse primer (0.1 mg/ml)
dNTPs (10 mM each dCTP, dGTP, dATP, dTTP)
template DNA (50-100ng)
polymerase
nuclease- free water
5 ~l
2.5 ~l
2.5 ~l
2.5 ~l
1 ~l
1 ul
to 50 ul
Tubes were then briefly vortexed before initiation of cycling. Typical cycling
conditions were as follows:
95°C 2 min
95°C 30 sec }55°C 30 sec 30 cycles
68°C 2min
68°C 10min
Following PCR 20 ul of reaction mixture was analysed by agarose gel
electrophoresis (see section 2.3.3.3).
2.3.3.2 Purification of PCR products
If a second round of PCR was to be performed, the first round PCR reaction was
purified using a Qiagen PCR purification kit, according to the manufacturer's
instructions, and using the buffers supplied. Briefly, 25 ~l of the reaction was mixed
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with 125 III of buffer PB and placed in a QIAspin column and centrifuged in a
microfuge at 14,000 rpm for 1 min. The column was then washed in 750 III buffer PE
containing ethanol, centrifuged again and the flow-through discarded. The column
was centrifuged again to ensure complete removal of the buffer, placed in a sterile
1.5 ml microfuge tube and 50 III of buffer EB (warmed to 40°C) was pipetted into
the centre of the column and incubated for 1 min. The DNA was then collected by
centrifugation in a microcentrifuge. For a further round of PCR 5 III of this was used
as a template.
2.3.3.3 Agarose gel electrophoresis
For standard small 1% agarose gels, 0.5 g agarose was dissolved in 50 ml TAE
buffer in a microwave oven. This was allowed to cool, before addition of 1 III
ethidium bromide (10 mg/ml), giving a final concentration of 200 ng/ml, After
mixing, the gel was poured into an electrophoresis cartridge and an appropriate comb
inserted. The gel was allowed to set at room temperature, before being transferred to
an electrophoresis tank containing TAE buffer. The comb was removed and samples
in DNA loading buffer (5% (v/v) glycerol, 0.05% bromophenol blue) applied to the
wells. 0.5-0.75 ug of a 1 kb DNA ladder was also used to allow determination of
DNA size. Electrophoresis was carried out at 80 V for 45-60 min. Gels were
visualised using an ultraviolet transilluminator and photographs were taken using a
Mitsubishi video copy processor.
2.3.3.4 Gel purification of DNA
Required bands visualised under W light were excised from agarose gels using a
clean scalpel blade. Gel slices were transferred to sterile 1.5 ml microfuge tubes and
DNA extraction was performed using a Qiagen gel purification kit, following the
manufacturer's instructions, using the buffers supplied. Briefly, 600 III of buffer QC
was added to each gel slice and the tubes incubated at 37°C for 10-15 min, or until
the agarose was completely dissolved. The solution was then applied to a QIAspin
column, and centrifuged in a bench-top microfuge at 14,000 rpm for 1 min. The
column was then washed with 750 III buffer PE, the column centrifuged and the
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flow-through discarded. The column was centrifuged agam to ensure complete
removal of the buffer, placed in a sterile 1.5 ml microfuge tube and 50 III of buffer
EB (warmed to 40°C) was pipetted into the centre of the column and incubated for 1
min. The DNA was collected in the microfuge tube by centrifugation for 1min.
2.3.3.5 Taq polymerase treatment of PIu-amplified products
If Piu-amplified PCR products were to be cloned into pCRIl-TOPO for sequencing
or sub-cloning, they were first treated with Taq polymerase to add overhanging 'A'
bases required for TA cloning. To do this 5 III of Taq buffer, 1 III dNTPs (10 mM
each dCTP, dGTP, dATP, dTTP) and 1 III Taq polymerase were added to gel
purified PCR products «50 Ill). These were mixed thoroughly and incubated at 72°C
for 20 min.
2.3.3.6 TA cloning of peR products
TA cloning was performed usmg the pCRII-TOPO™ kit, according to the
manufacturer's instructions. Typically, 2 III of Taq polymerase treated DNA was
mixed with 0.5 IIIpCRIl-TOPO vector and incubated at room temperature for 5 min,
before the addition of 0.5 III salt solution (supplied with the kit). The 3 III reaction
mixture was gently added to a vial of OneShot TOPIO competent Escherichia coli
cells (thawed on ice) and incubated on ice for 30 min. The cells were heat-shocked
for 30 sec at 42°C in a water bath, chilled on ice for 1 min and then incubated in
250 III SOC media (supplied with the kit) for 45 min at 37°C. The cells were plated
onto LB agar plates containing 50 ug/ml kanamycin and incubated overnight at
37°C. Colonies were picked and cultured overnight in LB containing 50 ug/ml
kanamycin. Small-scale DNA preparations were analysed by restriction digestion
and sequencing (see below).
2.3.3.7 DNA restriction digests
Restriction digests were routinely performed in 20 III volumes, containing 5 III
plasmid DNA, 2 III of an appropriate lOX buffer, 1 III of each restriction
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endonuclease, and the remaining volume made up with sterile water. Digests were
incubated at 37°C for 2-3 hrs. Following the addition of 6X DNA loading buffer, the
digested DNA was subject to agarose gel electrophoresis, as described in section
2.3.3.3.
2.3.3.8 Ligations
Digested inserts and vectors were purified by agarose gel electrophoresis, followed
by gel extraction, as described above. Ligation reactions were then set up in sterile
microfuge tubes using approximately a 3:1 molar ratio of insert:vector. These were
mixed together with 2 ul ligase buffer and 1 J.lIT4 ligase, in a final volume of 20 III
made up with sterile water. The ligation reactions were incubated overnight in an
ice/water slurry. For transformation of Escherichia coli strain DHSa or Xl.l-blue
5 J.llof the reaction was used.
2.3.3.9 Preparation of competent DHSa/ XLI-blue Escherichia coli cells
Sterile LB (10 ml) was inoculated with E. coli cells from a glycerol stock and
cultured overnight at 37°C with shaking at 200 rpm. 0.5 ml of this was sub-cultured
into 100 ml LB and further grown at 37°C with shaking until the optical density at
600 nm was 0.5-0.6 (typically this took around 2 hr). The cells were then chilled on
ice for 10 min and harvested by centrifugation in sterile 50 ml tubes at 3000 rpm for
5 min at 4°C in a Beckman bench-top centrifuge. The supernatant was discarded and
the cells gently resuspended in a total of 50 ml sterile 100 mM CaCh. The cells were
incubated on ice for a further 30 min and were centrifuged as before. The supernatant
was discarded and the cells were resuspended in a total of 5 ml 100 mM CaCI2• The
cells were divided into 250 III aliquots in pre-chilled, sterile microfuge tubes and
stored at -80°C until required.
2.3.3.10 Transformation of Escherichia coli
Competent E. coli cells, made as described in section 2.3.3.9, were thawed on ice and
50 ul per transformation were pipetted into pre-chilled sterile 1.5 ml microfuge
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tubes. For each transformation, 5 IIIof ligation reaction or 0.5 III of purified plasmid
DNA was added to the cells and gently mixed before incubation on ice for 15-30
min. The cells were then heat-shocked in a water bath at 42°C for 90 sec, then chilled
on ice for 1 min. LB (450 Ill) was added to each tube and incubated at 37°C for 45
min. The cells were pelleted by centrifugation for 10 sec at 14,000 rpm in a bench-
top microfuge. Around 350 IIIof LB was discarded and the cells resuspended in the
remaining 150 Ill. Cells were plated on to LB agar plates containing the appropriate
antibiotic, and grown overnight at 37°C.
2.3.3.11 Small-scale DNA preparations
Bacterial colonies were picked from selective LB agar plates and transferred to 5 ml
LB broth (containing 100 ug/ml ampicillin or 50 ug/ml kanamycin, as appropriate),
and grown overnight at 37°C with shaking at 200 rpm. DNA purification was then
performed using a Qiagen miniprep kit, according to the manufacturer's instructions
and using the buffers supplied. Briefly, the cells from 1.5 ml of the culture were
collected by centrifugation for 5 min at 14,000 rpm in a microfuge and resuspended
in 250 III buffer PI (containing RNase A). Buffer P2 (250 Ill) was added and the
tubes mixed by inverting. Buffer N3 (350 Ill) was added and the tubes mixed by
inverting. The tubes were centrifuged for 10 min at 14,000 rpm in a microfuge and
the supernatants were decanted into Qiagen miniprep spin columns and centrifuged
for 1min at 14,000 rpm in a microfuge. Buffer PE (750 Ill), containing ethanol, was
added to the column and the column was centrifuged again. The column was
centrifuged again to ensure complete removal of the buffer. Buffer EB (50 Ill),
warmed to 40°C, was then pipetted into the centre of the column and incubated for 1
min. The DNA was then collected in a microcentrifuge, by centrifugation for 1min.
2.3.3.12 Large-scale DNA preparations
Large-scale DNA preparations were performed using a Qiagen plasmid maxi kit,
following the manufacturer's instructions and using the buffers supplied. Briefly,
bacterial cultures of 100 ml were grown overnight in LB containing the appropriate
antibiotic for selection. Cells were harvested by centrifugation at 3000 rpm for 10
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min. The cells were resuspended in a total of 10 ml buffer PI (containing RNase A).
Buffer P2 (10 ml) was added and allowed to lyse the cells for 5 min. The reaction
was neutralised by the addition of 10 ml chilled buffer P3. The precipitate formed
was removed by centrifugation at 3000 rpm for 30 min, followed by filtration
through 2 layers of muslin. The supernatant was then applied to a PI 00 Qiagen
column, pre-equilibrated with 10 ml buffer QBT. The column was washed with 30
ml buffer QC (containing ethanol), before elution of DNA by the addition of 15 ml
buffer QF. To precipitate DNA, 10.5 ml isopropanol was added to the eluted DNA
and mixed well. The precipitated DNA was collected by centrifugation at 3000 rpm
for 30 min. The pellet was washed in 4 ml 70% (v/v) ethanol. The ethanol was
removed and the pellet air-dried prior to resuspension in 250 JlI TE. The DNA
concentration and purity were then assessed spectrophotometrically.
2.3.3.13 DNA sequencing
Initially, DNA sequencing was carried out by the University of Glasgow Molecular
Biology Support Unit. Latterly, sequencing was carried out by MWG Biotech,
Germany.
2.3.4 Yeast Two-Hybrid
2.3.4.1 Yeast media
YPD powder was dissolved in distilled water, according to manufacturer's
instructions. The media was sterilised by autoclaving and allowed to cool. Sterile-
filtered adenine hemisulphate (0.2% (w/v» was added to give YPAD which had a
final concentration of 0.003% adenine. For agar plates (containing 20gl1 agar), the
sterilised media was allowed to cool to 55-60°C before addition of adenine and
subsequent pouring.
Quadruple dropout synthetic selection media consisted of 0.67% (w/v) yeast nitrogen
base, 2% (w/v) glucose and 0.2% (w/v) complete supplement mixture (-Ade/-His/-
LeU/-Trp). Triple (-LeU/-Trp/-His) and double (-LeU/Trp) dropout media were
prepared by adding back the appropriate amino acids. Leucine and histidine were
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added before autoclaving to give final concentrations of 0.002% and 0.001 %
respectively. The media was sterilised by autoc1aving and allowed to cool. If
required, sterile-filtered adenine hemisulphate (0.2% (w/v)) was added to give a final
concentration of 0.003% adenine and sterile filtered tryptophan 1% (w/v) was added
to give a final concentration of 0.002%.
2.3.4.2 Amplification of library DNA
MATCHMAKER™ cDNA libraries were purchased from Clontech. These consisted
of E. coli cells expressing the pACT2 library and required amplification to obtain
enough plasmid for yeast two-hybrid screening. Amplification was performed using
agar plates, rather than in liquid media, to allow even representation of all the clones.
Thus, cells were plated directly onto LB agar containing 100 ug/ml ampicillin and
grown for 48 hr at 30°C. Cells were scraped into LB/glycerol (25% v/v), pooled and
mixed thoroughly, and stored overnight at 4°C. Aliquots were prepared and stored at
-70°C for future use. Around one third of the cells (equivalent to 3 litres of overnight
culture) were used for plasmid preparation. DNA was prepared in a similar manner
as described in section 2.3.3.12, large-scale DNA preparations.
2.3.4.3 Construction of the bait plasmid: pGBT9-f1otillin 152-427
Human flotillin 152-427 was PCR amplified from skeletal muscle cDNA (a generous
gift from Prof. K. Johnston, Molecular Genetics, University of Glasgow, Glasgow,
UK) usmg Piu polymerase and the following pnmers:
5'-GagatctGTAAGGACATTCACGATGACCAGG-3' (BgnI site in small letters) and
5' -ctcgagTCAGGCTGTTCTCAAAGGCTTG-3' (XhoI site in small letters, STOP codon
in bold). The resulting products were cloned into pCRII- TOPO, sequenced and
subcloned into the BamHI and San sites of pGBT9, according to the methods in
section 2.3.3.
75
2.3.4.4 Small-scale lithium acetate yeast transformations
A 25 ml overnight culture ofPJ69-2A was used to inoculate 300 ml ofYPAD to give
a starting OD6ooof between 0.2-0.3. This was further cultured at 30°C with shaking
at 200 rpm, until the OD6ooreached 0.4-0.6 (typically 3-4 hr). Cells were harvested
by centrifugation at 2000 rpm for 5 min at room temperature in a bench-top
Beckman centrifuge. The pelleted cells were resuspended and pooled in 25 ml sterile
water and spun again. Cells were then resuspended in 1.5 ml freshly prepared sterile
100 mM lithium acetate in TE buffer. 100 JlI of cells were transferred to a sterile 1.5
ml microfuge tube containing 10 JlI salmon sperm carrier DNA (10 mg/ml) and 1 JlI
of each plasmid to be transformed. These were briefly vortexed and 0.6 ml freshly
prepared sterile 5% (w/v) PEG-3350/100 mM LiAc solution was added to each tube.
Tubes were vortexed for 10 sec and incubated at 30°C for 30 min with shaking at
200 rpm. DMSO (70 ul) was then added to each tube and mixed by inverting before
being heat-shocked for 15 min at 42°C in a waterbath. The tubes were placed on ice
for 1 min before being centrifuged for 5 sec in a microcentrifuge. The cell pellets
were resuspended in 0.25 ml sterile TE and plated onto the appropriate synthetic
medium selective for the transformed plasmids (lacking leucine and tryptophan if
pGBT9 and pACT2 plasmids were co-transformed). After 3-4 days of growth at
30°C, colonies were picked and re-streaked onto selective media also lacking
histidine (triple dropout, TDO) or histidine and adenine (quadruple dropout, QDO),
to screen for the reconstitution of transcriptional activation and hence interactions.
2.3.4.5 Extraction of library plasmids from yeast cells
Yeast cells were grown overnight in liquid media lacking leucine and tryptophan.
Cells were harvested from 1.5 ml of this overnight culture by centrifugation at 5000
rpm for 1 min in a bench-top microfuge. Cells were resuspended in 0.5 ml buffer S
(10 mM K2HP04, pH 7.2, 10 mM EDTA, 50 mM j3-mercaptoethanol, 50 ug/ml
zymolyase) and incubated at 37°C for 30 min, before addition of 100 ul lysis buffer
(25 mM Tris-HCI, pH7.5, 25 mM EDTA, 2.5% (w/v) SDS). The tubes were vortexed
and incubated for a further 30 min at 65°C before the addition of 166 Jll of 3M
potassium acetate, pH 5.5. Tubes were mixed by inverting and incubated on ice for
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10 min. The tubes were centrifuged in a microfuge at 4°C for 10 min at 14,000 rpm.
The supernatants were transferred to fresh tubes on ice containing 800 J..lIof 100%
ethanol and incubated for 10 min. DNA was pelleted by centrifugation in a
microfuge at 4°C for 10 min at 14,000 rpm, washed in 70% ethanol and allowed to
air dry. The pellets were then resuspended in 40 J..lIdistilled water. This DNA
preparation contains both library and bait plasmid DNA, therefore to select for
library plasmids, these preparations were transformed into elecrocompetent KC8
cells.
2.3.4.6 Preparation of electrocompetent KC8 cells
KC8 cells contain a leuB mutation resulting in a requirement for leucine to sustain
growth which allows direct selection of the yeast LEU 2 gene, carried on the library
plasmids.
KC8 cells were cultured overnight at 37°C by inoculating 5 ml of LB broth with cells
scraped from an agar plate. 2 ml of this culture was used to inoculate another 200 ml
ofLB and incubated at 37°C with shaking at 200 rpm. When the OD6oo of the culture
had reached 0.5-0.6 (around 2-3 hr), cells were cooled on ice for 30 min, before
harvesting in 50 ml tubes by centrifugation at 4°C for 10 min at 4000 rpm in a
Beckman bench-top centrifuge. Cell pellets were resuspended in 50 ml ice cold,
sterile water, mixed and centrifuged as before. This washing step was repeated again,
and the cell pellets resuspended and pooled in 20 ml 10% (v/v) ice cold, sterile
glycerol. Cells were harvested by centrifugation as before and the pellet resuspended
in an equal volume of ice cold 10% glycerol. Cells were aliquoted (100
ul/transformation) into microcentrifuge tubes, and stored on ice until used.
2.3.4.7 Electroporation of KC8 cells (recovery of prey plasmids)
KC8 cells were prepared on day of use as described above. DNA extracted from
yeast (1 J..lI)was added to 100 J..lIof KC8 cells before transferring to a pre-chilled
sterile electroporation cuvette. Electroporation was carried out in a Bio-Rad
Micropulser. The cells were gently recovered in 0.5 ml LB broth and incubated for 1
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hr at 37°C. Cells were pelleted by centrifugation at 4000 rpm in a bench-top
microfuge and 300 ~l buffer was removed before resuspending and plating onto M9
minimal media agar plates lacking leucine. Plates were incubated at 37°C overnight.
Colonies were picked and cultured overnight in LB broth containing I00 ug/ml
ampicillin. Small-scale DNA preparations were then performed as described in
section 2.3.3.11 and the purified plasmids were digested with EgITI and EcoRI to
verify that the correct plasmids had been rescued and also to verify the sizes of the
inserts within those plasmids.
2.3.4.8 Re-transformation of recovered plasmids
Following the rescue of the pACT2 prey plasmids encoding the putative flotillin-l
interacting proteins, it was necessary to re-transform these back into the yeast with
the bait pGBT9-flotillin 152-427 plasmid to ensure that the yeast were growing as a
result of the plasmids and not due to mutation of the yeast. All transformations were
carried out as described in section 2.3.4.4.
2.3.4.9 Sequence analysis
Prey plasmids that appeared to confer interactions with flotillin were digested with
EgITI to determine the sizes of the inserts, and subjected to sequencing. This was
initially performed according to the procedure outlined in section 2.3.3.13 using a
primer designed against the GAU activation domain sequence
5'_TACCACTACAATGGAT-3'.Sequences obtained were then analysed in Editview
and by BLAST searching (Altschul et al., 1990).
2.3.4.10 Preparation of yeast Iysates
A match-head sized ball of yeast was resuspended in 1 m! distilled H20. Prior to
incubation on ice for 10 min, 150 ul of a 1.85 M NaOH, 7.5% p-mercaptoethano!
solution was added. TCA (150 ul, 55%, w/v) was then added before a further 10 min
incubation on ice. The precipitates were centrifuged for 15 min at 14,000 rpm, 4°C,
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and the supernatant removed. Precipitated proteins were resuspended in 100 1-11
sample buffer.
2.3.5 eNOS Antibodies
2.3.5.1 Preparation of peptide-keybole limpet baemocyanin conjugates
Peptides corresponding to residues 1172
CRll72IRTQSFSLQERl183 (dephosphorylated)
to 1183 of human eNOS,
and CRl172IRTQSpFSLQERI183
(phosphorylated) were linked to keyhole limpet haemocyanin (KLH). for use in
rabbit immunisation. Briefly, 100 1-1!of 25 mg/ml 3-maleimidobenzoic acid N-
hyroxysuccinimide ester (MBS) in dimethyl formamide was added to 1 m! KLH (15
mg/ml in PBS) drop wise in glass, with stirring at room temperature for 30 min. Free
MBS was separated from that bound to KLH by gel filtration on Sephadex G25 (PD-
10 disposable columns). The MBS-KLH was diluted to 2.5 ml in PBS and loaded
onto a column pre-equilibrated in 25 ml PBS. The flow-through was discarded and
elution of activated KLH was achieved using 3.5 ml PBS. The eluate was divided
into 3 aliquots containing 5 mg activated KLH in each. Activated KLH (5 mg) was
incubated with 2501-11of20 mg/ml peptide with stirring for 3 hr at room temperature.
The final mixes were divided into 5 aliquots, each containing 1 mg activated KLH
and stored at -20°C.
2.3.5.2 Immunisation of rabbits with peptide-keyhole limpet haemocyanin
conjugates
All of the immunisation and collection of sera was performed by the Scottish
Antibody Production Unit (Diagnostics Scotland), Carluke, Lanarkshire, Scotland.
One rabbit was immunised with one peptide and the immunisation schedule was as
follows. Rabbits were initially immunised with 1 mg of peptide conjugate. They
were re-immunised with the same amount of peptide conjugate one, two and three
months after the initial immunisation. Blood was taken one week after the second
and third immunisations and the animals were exanguinated after the fourth.
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2.3.5.3 Preparation of antibody affinity columns
For each anti-peptide antibody, an affinity column was prepared using the same
peptide. Activated CH Sepharose 4B (1 g) was placed into a Bio-Rad 'Econo-pak'
disposable column and mixed with 15 ml of 1 mM HCI. This was eluted and the
column washed with a further 200 ml of 1 mM HCI. The column was washed in 15
ml coupling buffer (O.lM NaHC03, pH 8.0), stoppered and 10 umol peptide in 6 ml
coupling buffer added. The peptide and CH Sepharose were then mixed for 4 hr on a
rotating mixer at room temperature. The column was allowed to drain and the flow-
through collected. The remaining active groups were blocked by the addition of 15
ml O.IM TrisIHCI, pH 8.0. The column was stoppered and the CH Sepharose-peptide
column resuspended and mixed for 1 hr on a rotating mixer at room temperature. The
column was allowed to drain under gravity and the Sepharose resuspended in 15 ml
TBS supplemented with 0.1% (v/v) Tween-20 and 0.02% sodium azide, and stored at
4°C.
2.3.5.4 Purification of anti-peptide antibodies
Peptide columns, prepared as described above, were used to purify anti-peptide
antibodies from immunised rabbit serum. Columns were washed with 200 ml TBS
supplemented with 0.1% (v/v) Tween-20. 5 ml rabbit serum was diluted three-fold in
TBS/O.l% Tween and then loaded onto the column. Serum obtained from the rabbit
immunised with phospho-peptide was first loaded 3 times onto the dephospho-
peptide column, and then 3 times onto the phospho column. Conversely, serum
obtained from the rabbit immunised with the dephospho peptide was loaded first 3
times onto the phospho-peptide column and then 3 times onto the dephospho-peptide
column. Columns were washed with 300 ml TBS/O.l% Tween containing 0.4 M
NaCI to remove non-specifically bound proteins. The column which had been the
latter to be loaded with serum was the one from which specifically bound antibodies
were eluted. This was achieved using 20 ml 50 mM glycine, pH 2.5 at 4°C. 1 ml
fractions were collected and 50 ul of 1.5 M TrisIHCI, pH 8.0 at 4°C added to each
fraction. The protein concentration of each fraction was assayed and the peak
fractions pooled. Columns were recycled by washing with 100 ml lOX TBS and
stored as described above.
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2.3.5.5 Preparation of eNOS protein
For characterisation of the antibodies concentrated eNOS protein was prepared from
homogenates of cell pellets, from cells infected with an eNOS adenovirus construct
driving the level of eNOS expression (prepared by Dr. A. Frater, Department of
Medicine and Therapeutics, University of Glasgow, Glasgow, UK). This cell debris
still contained a large amount of eNOS protein. The cell pellet was solubilised in
lysis buffer containing 1% (v/v) Triton X-lOO. The insoluble material was pelleted
by centrifugation at 14,000 rpm in a bench top microfuge at 4°C for 10 min. Lysis
buffer was again added to this insoluble fraction and was subject to sonication in a
sonicating waterbath for 20 min.
2.3.5.6 Preparation of 32p labelled eNOS
To specifically test the phospho-specific eNOS antibodies produced, eNOS was
phosphorylated using AMPK in the presence of 32P-IabelledATP. Soluble eNOS
protein (200 ug), prepared as described above, was incubated with 35 units of
AMPK, 200 JlM AMP, 200 JlM ATP (25 JlCi), 3 JlM CaCI2, 1 JlM calmodulin and
10mM MgCh, for 30 min at room temperature. The phosphorylated protein was then
resolved by SDS-PAGE, and subject to phosphorimage analysis or western blotting
using the antibodies described in chapter 5.
2.3.5.7 Alkaline phosphatase treatment of eNOS
To specifically test the dephospho-specific eNOS antibodies produced, eNOS protein
was subjected to treatment with alkaline phosphatase, to remove phosphates from
phosphorylated residues. Phosphatase inhibitors (in the soluble eNOS protein
described in section 2.3.4.5) were removed by concentrating the protein using a
microconcentrator, and centrifuging at 14,000 rpm in a bench top microfuge for 15
min, adding 10 mM TrisIHCI, pH 8.0 (containing protease inhibitors) and
centrifuging again. eNOS protein was then subjected to treatment with alkaline
phosphatase. 250 ug protein was incubated with 50 units of alkaline phosphatase in
the relevant volume of lOx reaction buffer (supplied by the manufacturer) for 30 min
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at 30°C. At this time another 50 units of alkaline phosphatase was added to the
reaction, which was allowed to proceed for a further 30 min at 30°C. eNOS protein
was subject to gel electrophoresis, proteins transferred to nitrocellulose and
antibodies tested.
2.3.5.8 Culture of Human Aortic Endothelial Cells (HAECs)
HAECs were grown in large vessel endothelial cell medium at 37°C in 5% CO2 and
passaged when 80% confluent. Cells were used for experiments between passages 3
and 6. Prior to use cells were maintained in serum free media for 4 hr. Incubations
were performed in serum free media or KRH. Endothelial celllysates were prepared
by scraping cells into standard lysis buffer (section 2.2).
2.3.5.9 Methanol fixation and preparation of covers lips for confocal microscopy
ofHAECs
HAECs were grown on collagen-coated 22 mm diameter glass coverslips in large
vessel endothelial cell medium at 37°C in 5% C02. Cells were fixed by the addition
of 4 ml methanol for 5 min at -20°C. The coverslips were washed three times with 5
ml PBS, and blocked in goat serum diluted 1:lOin PBS for 30 min. Coverslips were
washed a further three times with 5 ml PBS and incubated for 1 hour with primary
antibody diluted appropriately in PBS. The coverslips were again thoroughly washed
with PBS and then incubated for 1 hour with 1:100 FITC-linked goat anti-rabbit IgG.
Coverslips were again thoroughly washed and then mounted on slides and stored at
4°C until viewed on the confocal microscope.
2.4 Statistical analysis
Statistical analysis was performed using the Student's t-test (2-tailed independent
samples). Ap value < 0.05 was taken as a significant difference between two groups.
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CHAPTER3
PREPARATION AND CHARACTERISATION OF ANTI-ENDOTHELIAL
NITRIC OXIDE SYNTHASE ANTIBODIES, SPECIFIC FOR RESIDUE
SERINE 1177 (PHOSPHORYLATED OR UNPHOSPHORYLATED)
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3.1 Introduction
As described in Chapter 1, nitric oxide has been reported to have various effects on
basal, contraction- and insulin-stimulated glucose transport in skeletal muscle. It has
also been shown that insulin may have a role in endothelial cell nitric oxide
production, via activation of endothelial nitric oxide synthase. eNOS is regulated in a
number of ways, most notably by binding calmodulin at increased intracellular
calcium concentrations. In addition, eNOS is also subject to post-translational
modifications, including protein phosphorylation.
eNOS is phosphorylated on serine and threonine (Butt et aI., 2000, Michell et aI.,
2001), and tyrosine (Fisslthaler et aI., 2000) residues. However, research has
focussed on the phosphorylation of eNOS at serine 1177 and threonine 495 (human
sequence). Serine 1177 lies in the C-terminal reductase domain of the eNOS
molecule and its phosphorylation results in eNOS activation. Some researchers
(Chen et aI., 1999) hypothesise that eNOS is auto-inhibited by its C-terminus and
phosphorylation of Ser-II77 removes this auto-inhibition. Conversely,
phosphorylation of threonine 495 is suggested to be an inhibitory phosphorylation,
due to the fact that this residue lies within the calmodulin binding sequence (Fleming
et al., 2001). Phosphorylation of Thr-495 is thought to prevent calmodulin binding
and subsequent activation of the molecule.
Much of the research carried out to date on phosphorylation of eNOS has been
carried out using a variety of endothelial cell cultures. A number of external signals
have been identified which modulate the phosphorylation state of eNOS. These
include shear stress (Corson et aI., 1996, Fisslthaler et al., 2000), VEGF (Fulton et
aI., 2002), insulin (Montagnani et aI., 2001), bradykinin (Harris et aI., 2001), and
hydrogen peroxide (Thomas et aI., 2002). Various kinases have been identified
which are reported to mediate these phosphorylations. These include AMPK (Chen
et al., 1999), PKBIAkt (Fulton et aI., 1999, Dimmeler et aI., 1999, Michell et aI.,
1999), cAMP dependent protein kinase and cGMP dependent protein kinase (Butt et
aI., 2000) and calmodulin dependent kinase II (CaMKII) (Fleming et aI., 2001),
which all phosphorylate Ser-II77. In contrast, PKC phosphorylates eNOS on Thr-
495 (Michell et aI., 2001). A number of phosphatases have also been implicated in
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regulating eNOS activity. Protein phosphatase 2A (PP2A) was reported to be
responsible for Ser-II77 dephosphorylation (Michell et al., 2001) and PP1 was
shown to dephosphorylate Thr-495 (Michell et al., 2001, Fleming et al., 2001), while
another report implicated PP2B in Thr-495 dephosphorylation (Harris et al., 2001). It
is likely that the specific protein kinase that phosphorylates eNOS on Ser-II77 will
depend on the given stimulus, for example shear stress reportedly leads to activation
of PKB and phosphorylation of eNOS Ser-II77, in a PI3-kinase dependent manner
(Dimmeler et al., 1999). However, another study, (Boo et al., 2002), suggests that
VEGF stimulates eNOS Ser-II77 phosphorylation via PKB, but shear stress acts
through PKA-dependent and PKB-independent mechanisms. Additionally some
stimuli, for example bradykinin, have been suggested to promote co-ordinate
dephosphorylation of Thr-497 and phosphorylation of Ser-1179 (bovine sequence)
(Harris et aI., 2001). Thus, regulation of eNOS activity by phosphorylation is
somewhat complex and specific tools are required to study this in more depth.
3.1.1 Aims of Chapter
As phosphorylation of serine 1177 plays a pivotal role in regulation of eNOS
activity, anti-peptide antibodies specific for both the phosphorylated and
unphosphorylated forms of the eNOS protein at this residue, were prepared and
characterised. The aim was to use these antibodies to study eNOS
activation/inactivation in skeletal muscle in response to various stimuli, allowing the
role of eNOS activation and NO production to be explored in skeletal muscle.
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3.2 Results
3.2.1 Preparation of anti-peptide antibodies
As described in Materials and Methods sections 2.3.5.1-2.3.5.4, rabbits were
immunised with peptides corresponding to residues 1172 to 1183 of human eNOS,
CRl172IRTQSFSLQERl183 (unphosphorylated) and CRII72IRTQSpFSLQERI183
(phosphorylated), serum collected and antibodies purified on peptide columns.
Figure 3.1 shows Coomassie-stained gels of fractions collected from the affinity
columns. Typically the antibodies eluted from the columns in the early fractions. The
antibody fractions were then pooled and concentrated for later use.
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Figure 3.1 Preparation of anti-peptide antibodies
Antibody affinity columns were prepared as described in section 2.3.5.3. Purification
of anti-peptide antibodies was carried out as described in section 2.3.5.4. 20 JlI of
each fraction was subjected to SDS-PAGE, and gels were stained with coomassie
blue to visualise proteins. Panel A shows the first 9 fractions collected from
purification of the anti-phospho eNOS antibody. Panel B shows the first 9 fractions
collected from purification of the anti-dephospho eNOS antibody. The positions of
the molecular weight standards are shown on the left of the figure.
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3.2.2 Characterisation of anti-peptide antibodies
It was necessary to assess the specificity of the antibodies, Le. that the anti-phospho
antibody recognises only eNOS phosphorylated at Ser-1177, and not the
unphosphorylated protein. This was performed in a number of ways, as detailed
below.
3.2.2.1 Western blotting with anti-peptide antibodies in the presence and
absence of blocking peptides
Initially, western blotting (section 2.3.1.2) was carried out using the anti-peptide
antibodies in the presence and absence of the peptides to which the antibodies were
raised (see figure 3.2). The theory was that if the antibodies are specific, protein
binding will be prevented in the presence of the peptide to which the antibody was
raised, but in the presence of the converse peptide, no inhibition of binding should
occur. As a control, a commercial eNOS antibody was used (figure 3.2, lane 1). The
darkest band (-130kD) is assumed to be eNOS (and is highlighted with an arrow).
The anti-phospho eNOS antibody detected only a very faint band (lane 2),
corresponding to phospho eNOS Ser-1177, and this band was not detected when the
phospho antibody was incubated with the phospho peptide (lane 4). The anti-
phospho eNOS antibody in the presence of dephospho peptide is shown in lane 5. A
very faint band can be seen, similar to lane 2. The anti-dephospho eNOS antibody
detects a strong signal at around 130 kDa. Incubation with the phospho peptide does
not prevent the dephospho eNOS antibody recognising the eNOS protein (lane 6),
but in the presence of dephospho peptide, binding is prevented completely (lane 7).
These results suggest that the antibodies specifically recognise phosphorylated or
dephosphorylated eNOS, corresponding to the peptides they were raised against.
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Figure 3.2 Western blotting using phospho and dephospho antibodies in the
presence and absence of blocking peptides
Soluble eNOS protein (100 ug), prepared as described III section 2.3.5.5, was
subjected to SDS-PAGE, and subsequent western blotting. The nitrocellulose was
then cut into 7 strips and probed, as described below, with various antibodies in the
presence or absence of blocking peptide. 1 = anti-eNOS from Sigma, 1:1000 dilution
2 = anti-phospho eNOS, 1:200 dilution, 3 = anti-dephospho eNOS, 1:200 dilution,
4 = anti-phospho eNOS, and 0.25 mglml phospho peptide, 5 = anti-phospho eNOS,
and 0.25 mglml dephospho peptide, 6 = anti-dephospho eNOS, and 0.25 mglml
phospho peptide, 7 = anti-dephospho eNOS, and 0.25 mglml dephospho peptide.
The positions of molecular weight standards are shown on the left of the figure. The
arrow indicates the position of eNOS.
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3.2.2.2 Immunoprecipitations using anti-peptide antibodies
As the antibodies appeared to work well for western blotting (figure 3.2), the next
step was to test the ability of the antibodies to immunoprecipitate eNOS. Figure 3.3
shows that the antibodies effectively immunoprecipitate eNOS, in that with
increasing concentrations of antibody, the supernatant becomes depleted of protein.
A
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Figure 3.3 eNOS immunoprecipitations using antibodies prepared in-house
eNOS protein was prepared as described in section 2.3.5.5. eNOS protein
(50 Jlg) was subjected to immunoprecipitation (see section 2.3.1.5) using increasing
concentrations of antibodies as indicated. In panel A immunoprecipitations were
carried out using the anti-phospho eNOS antibody. In panel B immunoprecipitations
were carried out using the anti-dephospho eNOS antibody. Positions of molecular
weight standards are shown on the left of the figure.
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To analyse further the specificity of the antibodies, sequential immunoprecipitations
were performed In which the immuno-depleted supernatant from an
immunoprecipitation (IP) with one of the antibodies was subjected to
immunoprecipitation using the other antibody. It would be expected, for example,
that if an IP was carried out using the anti-phospho antibody, and the supernatant
again used for an anti-phospho antibody lP, that little or no protein would be
immunoprecipitated in the second instance, because the supernatant would have been
essentially depleted of phospho eNOS during the first IP. However if the anti-
dephospho antibody were used in the second instance, it would be expected that
protein would be immunoprecipitated, due to the fact that dephospho eNOS had not
previously been depleted.
The data from the sequential IP experiment is shown in figure 3.4. The results
observed are somewhat confusing and not as expected. When both IPs were carried
out using the anti-phospho antibody (figure 3.4, experiment 1) a small amount of
eNOS protein is observed in the pellet from the second IP, but the supernatant does
not appear to be depleted. However, when the anti-dephospho antibody is used for
the first IP, and the anti-phospho antibody for the second IP (figure 3.4, experiment
2), very little protein is observed in the second pellet, but the supernatant is
significantly depleted. When the anti-phospho antibody is used for the first IP the
anti-dephospho antibody for the second IP (figure 3.4, experiment 3), much more
protein is observed in the second pellet, and yet the supernatant is scarcely depleted.
Finally, when both immunoprecipitations were carried out using the dephospho
antibody (figure 3.4, experiment 4), no band of the correct size is present in the pellet
and yet the supernatant is largely depleted.
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Sequential eNOS immunoprecipitation with phospho and
dephospho antibodies
eNOS protein was prepared as described in section 2.3.5.5. Immunoprecipitations
(section 2.3.1.5) were carried out using 25 ug eNOS protein and 10 ug of either anti-
phopspho or -dephospho eNOS antibody. The supernatants from these
Figure 3.4
immunoprecipitations were then used to immunoprecipitate with the converse
antibody.
1 = IP with anti-phospho antibody first and anti-phospho antibody second
2 = IP with anti-dephospho antibody first and anti-phospho antibody second
3 = IP with anti-phospho antibody first and anti-dephospho antibody second
4 = IP with anti-dephospho antibody first and anti-dephospho antibody second.
The samples were subjected to SDS-PAGE, transferred to nitrocellulose and then
probed with the anti-eNOS antibody from Sigma, which does not discriminate
between the phospho and dephospho protein. P = phospho, D = dephospho, Pell =
pellet, Supt = supernatant. Positions of molecular weight standards are shown on the
left of the figure.
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3.2.2.3 Phosphorylation and dephosphorylation of eNOS protein
The data in figure 3.4 cast some doubt over the specificity of the antibodies,
therefore eNOS protein was treated with kinase or phosphatase (to promote
phosphorylation or dephosphorylation, respectively), and then subjected to western
blotting with the anti-phospho and dephospho antibodies.
eNOS protein was incubated with 32p_ATP, in the presence or absence of AMPK (a
kinase known to phosphorylate eNOS at Ser-II77) then subjected to
immunoprecipitation with a commercially available anti-eNOS antibody (Sigma).
Figure 3.5, panel A shows that in the presence of AMPK a band of eNOS size (130
kD) is phosphorylated to a greater extent than that in the absence of AMPK. The
eNOS previously incubated with 32p_ATP, in the presence or absence of AMPK was
also analysed by western blotting using a number of antibodies (figure 3.5, B). An
antibody that recognises both the phospho and dephospho eNOS (Sigma)
demonstrated equal loading of protein (blot 1). In addition, a commercially available
anti-phospho eNOS antibody (Thr-495) reacted to a far greater extent with eNOS
pre-incubated with AMPK (blot 4). In contrast to the ability of the commercial
antibody to specifically recognise phosphorylated eNOS, the anti-phospho and
-dephospho antibodies prepared in this study showed no discrimination between
phosphorylated and unphosphorylated protein (blots 2 and 3). Nevertheless, AMPK
is known to phosphorylate eNOS at Thr-495 and Ser-II77 in the absence of calcium
(Chen et al., 1999), so it maybe that if the reaction conditions were not optimised for
Ser-II77 phosphorylation, Thr-495 has been phosphorylated at the expense of Ser-
1177.
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eNOS (200 ug) protein was incubated in the absence or presence of 35 units AMPK
as described in section 2.3.5.6. Around 70 ug protein was immunoprecipitated using
the commercially available Sigma antibody, and subjected to SDS-PAGE and
subsequent phospho-image analysis (panel A). Panel B shows protein treated in the
same way (but without immunoprecipitation) subjected to SDS-PAGE (around 17 ug
per lane). The nitrocellulose was probed with various antibodies: 1= anti-eNOS from
Sigma, 1:1000 dilution, 2 = anti-phospho eNOS, 1:200 dilution, 3 = anti-dephospho
eNOS, 1:200 dilution, 4 = anti-phospho eNOS (Thr-495) from Upstate
Biotechnology, 1:1000 dilution. Positions of molecular weight standards are shown
on the left of the figure.
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To further analyse the specificity of the antibodies, eNOS protein was subjected to
dephosphorylation using the protein phosphatase PPI (data not shown). No effect
was observed using PPI, therefore eNOS protein was dephosphorylated using the
broad-spectrum phosphatase, alkaline phosphatase. eNOS protein was incubated with
or without alkaline phosphatase and analysed by western blotting using Sigma eNOS
antibody, anti-phospho eNOS antibody, anti-dephospho eNOS antibody and also an
anti-phospho eNOS Ser-II77 antibody donated by D.G. Hardie (figure 3.6, panel A).
Protein loading of the treated and untreated samples was not equal in this experiment
(see results using Sigma antibody) therefore the bands were quantified by
densitometric analysis (panel B). The relative intensity of the alkaline phosphatase
treated protein to that of the untreated protein detected by the Sigma antibody was
calculated to be 87%. This is similar to the relative intensity using the anti-
dephospho eNOS antibody (85%), indicating that increased amounts of dephospho
eNOS Ser-II77 are not being detected by the dephospho antibody. However, relative
intensities of alkaline phosphatase treated to untreated protein for the anti-phospho
eNOS antibody and the anti-phospho eNOS from Dundee were 62% and 38%
respectively. This suggests that alkaline phosphatase is dephosphorylating eNOS to
some extent, which is detected by less binding of the anti-phospho eNOS antibodies
to the alkaline phosphatase treated samples.
95
A+ + + AlkalinePhosphatase
175
_': .__ eNOS......-.- .......-
83 r
62
p """,~,
eNOS
Sigma Phospho Dephospho Phospho antibody(Dundee)
B
~100
~..
~
~....== 75..........
"e
~..
~
~
J,.;.. 5(}~
0
~e~
~.......
251;11=~
"e
"0=~= 0
I
Sigma Phospho Dephospho Phospho
(Dundee)
eNOS Antibody
96
Figure 3.6 Alkaline phosphatase treatment of eNOS
eNOS protein (250 ug) was incubated in the presence or absence of alkaline
phosphatase (a total of 100 units), as described in section 2.3.5.7. Proteins were then
subjected to SDS-PAGE (25 ug/lane), transferred to nitrocellulose and probed with
antibodies as described: anti-eNOS from Sigma, 1:1000 dilution, anti-phospho
eNOS, 1:200 dilution, anti-dephospho eNOS, 1:200 dilution, anti-phospho eNOS
from Dundee, 1:250 dilution (Panel A). Panel B shows desitometric analysis of the
immunoblots from panel A. Positions of molecular weight standards are shown on
the left of panel A.
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3.2.2.4 Western blotting in endothelial cells
As much of the work on eNOS is undertaken in endothelial cells, the ability of the
antibodies to detect eNOS phosphorylation in endothelial cells was assessed.
Endothelial cells lysates were prepared from HAECs that had undergone various
incubations (see figure 3.7). Lysates were probed with an anti-PKB antibody, and
with the Sigma anti-eNOS antibody, and show equal loading of protein. Lysates were
probed with anti-phospho PKB (Ser-473) antibody (figure 3.7). In the presence of
IGF-l, but not insulin or EGF, PKB phosphorylation is increased. The samples were
also probed with the phospho- and dephospho-eNOS antibodies, and with the
phospho-eNOS antibody from Dundee. None of these antibodies appear to show any
differences in eNOS phosphorylation state in response to any of the stimuli.
Bas Ins IGF EGF Bas Ins IGF EGF
PKB ~I I~:=--====l
t._______J1 I==______.I
Phospho-PKB
Sigma Dundee
Figure 3.7 Western blotting of HAEC Iysates
HAECs were cultured as described in section 2.3.5.8. HAEC lysates were prepared
using standard lysis buffer (section 2.2) after the following treatments: basal, 1 I-lM
insulin, 100 nM IGF-1, and 10 ng/ml EGF (all stimulations were for 10 min). 20 ug
protein was subjected to SDS-PAGE and transferred to nitrocellulose. Nitrocellulose
was incubated with antibodies as described: anti PKB, anti phospho-PKB (Ser-473),
and Sigma anti-eNOS, all at 1:1000 dilution; Dundee anti-eNOS, 1:1000 dilution,
anti phospho- and anti dephospho-eNOS at 1:200 dilution. Shown are representative
data from three experiments. The cells used in these experiments were cultured by
Dr.1. SaltlMrs V. Morrow.
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3.2.2.5 Confocal microscopy of endothelial cells
Studies were undertaken to test the efficiency of the antibodies for microscopy, in the
event that their specificity could be confirmed. Figure 3.8 shows confocal
microscope images of HAECs stained as described in section 2.3.5.9. Both the anti-
phospho and dephospho-eNOS antibodies appear to be effective for confocal
microscopy. Like the commercially available antibody they appear to show eNOS
protein present in an intracellular, peri-nuclear location and to a lesser extent, around
the plasma membrane.
Figure 3.8 Confocal microscopy of endothelial cells
HAECs were cultured and coverslips were subjected to methanol fixation and stained
with antibodies, as described in section 2.3.5.9. Dilutions of antibodies used were
Sigma 1:50, anti-phospho eNOS 1:50, anti-dephospho eNOS 1:50. Control is with
secondary antibody only. This experiment was performed by Dr. I. Salt.
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3.3 Discussion
The phospho- and dephospho-specific eNOS Ser-1177 antibodies, prepared and
characterised, as described above, are effective in detecting eNOS proetin for use in
western blotting, immunoprecipitation and microscopy (figures 3.2, 3.3 and 3.8).
They also recognise eNOS protein harvested from virally infected cells and in
endothelial cells (figures 3.2 and 3.7). However, some doubts exist regarding their
specificity for the phosphorylated/non-phosphorylated protein.
The data in figure 3.2, in which western blotting has been undertaken in the presence
and absence of blocking peptides, suggests the antibodies are specific, in that,
binding of protein is blocked only in the presence of the peptide to which the
antibody was raised.
However, sequential immunoprecipitation experiments usmg the phospho- and
dephospho-eNOS antibodies gave rather complex results, and the eNOS protein was
not immunoprecipitated as expected, and this cast doubts as to the specificity of the
antibodies. When the anti-dephospho antibody was used in the first instance, it
appears to have depleted most of the eNOS from the supernatant, therefore when the
second antibody was used (anti-phospho or -dephospho), there was little protein to
immunoprecipitate. However in the pellet from the first anti-phospho IP, there
appears to be a substantial amount of phospho protein. This suggests that when the
anti-phospho antibody was used to IP from the dephospho immuno-depleted
supernatant a substantial band of phospho eNOS should have been detected.
However, this was not the case and only a very slight band was observed. Therefore
it is possible that the anti-dephospho antibody has depleted the supernatant of both
the phospho and dephospho protein. Conversely, it may be that in the presence of
phospho and dephospho protein, the anti-phospho eNOS antibody has an affinity for
the dephosphorylated protein.
To examine the specificity of the antibodies further eNOS protein that had been
phosphorylated or dephosphorylated was prepared, the assumption being that only
the anti-phospho eNOS antibody would recognise eNOS treated with kinase and only
the anti-dephospho eNOS antibody would recognise phosphatase treated eNOS.
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AMPK was used to phosphorylate eNOS (figure 3.5). It was expected that AMPK
would phosphorylate all the serine and threonine residues (within consensus
sequences) in the eNOS protein (including Thr-495 and Ser-1177), due to the high
concentrations of kinase and substrate in the reaction. By phosphorimage analysis, it
was determined that eNOS had been phosphorylated by AMPK, and using antibodies
specific for phospho Thr-495, phosphorylation of this residue was detected.
However, neither the phospho-specific or the dephospho-specific eNOS Ser-II77
antibodies discriminated against eNOS incubated with or without AMPK. These
results suggest that the antibodies are not specifically recognising
phosphorylatedlunphosphorylated protein, or alternatively that the protein has not
actually been phosphorylated on Ser-1177. However, (Chen et al., 1999), showed
that AMPK can phosphorylate eNOS on Thr-495, as well as Ser-II77, in the absence
of calcium-calmodulin, and the reaction conditions to detect preferential
phosphorylation of Ser-II77 were similar to that used here. Therefore,
phosphorylation of eNOS on Ser-II77 would have been expected to occur.
Alkaline phosphatase was used to dephosphorylate eNOS (figure 3.6). The protein
sample treated with alkaline phosphatase contained less phospho-eNOS Ser-II77
(using both the antibody prepared in-house and the antibody gifted by D.G. Hardie).
However no increase in dephospho-eNOS was detected using the dephospho-specific
antibody. It would have been prudent to blot for phospho-Thr-495, to look for global
dephosphorylation as this would provide a control for global dephosphorylation.
However figure 3.5 shows untreated eNOS to have very low, almost undetectable
levels of phospho-Thr-495. Therefore, it has not been determined whether alkaline
phosphatase was efficient in dephosphorylating the eNOS protein, and whether any
differences would have been likely to be identified using these antibodies.
Dephosphorylation was also attempted using protein phosphatase 1 (PP1) (data not
shown), but no changes in phosphorylation could be detected using the phospho- and
dephospho-eNOS Ser-1l77 antibodies. One recent study (Michell et al., 2001)
suggests that PP2A is responsible for dephosphorylation of the Ser-II77 site,
therefore it is possibly not surprising dephosphorylation was not detected in the
presence ofPPI.
101
Prof. D.G. Hardie, University of Dundee gifted an anti-eNOS, phospho Ser-II77
antibody. It is presumed that this antibody is indeed specific for the phosphorylated
Ser-II77 residue, (although no evidence is available to support this). This antibody
reacts similarly to the phospho-specific antibody prepared in-house.
Phosphorylation of eNOS Ser-II77 in response to insulin (Montagnani et al., 2001)
and IGF-I (Michell et al., 1999) has been observed in endothelial cells. However,
this was not the case in this study. IGF-I, but not insulin, stimulated phosphorylation
(and presumably activation) of PKB, but neither of the stimuli resulted in
phosphorylation of eNOS Ser-II77 (figure 3.7) in HAECs, as determined by the
antibody prepared in-house or that gifted by D.G. Hardie. As insulin did not result in
activation of PKB, it would not be expected to cause eNOS activation, as it is well
documented that eNOS is down-stream of PKB (Fulton et al., 1999, Dimmeler et al.,
1999). It is possible that there was a problem with the cells, but this is unlikely, as
the experiment was carried out on 3 separate occasions, or again it may be possible
that the antibodies are not specific for the phosphorylated protein.
Confocal microscopy carried out usmg these phospho and dephospho eNOS
antibodies and the commercially available antibody (figure 3.8) showed two pools of
enzyme. The majority of staining was observed in a peri-nuclear region, with lesser
amounts around the plasma membrane. This peri-nuclear staining is probably the
Golgi, consistent with previous findings (Fulton et al., 2002).
At this stage, it cannot be stated conclusively whether the antibodies designed do
specifically recognise eNOS phosphorylated/unphosphorylated at Ser-II77.
Therefore they cannot at present be used for further studies of eNOS phosphorylation
in skeletal muscle.
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CHAPTER4
EXAMINATION OF SKELETAL MUSCLE OF THE STROKE-PRONE
SPONTANEOUSLY HYPERTENSIVE RAT FOR A DEFECT IN INSULIN
SIGNALLING
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4.1 Introduction
Reduced insulin-stimulated glucose uptake (insulin resistance) by skeletal muscle
and adipose tissue is of major pathogenic importance in several common human
disorders including type 2 diabetes, hypertension, obesity and combined
hyperlipidaemia but the underlying mechanisms are unknown. For this reason animal
models of insulin resistance are valuable tools for studying the phenotype and
elucidating the mechanisms involved.
As described in section 1.5.3 the SHRSP is an animal model of hypertension, which
also exhibits insulin resistance in adipose tissue and skeletal muscle. However, the
underlying mechanisms leading to development of hypertension and insulin
resistance in this animal have not been identified.
4.1.1 Aims of Chapter
The aim of the present study was to determine if any defects could be identified in
the 'classical' insulin-signalling cascade (see introduction, section 1.2) in skeletal
muscle of the SHRSP compared to the normotensive control WKY strain, and
determine whether this accounted for the insulin resistance. This involved analysis of
levels and localisation of a number of proteins by western blotting, and assessing
activity levels of key components of the signalling pathway. Similarly, the possibility
of a defect in the proteins involved in glycogen storage and metabolism was
investigated.
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4.2 Results
4.2.1 Skeletal muscle of SHRSP is insulin resistant
To confirm the results of James et al. (2001), the ability of insulin to stimulate
glucose transport in skeletal muscle of SHRSP and WKY was determined. Figure 4.1
shows that in response to insulin, glucose transport in the SHRSP is lower than that
observed in the WKY. Thus, SHRSP skeletal muscle exhibits insulin resistance
compared to WKY.
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Figure 4.1 The effect of insulin on 2-deoxyglucose uptake in FDB muscle
from SHRSP and WKY rats
Flexor digitorium brevis (FOB) muscles were incubated in KH buffer for 30 min in
the presence or absence of 1 ~M insulin in 95 % O2/5 % CO2 prior to assay of deGle
uptake as described in section 2.3.2.4. The results are expressed as fold stimulation
over basal. The results shown are the mean ± S.E.M. for three experiments.
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4.2.2 Analysis of the classical insulin-signalling pathway in WKY and SHRSP
skeletal muscle
4.2.2.1 Analysis of the sub-cellular distribution of insulin-signalling pathway
components
Many signalling pathways, including the insulin-signalling pathway, are subject to
strict compartmentalisation within cells, to allow correct propagation of the signal
and development of the appropriate response (Clark et al., 1998). Hence, the cellular
content and distribution of molecules involved in insulin signalling and glucose
uptake was characterised in skeletal muscle from SHRSP and control WKY rats, by
performing sub-cellular fractionation of skeletal muscle.
Initially complex fractionation procedures were attempted, following protocols from
(Bonen et al., 2000 and Dombrowski et al., 1996). These however, were unsuccessful
and a crude fractionation procedure was therefore undertaken, in which a low speed
centrifugation was first used to pellet heavy membranes and organelles. The
supernatant from this spin was then subjected to a high-speed centrifugation in order
to separate light membranes and cytosol (see section 2.3.2.6). Figure 4.2 panel A
shows the results of this work. The light membrane fraction contains the majority of
the intracellular membranes, as shown by the majority of the cellular GLUT 4 being
present in this fraction. IRS-l and IRS-2 are localised predominantly in the light and
heavy membrane fractions, whilst PI3-kinase (p85 subunit) is localised
predominantly in the light membrane and soluble protein fractions of skeletal
muscle. Quantification of this data (figure 4.2, panel B) shows there are no
significant differences between the protein levels and distribution of GLUT 4, IRS-I,
IRS-2 and the p85a subunit ofPI3-kinase in WKY and SHRSP skeletal muscle.
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Immunoblot analysis of insulin signalling proteins in skeletal
muscle from SHRSP and WKY rats
Crude skeletal muscle fractionation of soleus muscle was carried out as described in
Figure 4.2
section 2.3.2.6. Fractions (20 ug protein) were subjected to SDS-PAGE and
transferred to nitrocellulose (as described in sections 2.3.1.1 and 2.3.1.2). The
distribution of IRS-I, IRS-2 and the p85a subunit of PI3-kinase in skeletal muscle
fractions from SHRSP and WKY animals were analysed by immunoblotting (panel
A), all antibodies were used at a dilution of 1:1000. LM = light membranes, HM =
heavy membranes, Cyt = soluble protein fraction. The data presented are
representative of three experiments of this type. Panel B shows quantification of data
from three experiments of this type. No differences were observed in either
expression level or sub-cellular distribution for any of the proteins studied.
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4.2.2.2 Analysis of PKB protein levels and activity
PKB is activated in response to insulin and lies downstream of PI3-kinase in the
insulin-signalling cascade. PKB activates a number of downstream signals in
response to insulin (see introduction, section 1.2.4). Three isoforms of PKB are
expressed in mammalian cells (PKB c, ~ and y), with PKB <l and ~ being the major
isoforms expressed in skeletal muscle.
The total levels of PKB protein in skeletal muscle from WKY and SHRSP were
examined. This was carried out using an antibody directed against the PH domain of
PKB, which recognises all the isoforms. Figure 4.3 panel A shows levels of PKB
protein are similar in EDL and soleus muscle from WKY and SHRSP. PKB is
activated by phosphorylation at residues Thr-308 and Ser-473 (Alessi et aI., 1996).
Using an antibody which specifically recognises PKB phosphorylated at threonine
308 it was determined that in response to insulin, PKB from EDL and soleus muscle
is phosphorylated to a similar extent on Thr-308, whether from WKY or SHRSP
(Figure 4.3, panel B).
PKB activity was also measured, to determine if the cascade from the insulin
receptor, leading to PKB activation is intact. PKB activity was determined on PKB
immunoprecipitated from muscle lysates using the anti-PKB-PH domain antibody.
Figure 4.3, panel C shows basal levels ofPKB activity from EDL and soleus muscles
to be similar between the two strains. In the presence of insulin a robust activation of
PKB occurs in skeletal muscle from both WKY and SHRSP, and levels of PKB
activity are similar in each strain. This suggests that the defect in the SHRSP causing
insulin resistance does not occur in the 'classical' insulin-signalling cascade, due to
the fact that the insulin-signalling pathway leading to PKB activation is intact.
109
Band intensity -::s
(arbitrary units)
enc-.....::s
to~ trJen
~ ~ Cl-t::; S' + t'"' ~e- en ~S C/)
S· 0 --<er
+ Cen
to trJ~ Cl
r./'.J en C/)
Q e. + t'"' ::r::-~ S ~='" en C/) C/)S 0 '"tj
S· -('1)+ =en• []
C/J
~ t::c:?;:J
C/J -< '"tj'"C g;
-o
Band Density
(arbitrary units)
t
+
+
+
+
C/)
o-('1)
Cen
C/)
o-('1)
Cen
C
2 D WKY
• SHRSP
1.5
--~~;:::e~-;: = 1Cj ....~ e
~~~ eQ,.._
0.5
EDL
Basal Insulin
Soleus
Basal Insulin
Figure 4.3 Analysis of PKB levels and activity in skeletal muscle from
SHRSP and WKY
Panels A and B: skeletal muscle lysates were prepared as described in section
2.3.2.5. Protein (20 I-lg)was subjected to SDS-PAGE and western blotting (sections
2.3.1.1 and 2.3.1.2). Panel A: total PKB levels were determined by immunoblotting
with an antibody specific for PKB-PH domain. Quantification of three experiments
of this type shows PKB levels are similar in skeletal muscle from WKY and SHRSP.
Panel B: levels of phosphorylated PKB were determined using an antibody that
specifically recognises PKB phosphorylated at Thr-30S. Quantification of three
experiments of this type showed insulin induces similar levels of phosphorylation of
PKB at Thr-308 in WKY and SHRSP skeletal muscle. Panel C: EDL and soleus
muscles were incubated for 30 minutes in the presence or absence of 1 I-lMinsulin.
Muscle extracts were prepared as described in section 2.3.2.5. PKB activity was
determined in PKB immunoprecipitates, by the ability of PKB to phosphorylate a
substrate peptide, as described in section 2.3.2.7. The results are the mean ± S.E.M.
for three experiments. The levels of PKB activity are similar in EDL and soleus
muscle for WKY and SHRSP.
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4.2.2.3 Analysis of protein levels of various PKC isoforms
A number of PKC isoforms have been implicated in insulin action (see introduction,
section 1.2.5). For example, the conventional and novel PKCs have been implicated
to function as negative feedback inhibitors of the insulin and IRS proteins, whilst the
atypical PKCs are suggested to be downstream targets for signals generated by the
insulin receptor (Farese, 2002). Therefore it was deemed prudent to analyse
expression levels of a number of PKC isoforms in skeletal muscle from SHRSP and
WKY.
Expression of the conventional PKC isoforms, PKC a. and PKC p, was determined in
skeletal muscle from SHRSP and WKY. PKC a. is an 82 kDa protein whose level of
expression appears to be similar in EDL, soleus and tibialis muscle from SHRSP and
WKY (figure 4.4). A band is also recognised by the anti-PKC a. antibody that is
smaller in size than that expected for PKC a.. The identity of this band has not been
determined. Levels of expression of PKC p also appear to be similar in EDL, soleus
and tibialis muscle from SHRSP and WKY (figure 4.4). PKC P is an 80 kDa protein,
but again, the anti-PKC p antibody also recognises an additional band, smaller in size
(around 70 kDa) than that expected for PKC p. Again the identity of this band is
unknown. Expression of another conventional PKC was also examined in these
skeletal muscles, however expression of PKC 'Y could not be detected in these rat
skeletal muscle lysates.
Expression levels of the novel PKC isoforms (PKCs 8, E and 9) was also assessed in
WKY and SHRSP skeletal muscles. Of the muscles analysed, PKC 8 expression is
highest in soleus muscle with less in EDL and tibialis muscle (figure 4.4), however
levels ofPKC 8 expression appears to be similar in WKY and SHRSP strains. PKC 8
is an 80 kDa protein, and again the antibody raised against this protein recognises a
non-specific band of lower molecular mass. PKC E is a 90 kDa protein, whose
expression is highest in tibialis muscle, followed by EDL muscle and is lowest in
soleus muscle (figure 4.4), however PKC E expression appears to be similar in the
two strains. The anti-PKC E antibody also recognises a non-specific band at around
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70 kDa (data not shown). PKC e is a 79 kDa protein which is expressed at similar
levels in EDL, soleus and tibialis muscle. This protein is also expressed at similar
levels in muscle from both WK.Yand SHRSP animals.
Expression of the atypical PKC isoforms was also studied in these muscles. PKC t is
a 74 kDa protein whose expression levels are similar in EDL, soleus and tibialis
muscle and is also expressed at similar levels in muscle from both WK.Yand SHRSP
animals (see figure 4.4). A number of bands are recognised by the antibody directed
against this protein, the one that is PKC t being determined using a positive control
(not shown), but the identity of the non-specific bands is unknown. Expression of the
other atypical PKC isoforms, PKCs A and S, were also examined in these muscles.
However, PKC A could not be detected, and antibodies specific for PKC S did not
prove effective when blotting skeletal muscle lysates.
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4.2.3 Regulation of glycogen storage and metabolism in SHRSP skeletal muscle
4.2.3.1 Analysis of GSK-3 expression and activity
The major role of insulin in skeletal muscle is in regulating glycogen metabolism.
This occurs via activation of PKB, which phosphorylates and inactivates GSK-3
(Cross et aI., 1995). GSK-3, when active, phosphorylates and inactivates glycogen
synthase. Therefore activation of PKB by insulin results in dephosphorylation of
glycogen synthase due to inhibition of GSK-3. Two isoforms of GSK-3 exist (GSK-
3a and GSK-3P), which are ubiquitously expressed. The proteins exhibit 97%
sequence similarity in the kinase domain, but vary significantly outwith this region
(see section 1.2.6.1). The levels and activity of both GSK-3 isoforms were studied in
skeletal muscle from WKY and SHRSP.
Figure 4.5 panel A shows GSK-3a activity in basal and insulin-stimulated WKY and
SHRSP EDL and soleus muscles. GSK-3a activity is slightly lower in skeletal
muscle from SHRSP, compared to WKY, however this did not reach statistical
significance. Of note is that inhibition of GSK-3a activity is not observed in the
presence of insulin, in skeletal muscle from either strain. Panel B shows that in both
EDL and soleus muscle from SHRSP, GSK-3a protein is greatly reduced in
comparison to that from WKY. From the immunoblot it appears the protein which is
expressed in the SHRSP has a lower molecular weight to that in the WKY and it was
hypothesised that this may be due to dephosphorylation of the GSK-3a present. In
order to dephosphorylate the WKY protein, WKY and SHRSP muscle lysates were
treated with the protein phosphatase PP1. This treatment did not appear to change the
banding pattern observed for GSK-3a from either WKY or SHRSP (data not shown).
Figure 4.6 panel A shows that like GSK-3a, GSK-3p activity is also similar in the
two strains, again with a slight reduction in the activity of the protein from SHRSP,
but not reaching statistical significance. Also, no inhibition of GSK-3p activity is
observed in the presence of insulin. Figure 4.6, panel B shows the levels of GSK-3p
protein to be similar in skeletal muscle from SHRSP and WKY, unlike the
differences observed for GSK-3a.
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Analysis of GSK-3a levels and activity in skeletal muscle from
SHRSP and WKY rats
EDL and soleus muscles were incubated for 30 minutes in the presence or absence of
1 ).lMinsulin. Muscle extracts were prepared as described in section 2.3.2.5. GSK-3a
Figure 4.5
activity was then determined as described in section 2.3.2.8 (panel A). The results are
the mean ± S.E.M. for three experiments. GSK-3a activity in WKY and SHRSP is
not significantly different. Shown in panel B is an immunoblot for GSK-3a.. Skeletal
muscle lysates were prepared as described in section 2.3.2.5. 20 ug protein was
subjected to gel electrophoresis and western blotting (sections 2.3.l.1 and 2.3.l.2).
The immunoblot shown is representative of data from 4 separate experiments.
SHRSP expresses less GSK-3a than does the WKY.
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Analysis of GSK-3J3 levels and activity in skeletal muscle from
SHRSP and WKY rats
EDL and soleus muscles were incubated for 30 minutes in the presence or absence of
1 ~M insulin. Muscle extracts were prepared as described in section 2.3.2.5. GSK-3J3
Figure 4.6
activity was then determined as described in section 2.3.2.8 (panel A). The results are
the mean ± S.E.M. for three sets of samples assayed three times each. GSK-3J3
activity is not significantly different in EDL and soleus muscle from SHRSP and
WKY. Shown in panel B is an immunoblot for GSK-3J3. Skeletal muscle lysates
were prepared as described in section 2.3.2.5. 20 ug protein was subjected to gel
electrophoresis and western blotting (sections 2.3.1.1 and 2.3.1.2). The immunoblot
shown is representative of data from 3 separate experiments. GSK-3J3protein levels
are similar in SHRSP and WKY.
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4.2.3.2 Determination of muscle glycogen levels in SHRSP and WKY
To determine if glycogen storage differed in WKY and SHRSP skeletal muscle,
glycogen levels were analysed in EDL and soleus muscles. Glycogen was measured
using a fluorescence-linked assay in which glucose is liberated from cellular
glycogen using amyloglucosidase. Hexokinase is used to catalyse the conversion of
glucose to glucose-6-phosphate (G6P), and G6P-deyhdrogenase is used to convert
G6P to gluconate-6-phosphate, with the subsequent reduction of NADP. Production
ofNADPH is determined by changes in fluorescence.
Initial experiments (data not shown) suggested that SHRSP skeletal muscles had
elevated glycogen levels compared to the WKY. However, refinement of the method,
suggested that this was not the case and that the SHRSP has similar muscle glycogen
levels to the WKY (figure 4.7). There is a tendency for SHRSP EDL to have less
glycogen per milligram of protein, and soleus muscle to have more, compared to
WKY. However, neither of these data were statistically significant. Again, insulin
had little effect on glycogen levels in these samples.
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Figure 4.7 Analysis of glycogen levels in EDL and soleus muscle of SHRSP
andWKY
Glycogen assays were performed on EDL and soleus muscle as described in section
2.3.2.9. The data presented are the mean ± S.E.M. of three independent experiments.
Muscle glycogen levels are not statistically different between the two strains.
121
4.2.3.3 Analysis of glycogen metabolism in WKY and SHRSP muscle
To determine if any alterations in glycogen metabolism were present in SHRSP
skeletal muscle, the processes of glycogen synthesis and breakdown were studied.
Glycogen synthesis was measured as [14C]-glucose incorporation into glycogen.
Figure 4.8 shows that insulin stimulates glycogen synthesis in FBD muscle around 3-
fold and levels of both basal and insulin-stimulated glycogen synthesis are similar in
both strains.
12000 D Basal
10000 1 • Insulin
8000
6000
4000
2000
WKY SHRSP
Figure 4.8 Comparison of glycogen synthesis in FDB muscle from WKY and
SHRSP
FDB muscles were incubated in the presence or absence of 1 JlM insulin for 1 hr at
37°C. Glycogen synthesis was measured as described in section 2.3.2.10. The results
are the mean ± S.E.M. for three experiments. Basal and insulin-stimulated glycogen
synthesis are not significantly different between WKY and SHRSP.
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Glycogen is degraded by the action of phosphorylase and debranching enzyme (see
section 1.2.6.3). Therefore, glycogen phosphorylase activity was measured to give an
indirect measurement of glycogen breakdown in skeletal muscle from WKY and
SHRSP animals. Phosphorylase exists in two forms: phosphorylase a, which is active
and phosphorylase b, which is usually inactive. Phosphorylase b can be converted to
phosphorylase a by phosphorylation by phosphorylase kinase. In muscle
phosphorylase b is active only in the presence of high levels of AMP. Therefore
when studying phosphorylase activity, the activity of both the isoforms are measured
and phosphorylase activity is expressed as a ratio of the two.
Glycogen phosphorylase activity ratio is higher is EDL muscle, than in soleus
muscle. However, glycogen phosphorylase activity ratio is not significantly different
in EDL or soleus muscle from SHRSP and WKY (figure 4.9). Also, insulin did not
produce any significant changes in the activity ratio of glycogen phosphorylase in
muscles from either strain.
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Figure 4.9 Analysis of glycogen phosphorylase activity in EDL and soleus
muscle from WKY and SHRSP
EDL and soleus muscles were incubated in the presence or absence of 1 J.lMinsulin
for 30 min. Glycogen phosphorylase activity was determined (using 200-250 ug
muscle extract) as described in section 2.3.2.11. The results are the mean ± S.E.M. of
four experiments. Glycogen phosphorylase activity (basal and insulin-stimulated) is
not significantly different in WKY and SHRSP skeletal muscle.
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4.2.4 Skeletal muscle fibre-typing
Skeletal muscles consist of a variety of oxidative and glycolytic fibres that have
specific roles in muscle metabolism (see introduction, section 1.3.1). Fibre type
distribution is known to differ in various muscle types and different skeletal muscle
fibre types have varying sensitivities to insulin and exercise. Therefore, skeletal
muscle fibre-typing was performed (by Dr Ian Montgomery) to determine if any
alterations in fibre type number or distribution were present in SHRSP skeletal
muscle which could account for the insulin resistance observed.
Two different approaches are typically used when fibre typing skeletal muscles
histochemically. These are determination of myosin ATPase activity and analysing
reference enzymes of anaerobic and aerobic metabolism, for example succinate
dehydrogenase and glycerol phosphate dehydrogenase (reviewed in Pette and Staron,
1990), which have been shown to differ in the various skeletal muscle fibre types.
Skeletal muscles from WKY and SHRSP were extensively fibre typed using these
techniques. Shown are stains for succinate dehydrogenase and myosin ATPase,
undertaken at pH 9.4 (figure 4.10). Fibre number and distribution appear to be
similar in EDL muscle from WKY and SHRSP (figure 4.10). Similar results were
also obtained in soleus and FDB muscle (data not shown).
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Figure 4.10 Fibre typing of EDL muscles
Upper panel: EDL muscles were sectioned and stained for succinate dehydrogenase
as described in section 2.3.2.12.1. Type 1 fibres stain most intensively for succinate
dehydrogenase, type 2A fibres have an intermediate staining pattern and type 2B
fibres show low levels of staining for succinate dehydrogenase. Lower panel: EDL
muscles were sectioned and stained for myosin ATPase as described in section
2.3.2.12.2. This experiment was performed by Dr I Montgomery.
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4.3 Discussion
The cause of the insulin resistance observed in the SHRSP remains elusive, as no
defects in the 'classical' insulin-signalling cascade, or in insulin-regulated glycogen
metabolism have been identified in this study.
In the SHRSP, the insulin-signalling cascade leading to PKB activation is intact
(figure 4.3, panel B) as evidenced by the data showing that basal and insulin
stimulated PKB activity is similar in magnitude in both WKY and SHRSP skeletal
muscle. This is further shown by the presence of similar levels of PKB
phosphorylated on Thr-308 (a phosphorylation required for activation of the protein),
in response to insulin.
The compartmentalisation of proteins downstream of insulin in the signalling
pathway is likely to be important in regulation of signal propagation. For example,
the glucose transporter GLUT 4 is reported to reside predominantly in intracellular
GLUT 4 storage vesicles in the basal state. It has also been suggested that
localisation of IRS-1 and PI3-kinase to the cytoskeleton in adipocytes is important in
activation of GLUT 4 translocation and increases in glucose transport in response to
insulin (Clark et al., 1998). It was further suggested that release of IRS proteins from
this compartment may lead to development of insulin resistance (Clark et al., 2000).
Therefore, subcellular localisation of a number of proteins involved in insulin
signalling was examined by subcellular fractionation of skeletal muscle. The data in
figure 4.2 confirms that in the SHRSP, there are no alterations in expression or sub-
cellular localisation of the insulin-signalling proteins, GLUT 4, the insulin receptor
substrate proteins IRS-1 and IRS-2 and the p85a (regulatory) subunit of PI3-kinase.
This further suggests that the 'classical' insulin-signalling pathway is intact.
However, it should be noted that in one study, insulin activation of PKB was normal
in skeletal muscle from obese and diabetic patients, despite decreases in insulin-
stimulated PI3-kinase activity (Kim et al., 1999).
Another downstream target of insulin is PKC. A number of isoforms of PKCs exist,
many of which are expressed in skeletal muscles (figure 4.4). The level of expression
of all of the PKC isoforms examined was similar in WKY and SHRSP muscles.
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However, expression of the atypical PKC isoforms (PKCs A and s) which are most
likely insulin effectors could not be determined. In the case ofPKC S, this was due to
the lack of a good positive control and the non-specific nature of the antibody. PKC
A is the mouse homologue of PKC t therefore its expression may not be expected in
rat skeletal muscle. A non-specific band of around 70 kDa was detected using a
number of the antibodies (anti PKC ex,~, 8, f: and t), These antibodies were all raised
against different regions of the proteins of interest, suggesting the non-specificity has
not resulted due to the nature of the immunogen. The identity of the non-specific
bands was not determined.
The primary role of insulin in skeletal muscle is the storage of elevated blood
glucose as glycogen and muscle glycogen synthesis has been reported to be
decreased by up to 50% in diabetic individuals (Shulman, 2000). Therefore, the role
of insulin in regulating glycogen metabolism was studied in SHRSP skeletal muscle
as in the presence of decreased glucose uptake into the skeletal muscle it might be
expected that glycogen storage would be decreased. Glycogen metabolism in these
muscles was examined by determining protein levels and activity of the glycogen
synthase kinases GKS-3ex and ~, by analysing the processes of glycogen synthesis
and breakdown in SHRSP skeletal muscle, and by determining muscle glycogen
levels. No differences in the levels of glycogen synthesis, glycogen phosphorylase
activity or GSK-3 activity were observed in skeletal muscle from SHRSP compared
to that from WKY.
However, in this study insulin did not inhibit either GSK-3a or ~ activity (insulin
incubation was 1 IlM for 30 minutes at 37°C), figures 4.5 panel A and 4.6 panel A, in
skeletal muscle from WKY or SHRSP. Neither did insulin affect cellular glycogen
levels (figure 4.7), and only a minor effect was observed on glycogen phosphorylase
activity (figure 4.9). This is surprising, as insulin is known to inhibit GSK-3 in
skeletal muscle (Cross et aI., 1997), and insulin was seen to activate PKB (figure 4.3)
and glycogen synthesis (figure 4.8) in this study. One possibility may be that GSK-3
inhibition and glycogen phosphorylase activation occurs transiently in response to
insulin. Hence, during the course of the 30 minute stimulation which has been chosen
for these experiments, GSK-3 and phosphorylase activities may have returned to
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basal levels, and thus inhibition/activation was not detected. This was not a problem
when assaying glycogen synthesis, as radiolabelled product accumulates with time.
Activation of PKB has also been reported to be transient with maximal activation in
response to insulin being reported to occur within 5 minutes, and return to basal
levels after around 30 minutes (Cross et al., 1997). However, in this study, a robust
activation of PKB by insulin was observed (figure 4.3), using a method similar to
that for GSK-3.
As previously stated, no significant differences in GSK-3a or p activity were
observed in EDL or soleus muscle from SHRSP, as compared to WKY. However
some problems were encountered on assaying GSK-3p as the samples showed intra-
and inter-sample variation, as shown by the large error bars on the graph (figure 4.6,
panel A). GSK-3p protein levels were similar between the two strains, however
GSK-3a protein expression was shown to be decreased in SHRSP skeletal muscle
(EDL and soleus), compared to WKY (figure 4.5, panel B). The presence of less
GSK-3a protein in SHRSP skeletal muscle did not affect the levels of activity
observed (figure 4.5, panel A), suggesting that the small amount of protein present in
the SHRSP has a relatively high specific activity. From the immunoblot it appears
the protein which is expressed in the SHRSP has a lower molecular weight to that in
the WKY. The samples were prepared in the presence of the protease inhibitors
SBTI, benzamidine and PMSF therefore it was presumed that the lower molecular
weight species were not due to degradation of the protein. It was hypothesised that
dephosphorylation of the GSK-3a protein may have resulted in the lower molecular
weight observed, which would presumably make the protein more active. However,
this again would not have been expected due to the prsence of phosphatase inhibitors
in the lysis buffer. Treatment of muscle lysates from WKY and SHRSP with PP! did
not change the banding pattern observed for either of the strains, suggesting the
change in molecular weight observed in the SHRSP protein was not due to
dephosphorylation. However, no other phosphatase was utilised in this experiment
and it may be that another phosphatase e.g. PP2A would bring about
dephosphorylation of the protein.
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Initial experiments on glycogen storage (data not shown) suggested that SHRSP
muscle had elevated glycogen levels compared to the SHRSP. However, refinement
of the method, suggested that this was not the case and that the SHRSP has similar
muscle glycogen levels to the WKY (figure 4.7). However, the error bars on the
graph are large in some cases. This is believed to be due to the technically
challenging nature of the assay, and possibly due to some variation among animals.
As an alternative methodology, glycogen metabolism was investigated more fully by
studying glycogen synthesis (figure 4.7) and glycogen phosphorylase activity (figure
4.8). No significant differences in glycogen synthesis or glycogen phosphorylase
activity were detected in skeletal muscle from WKY and SHRSP skeletal muscle.
This further supports the data suggesting there are no differences in glycogen storage
in skeletal muscle from SHRSP and WKY. Skeletal muscle glycogen content in these
two strains has also been analysed histochemically and by electron microscopy (Dr. I
Montgomery, personal communication). Again no differences in glycogen storage
were identified.
Skeletal muscle from WKY and SHRSP has been fibre-typed immuno-
histochemically (figure 4.10). The results from this work show similar distribution
and number of fibre types in skeletal muscle from SHRSP and WKY. Also, no gross
morphological differences were apparent in the muscle from SHRSP, which could
account for the insulin resistant, hypertensive phenotype observed in these animals.
Thus, the defect resulting in the insulin resistant phenotype in the SHRSP remains
unidentified, although a number of possibilities exist which have not been clarified.
A second pathway (involving the CAP-CbI complex) that is modulated by insulin,
and is required for GLUT 4 translocation, was recently identified (Baumann et aI.,
2000, see introduction). During the course of this study, two components of this
pathway, caveolin-l and flotillin, were observed to be over-expressed in SHRSP
skeletal muscle (James et aI., 2001). Various other components of this pathway have
been studied, but the lack of good reagents made this somewhat difficult and
unfruitful. Another possibility is that while GLUT 4 appears to be in the correct
compartment in these muscles, translocation to the plasma membrane on insulin
130
stimulation may be in some way impaired. This has not yet been analysed due to the
lack of a robust fractionation procedure.
131
CHAPTER5
A YEAST TWO-HYBRID SCREEN WITH FLOTILLIN-l
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5.1 Introduction
5.1.1 Flotillin is a protein found in lipid rafts
Flotillin-l is a 47 kDa protein, which was originally isolated from murine lung tissue,
and identified as a protein which resides in caveolae/lipid rafts (Bickel et al., 1997).
Flotillin was predicted to be an integral membrane protein due to the presence of two
hydrophobic regions in its N-tenninus (amino acids 10-36 and 134-151) and its
membrane localisation has been confirmed using a variety of methods (Bickel et al.,
1997). Flotillin-l was also reported to have two potential tyrosine phosphorylation
sites and predicted sites for phosphorylation by PKC and PKA. Regions of the C-
terminus were also reported to have the ability to form triple coiled-coils with other
flotillin monomers (Bickel et al., 1997). Subsequently human flotillin-l was cloned,
and it was reported to have 98% identity with the mouse flotillin-l (Edgar and Polak,
2001). The 42 kDa human flotillin-2 was also isolated (Hazarika et al., 1999) and the
two human flotillin isoforms were reported to have 47% sequence identity (Edgar
and Polak, 2001).
The flotillin proteins are expressed in a variety of tissues, with flotillin-2 being more
widely expressed than flotillin-l (Volonte et al., 1999). Co-immunoprecipitation
studies have resulted in the suggestion that flotillins-l and -2 form stable complexes
with caveolins-l and -2 (Volonte et al., 1999), with implications for a possible role
for the flotillin proteins in caveolae structure. Flotillin-l is highly expressed in brain
and flotillin homologues have also been identified in Drosophila (Galbiati et al.,
1998) and in goldfish (Schulte et al., 1997) and these studies suggested a role for
flotillin in neural development. James et al. (2001) also reported the over-expression
of flotillin-I and caveolin-l in skeletal muscle of the SHRSP, suggesting a possible
role for these proteins in the insulin resistantlhypertensive phenotype observed in
these animals.
5.1.2 The yeast two-hybrid system
The yeast two-hybrid system was first reported by Fields and Song (1989) and is a
powerful tool for detecting protein-protein interactions. A reporter yeast strain is
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used, containing inducible reporter genes fused to an upstream activator/promoter
sequence (for example, the GAL 4 promoter). The yeast are transformed with
plasmids containing gene fusions. The protein of interest (bait) is encoded as a gene
fusion to the GAL 4 DNA binding domain, while the second plasmid contains the
GAL 4 activation domain as a gene fusion to the library of proteins (termed the
prey). Interaction of two proteins (in this case the bait with a protein expressed in the
library) brings the activation domain into the proximity of the DNA, allowing
activation of reporter gene transcription to occur (see figure 5.1). The reporter genes
used are often nutritional genes, required for yeast growth. Hence, transformed yeast
will grow on selection media (media lacking these nutrients) if an interaction occurs
between two proteins that allows transcription of the reporter gene(s), and production
of the required nutrients.
Figure 5.1 Schematic diagram of the principle of the yeast two-hybrid system
5.1.3 Aims of Chapter
The aim of this study was to identify novel tlotillin-interacting proteins by the
method of the yeast two-hybrid system and in so doing hopefully define more clearly
the functional role of tlotillin in insulin signalling. A further aim was to study these
proteins with respect to the insulin resistanceihypertension observed in the SHRSP.
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5.2 Results
5.2.1 Flotillin expression is increased in the SHRSP
To confirm the data of James et al. (2001) who reported increased expression of
flotillin in skeletal muscle ofSHRSP, skeletal muscle lysates from WKY and SHRSP
were probed with an anti-flotillin antibody. In the three muscles tested, flotillin
expression was greater in the SHRSP compared to the WKY (see figure 5.2).
WKY SHRSP
E S T E S T
+- Flotillin
Analysis of flotillin-1 expression in skeletal muscle from WKY
and SHRSP
Muscle lysates were prepared as described in section 2.3.2.5. Protein (20 ug) was
Figure 5.2
subjected to SDS-PAGE and transferred to nitrocellulose, as described in sections
2.3.1.1 and 2.3.1.2. The nitrocellulose was probed with an anti-flotillin antibody (at
1:1000 dilution) following a similar protocol to that described in section 2.3.1.4. In
the SHRSP flotillin protein expression is increased in all three muscles tested. E =
EDL, S = soleus, T = tibialis. The data presented is representative of two
experiments of this type. Quantification of the data from these two experiments (data
not shown) revealed flotillin expression was increased on average 3-fold in EDL and
tibialis muscle and 2-fold in soleus muscle from SHRSP compared to WKY.
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5.2.2 Construction of the bait plasmid for the yeast two-hybrid screen
5.2.2.1 Cloning of human flotillin 152-427 from cDNA
When studying the interaction of proteins in the yeast two-hybrid system it is
necessary that any potential transmembrane regions of the protein of interest be
removed, to prevent the protein being targeted away from the yeast nucleus, where it
is required to activate transcription of the reporter genes. Initial studies on murine
tlotillin-l suggested the presence of two hydrophobic regions (shown in red in figure
5.3) which are suggested to be putative membrane spanning regions (Bickel et aI.,
1997). Later studies on human tlotillin-l suggested the presence of only one
membrane-spanning region (Edgar and Polak, 2001). However, to be sure the protein
would not be targeted away from the nucleus in the yeast two-hybrid screen, primers
were designed to clone the DNA encoding only amino acids 152-427 of the human
flotillin-I protein (the human flotillin-I is 1 residue shorter than the mouse isoform,
as it lacks an asparagine residue close to the C-terminus (Edgar and Polak, 2001)).
1 428
N c
10 36 134 151
Schematic diagram of mouse flotillin-l (adapted from Volonte et
al., 1999)
Putative hydrophobic/membrane spanning regions are shown in red, the suggested
Figure 5.3
cytosolic portion of the molecule is shown in blue. The numbers on the diagram
correspond to the amino acids in the protein.
DNA corresponding to amino acids 152-427 of tlotillin was PCR amplified from
human heart and skeletal muscle cDNA using the following primers:
5'-GagatctGTAAGGACATTCACGATGACCAGG-3'(BgnI site in small letters) and
5'-ctcgagTCAGGCTGTTCTCAAAGGCTTG-3'(XhoI site in small letters, STOP codon
in bold), following the protocol described in section 2.3.3.1. Agarose gel
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electrophoresis of the peR products revealed a band of the expected size (figure 5.4,
top panel), the flotillin 152-427 DNA fragment being 828 base pairs. Furthermore,
digestion of the peR product with the restriction enzyme SmaI should cut the DNA
once producing two fragments of around 440 and 390 base pairs each. Figure 5.4,
bottom panel shows such a digest and as expected two bands of the expected sizes
are observed, suggesting that flotillin 152-427 has been amplified.
Heart Sk. M
1000 bp
500bp
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Heart SkM
Uncut
Figure 5.4 peR amplification of flotillin 152-427 from beart and skeletal
muscle cDNA
Flotillin 152-427 was peR amplified as described in sections 2.3.3.1 and 2.3.4.3
from heart and skeletal muscle cDNA. Top panel: the peR product was subjected to
agarose gel electrophoresis as described in section 2.3.3.3. A band of around 850
base pairs is observed, as expected. Lower panel: the peR product was subjected to
restriction digestion with the enzyme SmaI as described in section 2.3.3.7, followed
by agarose gel electrophoresis. Two bands of less than 500 base pairs are expected,
these are not clearly resolved in the figure, but further electrophoresis did resolve
two bands (data not shown).
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5.2.2.2 TA cloning of flotillin 152-427
PCR amplified flotillin 152-427 (from muscle cDNA) was treated with Taq
polymerase as described in section 2.3.3.5, to add 'A' base overhangs onto the DNA.
This DNA was subsequently cloned into the pCRII vector, as described in section
2.3.3.6. As described, colonies were picked and small overnight cultures prepared.
From these, DNA was extracted, as described in section 2.3.3.11. The DNA was then
analysed by restriction digest using EeaRI (figure 5.5). No EeaRI sites are present in
flotillin 152-427, therefore bands of around 850 bases, corresponding to the insert,
and a larger band, corresponding to the vector, are expected. It can be seen in figure
5.5 that three of the four colonies picked contained an insert of the expected size.
DNA from colony number 2 was sequenced to confirm the insert was flotillin 152-
427, before any subsequent experimentation was carried out.
M 1 2 3 4
1000 bp
Figure 5.5 Restriction analysis of TA cloned flotillin 152-427
TA cloned flotill in 152-427 was prepared as described above, and in sections 2.3.3.5
and 2.3.3.6. Colonies were picked and grown overnight in liquid culture. DNA was
extracted from these cultures as described III section 2.3.3.11. The DNA was
subjected to restriction digest using EeaRI, as described in section 2.3.3.7, and
subsequently subjected to agarose gel electrophoresis (section 2.3.3.3). In three out
of the four colonies picked a band of around 850 bases is observed, as expected.
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5.2.2.3 Sub-cloning of flotillin 152-427 into the yeast two-hybrid bait vector,
pGBT9
The pnmers used for amplification of flotillin 152-427 had been designed to
incorporate a restriction site for BglII in the forward primer and Xhol in the reverse
primer, to allow cloning into the yeast two-hybrid vector using the complementary
BamHI and SalI sites. The pCRII-flotillin 152-427 DNA was therefore digested with
the restriction enzymes Bgill and Xhol, as described in section 2.3.3.7. pCRII has an
internal BglII site and thus three bands (of sizes around 3000, 926 and 850 bases)
were expected on restriction with these enzymes. pGBT9 was digested with BamHI
and Sail, which is expected only to linearise the plasmid, as these restriction sites are
present only in the multiple cloning site of the plasmid (see appendix). Figure 5.6
shows the DNA was cut as expected by these enzymes.
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Figure 5.6 Restriction digests of pGBT9 and pCRII-flotillin 152-427
The pCRII-flotillin 152-427 DNA was digested with BglII and XhoI, as described in
section 2.3.3.7. As expected three bands (of sizes around 3000, 926 and 850 bases)
are observed, the lower band being flotillin 152-427. pGBT9 was digested with
BamHI and SalI, which is seen to linearise the plasmid.
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The linearised pGBT9 and the flotillin 152-427 bands were excised from the gel, and
gel purified as described in section 2.3.3.4. The DNA was then ligated overnight
(described in section 2.3.3.8) and the ligated DNA transformed into XLI-blue E. coli
cells, as described in section 2.3.3.10. Colonies were picked and grown overnight in
liquid culture. DNA was extracted from these cultures as described in section
2.3.3.11. Ligation of the pGBT9 vector and the flotillin 152-427 insert using the
BamHIIBglII and XhoVSalI sites described does not result in reconstitution of
functional restriction sites. Therefore, the DNA was subjected to restriction digest
using EcoRI and Psti (as there are Psti and EcoR! sites in the multiple cloning site of
the vector, which will allow excision of the insert), as described in section 2.3.3.7,
and subsequently subjected to agarose gel electrophoresis (section 2.3.3.3). Figure
5.7 shows restriction digests of DNA prepared form DNA isolated from 4
independent colonies. Each clone appears to contain the flotillin 152-427 DNA
insert. This was confirmed by sequencing DNA from colony F. This DNA was used
in all future experiments.
M E F G H
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Figure 5.7 pGBT9-flotillin 152-427 restriction digests
Linearised pGBT9 and the flotillin 152-427 bands were ligated overnight (described
in section 2.3.3.8) and the ligated DNA transformed into Xl.l-blue E. coli cells, as
described in section 2.3.3.10.4 colonies were picked and grown overnight in liquid
culture. DNA was extracted from these cultures as described in section 2.3.3.11. The
DNA was subjected to restriction digestion using EcoRI and Psti as described in
section 2.3.3.7, and subsequently subjected to agarose gel electrophoresis (section
2.3.3.3). Each clone appears to contain the flotillin 152-427 DNA insert.
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5.2.3 Control yeast transformations
The genotype of the yeast strain (PJ692A) used in this screen is described in section
2.1.6. This yeast strain requires the presence of uracil, leucine, tryptophan, histidine
and adenine in the growth medium. The bait plasmid used in the screen encodes
expression of an enzyme required for tryptophan synthesis, and the library vector
encodes for a protein required for synthesis of leucine. Thus, PJ692A transformed
with both bait and library plasmids no longer require addition of tryptophan and
leucine to the growth medium. The reporter genes in the strain encode the expression
of histidine and adenine, therefore if bait and library proteins interact, leading to
reporter gene expression, the need for histidine and adenine in the growth medium
will also be subverted.
However, prior to performing the yeast two-hybrid screen it was necessary to check
that the bait plasmid, containing the flotillin 152-427, and the library plasmid did not
cause self-activation of reporter gene expression in the absence of an interaction
occurring. Hence, wild-type yeast were transformed with the bait vector (pGBT9-
flotillin 152-427) and the empty pACT2, as described in section 2.3.4.3. These were
plated onto media lacking leucine and tryptophan to select for yeast which had taken
up both plasmids. Six colonies were then picked and re-streaked onto media lacking
leucine and tryptophan (double drop-out, DDO) media lacking leucine, tryptophan
and histidine (triple drop-out, TDO) and media lacking leucine, tryptophan, histidine
and adenine (quadruple drop-out, QDO).
As expected, the yeast (5 of 6 colonies selected) grew on the DDO media (figure
5.8). A small amount of growth was observed on the TDO plates and almost no
growth was observed on the QDO plates (figure 5.8). No growth was expected on the
TDO plates and to prevent this 3-AT (3-amino-l,2,4-triazole), which reduces leaky
histidine expression, was included in the media at a concentration of 5 mM which
was sufficient to reduce this background growth (data not shown).
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Figure 5.8 Analysis of growth requirement of control transfected yeast
PJ692A was transformed with the bait vector pGBT9-flotillin 152-427 and empty
pAeT2, as described in section 2.3.4.3. Yeast were plated onto DDO, TDO and
QDO media and their growth monitored. 5 of 6 colonies picked grew well on DDO
media. Some residual growth was observed on TDO media, which has since been
resolved by including 3-AT in the media (data not shown).
5.2.3.1 Expression of flotillin/GAL 4 BD in control transformed yeast
Before performing the screen it was also necessary to check the bait protein was
being expressed in the transformed yeast cells. Therefore yeast lysates were prepared
and western blot analysis performed. Figure 5.9 shows a band of around 47 kDa is
present in skeletal muscle, corresponding to flotillin-l. In 5 of the 6 yeast lysates a
band of slightly smaller than 47 kDa is present, corresponding to flotillin 152-
427/GAL 4 DNA binding domain fusion protein.
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Figure 5.9 Western blots analysis of transfected yeast lysates
Yeast lysates and skeletal muscle lysates were prepared as described in sections
2.3.4.10 and 2.3.2.5. 20 ug muscle lysate and 20 !-L1yeast lysate was subject to gel
electrophoresis as described in section 2.3.1.1. Proteins were transferred to
nitrocellulose and detected by immunoblotting as described in section 2.3.1.2 and
2.3.1.4. Flotillin-I protein is detected in 5 of the 6 yeast lysates.
5.2.4 The yeast two-hybrid screen
In the first instance a small-scale screen was performed using a skeletal muscle
library from Clontech, amplified as described in section 2.3.4.2. However, this screen
was unsuccessful with no flotillin interacting proteins being identified. It is believed
there may be a problem with this library and therefore subsequent work was
performed using a human testis cDNA library, also from Clontech and amplified in a
similar manner as described for the skeletal muscle library.
Initially a small-scale screen was performed in which around 50,000 clones were
screened. Yeast were sequentially transformed, initially with the bait plasmid
followed by the library plasmid, as described in section 2.3.4.4, and plated onto TDO
media. Colonies were picked over a 21 day period, and re-streaked onto TDO and
QDO media (see figure 5.10), resulting in 95 positive clones. From the first 60 of
these clones library plasmids were isolated as described in sections 2.3.4.5-2.3.4.7.
These plasmids were subjected to sequence analysis and BLAST searching (Altschul
et al., 1990) to determine the identity of the protein encoded. Of the 60 clones
sequenced, 31 encoded regions of known or hypothetical proteins (see table 5.1).
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Figure 5.10 Yeast growth as a result of a protein interaction in a small-scale
testis yeast two-hybrid screen
PJ692A were sequentially transformed with bait and library as described in section
2.3.4.4. Colonies were picked and re-streaked onto TDO and QDO as shown. Around
50% of the clones grew on the QDO media.
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Subsequently a larger screen was performed in which around 500,000 clones were
screened. Again yeast were sequentially transformed, but this time colonies were
only picked for 10 days. This resulted in isolation of 256 positive clones (example
plates from this screen are shown in figure 5.11). Library plasmids were isolated
from the clones which grew on QDO media (102 clones) and of these 23 have been
sequenced so far with 12 encoding known or hypothetical proteins (see table 5.2).
Figure 5.11 Yeast growth as a result of a protein interaction in a large-scale
testis yeast two-hybrid screen
PJ692A were sequentially transformed with bait and library as described in section
2.3.4.4. Colonies were picked and re-streaked onto TDO and QDO as shown. Over
50% of the clones grew on the QDO media.
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The protein sequences of the putative flotillin interacting proteins were subjected to
PIX analysis (http://www.hgmp.mrc.ac.uklRegisterediWebapp/pixD.This is a tool
that runs a number of peptide analysis programs, allowing various predictions to be
made about the peptide/protein of interest. It can be used to predict the secondary
structure of a protein, detailing the presence of a-helices and p-sheets. The presence
of transmembrane regions and various other structural and functional domains is also
predicted, as well as the presence of any putative coiled-coil structure. The program
will also predict the intracellular location of the protein of interest. The output from a
PIX analysis of SNAP-29 (clone D6 is shown in figure 5.12). Details of the
predictions made by PIX analysis of the putative flotillin interacting proteins are also
detailed in tables 5.1 and 5.2.
While many interesting proteins have been identified as putatively interacting with
flotillin, these results have to be viewed with caution. DNA from 18 of the positive
clones (chosen at random) was used to re-transform the P1692A-flotllin 152-427
yeast strain (as described in section 2.3.4.8), and each of these supported growth on
•triple drop out media (data not shown). This suggests that the yeast grew due to
activation of the reporter genes, and not because a mutation had occurred. However,
due to time constraints it has not been possible to do follow up bench work on any of
these proteins and until such times as a biochemical interaction can be shown, these
proteins must be viewed as putative flotillin-binding proteins.
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Figure 5.12 PIX analysis ofSNAP-29 (clone D6)
Shown in red is the predicted coil structure of this protein. Transmembrane regions
are shown in pink, none of which are present in this protein. In blue (Pfam) predicts a
domain with homology to SNAP-25.
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S.3 Discussion
A large number of proteins have been identified in this study by yeast-two hybrid
screening, which may be flotillin interacting proteins. However as no biochemical
analysis has been undertaken on these proteins, they must be viewed with some
caution.
Flotillin has been reported to form triple coiled-coils with other flotillin monomers
via interactions in the C-terminus (Bickel et al., 1997) and thus it is possible that
positive interacting proteins, will also contain coil forming regions and interact with
flotillin by forming coiled-coils. A number of proteins were identified in this yeast
two-hybrid screen which by PIX analysis are predicted to contain coil-forming
regions, for example, SNAP-29, annexin A2, HeR (a-helix coiled-coil rod
homologue), TACC1 (transforming acidic coiled-coil containing protein 1). However
it is also possible that coiled-coil interactions may occur non-specifically in the yeast
two-hybrid system and these interactions would have to be analysed biochemically to
be sure of their integrity.
Around half of the proteins identified are predicted to be localised predominantly to
the nucleus by PIX analysis. Flotillin has previously been described as an integral
membrane component of caveolae (Bickel et aI., 1997), and therefore is not expected
to have nuclear localisation. It is possible that a nuclear localisation signal is present
on the molecule, but that this is overridden by the transmembrane domain, or it may
be that flotillin is also present in nuclear membranes. However, the likelihood is that
the flotillin 152-427 protein encoded in the screen, which is localised to the yeast
nucleus with the Gal-4 binding domain has formed non-specific interactions with
these nuclear proteins. Again this would need to be determined by the presence or
absence of a biochemical interaction. It should be noted that PIX analysis also
predicts the flotillin to be nuclear, therefore it is possible that this protein is nuclear
and does interact with other nuclear proteins, or possibly more likely that the PIX
analysis program tends to falsely predict nuclear localisation. Also the PIX program
predicts a number of proteins to be localised to the cytoplasm whilst also predicting
the somewhat contradictory presence of transmembrane domains. Therefore it must
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be remembered that this program can only make predictions which really need to be
followed up by bench work.
It was hypothesised that caveolin (the marker protein for caveolae) would have been
identified as a flotillin interacting protein in this screen, as flotillin has been
suggested to be present in caveolae. However this was not the case. This may
possibly be due to the fact that the whole flotillin protein was not used in the screen.
It is possible that an interaction between caveolin and flotillin may occur in the
region of amino acids 1-151 of flotillin, which has been removed for the screen to
prevent membrane targeting. Itmay also be a possibility that caveolin and flotillin do
not actually participate in a protein-protein interaction. Caveolins and flotillins have
been reported to form hetero-oligomeric complexes by co-immunoprecipitation of
the proteins (Volonte et aI., 1999). However a direct interaction of the two proteins
was not shown and it may be possible that the proteins are complexed to another
protein resident in caveolae.
Recently the sorbin homology domain has been suggested to be a flotillin-binding
motif, as deletion of this region in the proteins CAP and vinexin prevented flotillin
binding (Kimura et aI., 2001). For this reason the PIX analyses of the putative
flotillin interacting proteins were examined for the presence of sorbin homology
domains. However, using PIX analysis, none of the proteins identified appear to
contain this sorbin homology domain which has been reported to confer flotillin
binding. Again it is possible that the region of flotillin which is bound by the sorbin
homology domain has been removed in order to undertake the yeast two-hybrid
screen. It is also possible that other as yet unidentified protein domains/motifs are
involved in flotillin binding.
A disappointing aspect of this screen was that none of the clones identified have been
duplicated. In a quality yeast two-hybrid screen where strongly interacting proteins
are identified only a small number of clones would be expected and the same clone
would normally be detected on numerous occasions. However, this was not the case
in this study, for which there may be a number of reasons. In the initial small-scale
screen, colonies were picked over a 21-day period, which in hindsight was too long,
as the yeast may begin to grow as a result of non-specific interactions. When the
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second larger-scale screen was performed, this was rectified with colonies being
picked over a 10-day period. Also in the small-scale screen DNA was isolated from
colonies which grew on either the triple or the quadruple dropout media. Again this
was altered in the large-scale screen with only colonies being investigated which
grew on the quadruple dropout media, in which there is presumably a more stringent
interaction. In the small-scale screen the majority of the clones were sequenced and
analysed. However in the large-scale screen a smaller number were sent for
sequencing, with only 12 known or hypothetical proteins being identified. Therefore
it is possible if more of the clones from this larger screen were sequenced duplication
of clones would be observed. However, as only half of the clones screened initially
from the large-scale screen encoded known or hypothetical proteins it was not
expected that further screening would produce duplication of interesting proteins.
Therefore in the interests of finance and time constraints, further sequencing was not
performed,
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CHAPTER6
DISCUSSION
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In humans, insulin resistance and hypertension are frequently associated (see section
1.4), however the underlying mechanisms leading to this association have not been
identified. In some rodent models, hypertension and insulin resistance are also
observed in concert, for example the SHR has been reported to be insulin resistant
(Mondon and Reaven, 1988, Reaven et al., 1989). Furthermore, the rodent model of
hypertension used in this study, the SHRSP, has also been reported to exhibit
peripheral insulin resistance in adipose tissue (Collison et al., 2000). During the
course of this study insulin resistance in skeletal muscle of the SHRSP was also
demonstrated (James et al., 2001). Hence, the aim of this study was to determine any
possible defects in insulin signalling in skeletal muscle of the SHRSP, which may be
responsible for the observed insulin resistant phenotype.
eNOS is a protein, which has been suggested to be involved in regulation of glucose
transport in skeletal muscle. Nitric oxide (NO) release occurs in response to muscle
contraction and the use of NOS inhibitors in skeletal muscle has been reported to
decrease contraction-stimulated (but not insulin-stimulated) NO release and glucose
transport (Balon and Nadler, 1994, Balon and Nadler, 1997). Furthermore, in
endothelial cell cultures both shear stress (Corson et al., 1996, Fisslthaler et al.,
2000) and insulin (Montagnani et al., 2001) have been reported to bring about the
phosphorylation and activation of eNOS (see section 3.1). Hence it was decided to
study eNOS regulation in the SHRSP in response to insulin and AICAR (an activator
of AMPK, a kinase thought to function in contraction-stimulated glucose transport,
see section 1.3.3.3).
In order to study eNOS regulation by phosphorylation at serine 1177, anti-peptide
antibodies were prepared which were raised against peptides corresponding to eNOS
protein either phosphorylated or dephosphorylated at this site (described in chapter
3). These antibodies were affinity purified and their specificity characterised (also
described in chapter 3). The anti-phospho and -dephospho eNOS antibodies appear
to work well when undertaking western blotting, immunoprecipitation and confocal
microscopy however, there is some question over the specificity of the antibodies
and further experimentation on the SHRSP has not been carried out to date. Using
these antibodies in western blotting experiments in the presence and absence of
blocking peptides suggested these antibodies were in fact specific to the peptide
155
against which they had been raised. Antibody binding was blocked only in the
presence of the peptide to which the antibody was raised (figure 3.2). Experiments
were carried out in which eNOS protein was specifically phosphorylated with AMPK
or dephosphorylated using alkaline phosphatase, in order to test the specificity of the
antibodies. However, these experiments were inconclusive, as no methodology was
available to test the extent of phosphorylation or dephosphorylation of the eNOS
protein specifically at serine 1177. Despite this fact, the results described in this
thesis suggest the anti-phospho eNOS antibody may be specific however, the anti-
dephospho eNOS antibody appears not to discriminate against the phosphorylated or
dephosphorylated protein.
The reasons behind the difficulty in determining the specific nature of these
antibodies are not clear. Previous studies have reported the generation of phospho-
specific eNOS antibodies (Ser-1177) using a method analogous to that used here
(Chen et al., 1999), however no reports have been identified describing production of
dephospho-specific eNOS antibodies. To further characterise the antibodies an
appropriate eNOS phospho Ser-1177 control is required. Using AMPK to
phosphorylate eNOS protein, phosphorylation of eNOS at Thr-495 was demonstrated
(figure 3.5), under conditions in which AMPK would also have been expected to
phosphorylate Ser-1177. In the future it would be important to phosphorylate eNOS
protein using another kinase, which has also been reported to phosphorylate eNOS at
Ser-1177, for example PKB (Fulton et al., 1999).
Studies of the classical insulin-signalling pathway were also undertaken in skeletal
muscle from the SHRSP in order to determine if any defect could be identified.
Crude fractionation of unstimulated skeletal muscle showed that various components
of the insulin-signalling cascade (GLUT 4, IRS-I, IRS-2 and PI3-kinase p85 subunit)
appeared to reside in similar subcellular compartments to that of the normotensive
control strain, the WKY. Furthermore, protein expression and activity of PKB was
also similar in skeletal muscle from the two strains, thus suggesting that the classical
insulin-signalling pathway leading to activation of PKB is intact in the SHRSP.
However, it should be noted that one study reported activation of PKB in response to
insulin to be normal in skeletal muscle from obese and diabetic patients, despite
decreases in insulin-stimulated PI3-kinase activity (Kim et al., 1999). The authors
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suggested that only a small activation of PI3-kinase is necessary to promote full
activation of PKB. PI3-kinase activity was not examined in this study and future
studies could be undertaken to examine IRS-lIIRS-2-asscociated PI3-kinase activity,
or recruitment of PI3-kinase to IRS-lIIRS-2 in response to insulin. Expression and
tyrosine phosphorylation of the insulin receptor and tyrosine phosphorylation of IRS-
lIIRS-2 could also be investigated to ensure the functionality of the insulin-
signalling pathway.
Expression of a number of PKC isoforms was studied in skeletal muscle from the
SHRSP. Atypical PKCs have been reported to be activated in response to insulin and
defects in their activation has been observed in skeletal muscle from type 2 diabetic
patients and in various rodent models of insulin resistance (Farese, 2002). However
in this study, expression of a number of PKC isoforms was observed to be similar in
a variety of skeletal muscles from WKY and SHRSP rats (figure 4.4). In future
studies, PKC activity could be examined to check that PKC activity, like PKC
expression, is also similar in skeletal muscle from WKY and SHRSP.
The defect in insulin-stimulated glucose transport in skeletal muscle from the SHRSP
is therefore not due to defects in expression of IRS-lIIRS-2, PI3-kinase, p85 subunit,
PKB or PKC. Neither is it due to a defect in PKB activity.
Therefore, in order to determine if a defect existed in more distal insulin-regulated
pathways, regulation of glycogen metabolism was also studied in skeletal muscle of
the SHRSP. It is suggested that the primary role of insulin in skeletal muscle is the
storage of elevated blood glucose as glycogen and muscle glycogen synthesis has
been reported to be decreased by up to 50% in diabetic individuals (Shulman, 2000).
Levels of GSK-3a and GSK-3p protein and activity were studied in skeletal muscle
from SHRSP and WKY animals (figures 4.5 and 4.6). GSK-3a protein expression
was decreased in SHRSP skeletal muscle, compared to WKY, however GSK-3p
expression was normal. Furthermore, the levels of both GSK-3a and GSK-3p
activity were similar between the two strains, suggesting the GSK-3a protein present
has a high specific activity. It is not clear from the current literature, which of the
GSK-3 isoforms is most functionally important in regulation of glycogen synthase
157
activity. However, the data presented in this thesis would suggest that there is some
functional redundancy between the two isoforms. It is also possible that GSK-3a is
present in skeletal muscle in vast excess, as in the SHRSP where protein levels are
greatly reduced, activity of the protein appears to be normal. In addition to GSK-3a.
expression being reduced in skeletal muscle from SHRSP, the protein present
appeared to have a lower molecular weight than the protein present in the WKY
muscle. The reason for the decreased molecular weight of the SHRSP protein has not
been determined. Studies were carried out to determine if the decreased molecular
weight was due to dephosphorylation of the protein, but this does not seem to be the
case. Insulin is known to inhibit GSK-3 activity by promoting its phosphorylation via
activation of PKB (Cross et al., 1995), it should be noted however that in this study
insulin did not inhibit GSK-3 and the reasons for this are unknown. Further studies of
glycogen metabolism in these animals showed no differences in the levels of
glycogen, glycogen synthesis, or glycogen phosphorylase activity in skeletal muscle
from SHRSP compared to that from WKY.
Skeletal muscles consist of a variety of fibres that have specific roles in muscle
metabolism and fibre distribution is known to differ in various muscle types and
different skeletal muscle fibre types are known to have varying sensitivities to insulin
and exercise (see section 1.3.1). Skeletal muscles from WKY and SHRSP were
extensively fibre-typed in order to determine if any morphological differences could
be observed that might account for the insulin resistant phenotype (figure 4.10).
Muscle fibre typing showed the fibre staining patterns to be similar in skeletal
muscle from WKY and SHRSP, suggesting there are similar numbers of the various
fibre types in each of these strains. Thus it is unlikely that fibre-type differences are
the reason behind the observed insulin resistance in the SHRSP.
During the course of this work, studies in skeletal muscle of the SHRSP reported the
over expression of the lipid raft associated proteins caveolin and flotillin (James et
al., 2001). Lipid rafts and caveolae have been suggested to be important in insulin
signal transduction, for example the insulin receptor has been reported to reside in
caveolae (Gustavsson et al., 1999, Yamamoto et al., 1998). Furthermore, PI3-kinase
is reported to be required, but not sufficient, to promote increased glucose uptake and
GLUT 4 translocation in response to insulin (Wiese et al., 1995, Sharma et al., 1997,
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Guilhenne and Czech, 1998). A PI3-kinase independent pathway required for
insulin-stimulated GLUT 4 translocation and glucose uptake has recently been
identified (Baumann et al., 2000) and has been suggested to require components of
lipid raft domains (see section 1.2.7.3).
To investigate further the role of flotillin in insulin-stimulated glucose uptake a
yeast-two hybrid screen was performed, using human flotillin-1 as the bait protein
(chapter 5). However, although many interesting proteins were identified in the
screen, a number of positive clones have been generated, which have likely resulted
from non-specific interactions, the reasons for which are discussed in chapter 5. Due
to time constraints and the lack of duplication of positive clones, biochemical studies
have not been performed on the more interesting clones identified and therefore it
cannot be conclusively stated whether these proteins are indeed flotillin interacting
proteins, with possible roles in insulin signal transduction.
In future studies it will be important to investigate the expression and activity of the
proteins involved in the CAP-CbI (PI3-kinase independent pathway) required for
GLUT 4 translocation in skeletal muscle, and specifically determine if any defects in
this pathway are observed in the SHRSP. For example studies could be undertaken to
determine levels of expression of CAP, CbI and TC10. Furthermore, phosphorylation
ofCbl and activation ofTC10 in response to insulin could also be determined,
Therefore, the only alterations observed in components of the insulin-signalling
pathway in this study have been decreased expression of GSK-3a and increased
expression of flotillin. There are a number of possibilities as to why this is the case.
It has been suggested in the Zucker rat that the defect in insulin signalling in skeletal
muscle is due to decreased GLUT 4 translocation to the plasma membrane as
opposed to decreased expression of the protein (Abel et al., 1996). Furthermore, in
insulin resistant and diabetic individuals, GLUT 4 translocation to the plasma
membrane in response to insulin is also suggested to be defective (Hunter and
Garvey, 1998). However, due to the lack of a robust skeletal muscle fractionation
procedure, the translocation of GLUT 4 to the plasma membranelT -tubules in
response to insulin was not determined in this study. During the course of this work,
increased expression of the SNARE proteins VAMP 2 and syntaxin 4 was reported in
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skeletal muscle from the SHRSP (James et aI., 2001). These proteins likely have a
role in GLUT 4 trafficking in skeletal muscle and their over expression may possibly
function to perturb GLUT 4 vesicle trafficking. It is also possible that these SNARE
proteins are over expressed in order to compensate for other unknown defects. Over
expression of SNARE proteins has previously been reported in the insulin resistant
Zucker diabetic fatty rat (Maier et aI., 2000), suggesting that upregulation of SNARE
proteins may be evident in a range of insulin resistant models.
It is possible that the 'classical' insulin-signalling pathway is indeed intact in skeletal
muscle from the SHRSP, but in the realms of the unknown where insulin-signalling
meets GLUT 4 vesicle trafficking, there is an as yet unidentified defect preventing
GLUT 4 insertion into the surface membrane. This defect may be a defect in vesicle
trafficking, in vesicle docking and fusion or in activation of a latent activity present
in the transporter.
6.1 Conclusion
In this study, the expression levels and intracellular localisation of a variety of
components of the insulin-signalling cascade have been reported to be normal in
skeletal muscle from SHRSP, as compared to the normotensive WKY control.
Expression and activity of PKB was also observed to be similar in the two strains.
Expression and activity of a variety of proteins involved in glycogen metabolism was
also observed to be normal in skeletal muscle from SHRSP, with one exception.
GSK-3a protein levels are reduced in SHRSP skeletal muscle, however activity of
this protein appears normal. Flotillin-l, a component of lipid rafts and a protein
involved in a PI3-kinase independent pathway required for GLUT 4 translocation, is
over expressed in SHRSP skeletal muscle. However, the significance of the alteration
in expression of these proteins is not known.
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